Movatterモバイル変換


[0]ホーム

URL:


USD962433S1 - Implant placement guide - Google Patents

Implant placement guide
Download PDF

Info

Publication number
USD962433S1
USD962433S1US29/667,595US201829667595FUSD962433SUS D962433 S1USD962433 S1US D962433S1US 201829667595 FUS201829667595 FUS 201829667595FUS D962433 SUSD962433 SUS D962433S
Authority
US
United States
Prior art keywords
implant placement
placement guide
design
guide
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US29/667,595
Inventor
Jay S. Smith
Michael R. Cole
Amy K. Whitson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics IncfiledCriticalIntarcia Therapeutics Inc
Priority to US29/667,595priorityCriticalpatent/USD962433S1/en
Assigned to MIDCAP FINANCIAL TRUST, AS AGENTreassignmentMIDCAP FINANCIAL TRUST, AS AGENTSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: INTARCIA IRELAND LIMITED, INTARCIA THERAPEUTICS, INC.
Assigned to BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENTreassignmentBAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENTSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: INTARCIA THERAPEUTICS, INC.
Assigned to INTARCIA THERAPEUTICS, INC.reassignmentINTARCIA THERAPEUTICS, INC.RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
Assigned to INTARCIA IRELAND LIMITED, INTARCIA THERAPEUTICS, INC.reassignmentINTARCIA IRELAND LIMITEDRELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: MIDCAP FINANCIAL TRUST, AS AGENT
Application grantedgrantedCritical
Publication of USD962433S1publicationCriticalpatent/USD962433S1/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Images

Description

FIG. 1 is a perspective view of a design for an implant placement guide;
FIG. 2 is a first side view of the design for the implant placement guide ofFIG. 1;
FIG. 3 is a second side view of the design for the implant placement guide ofFIG. 1;
FIG. 4 is a front view of the design for the implant placement guide ofFIG. 1;
FIG. 5 is a back view of the design for the implant placement guide ofFIG. 1;
FIG. 6 is a top view for the design for the implant placement guide ofFIG. 1; and,
FIG. 7 is a bottom view for the design of the implant placement guide ofFIG. 1.
The dot-dash broken lines immediately adjacent the shaded areas represent the bounds of the claimed design while all other broken lines are included for the purpose of illustrating portions of the implant placement guide; the broken lines form no part of the claimed design.

Claims (1)

    CLAIM
  1. The ornamental design for an implant placement guide, as shown and described.
US29/667,5952016-06-022018-10-23Implant placement guideActiveUSD962433S1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US29/667,595USD962433S1 (en)2016-06-022018-10-23Implant placement guide

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US29/566,823USD840030S1 (en)2016-06-022016-06-02Implant placement guide
US29/667,595USD962433S1 (en)2016-06-022018-10-23Implant placement guide

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US29/566,823DivisionUSD840030S1 (en)2016-06-022016-06-02Implant placement guide

Publications (1)

Publication NumberPublication Date
USD962433S1true USD962433S1 (en)2022-08-30

Family

ID=59505964

Family Applications (3)

Application NumberTitlePriority DateFiling Date
US29/566,823ActiveUSD840030S1 (en)2016-06-022016-06-02Implant placement guide
US29/604,792ActiveUSD835783S1 (en)2016-06-022017-05-19Implant placement guide
US29/667,595ActiveUSD962433S1 (en)2016-06-022018-10-23Implant placement guide

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
US29/566,823ActiveUSD840030S1 (en)2016-06-022016-06-02Implant placement guide
US29/604,792ActiveUSD835783S1 (en)2016-06-022017-05-19Implant placement guide

Country Status (4)

CountryLink
US (3)USD840030S1 (en)
JP (3)JP1595315S (en)
AU (6)AU201710847S (en)
CA (3)CA171690S (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
USD985377S1 (en)*2021-11-042023-05-09Arjo Ip Holding AbCaster cover

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9119732B2 (en)2013-03-152015-09-01Orthocision, Inc.Method and implant system for sacroiliac joint fixation and fusion
USD1086449S1 (en)2015-03-252025-07-29Orthocision Inc.Surgical cannula
USD840030S1 (en)*2016-06-022019-02-05Intarcia Therapeutics, Inc.Implant placement guide
USD875925S1 (en)*2017-09-202020-02-18Fresenius Vial SasCover for a medical infusion pump
USD889638S1 (en)*2018-04-302020-07-07Bigfoot Biomedical, Inc.Replacement cap for pen-injector device
USD893706S1 (en)*2018-05-012020-08-18Juan LessmannDevice to aid insertion of a urinary catheter
USD865173S1 (en)2018-07-092019-10-29Paragon 28, Inc.Cut guide
USD916138S1 (en)*2019-04-192021-04-13Cummins Emission Solutions Inc.Routing guide
JP1650160S (en)*2019-06-142020-01-20
USD976439S1 (en)2019-12-102023-01-24Spd Swiss Precision Diagnostics GmbhTest device comprising a pipette holder
USD972745S1 (en)*2020-05-072022-12-13Owen Mumford LimitedTesting device
USD952846S1 (en)*2020-08-052022-05-24Integrity Implants Inc.Surgical instrument
JP1708399S (en)*2021-02-162022-02-25 Needle guide device housing
USD977096S1 (en)*2021-07-142023-01-31Innovative Medical Products, Inc.Distractor body
USD1078052S1 (en)2021-11-032025-06-03Owen Mumford LimitedMedical device
USD1071168S1 (en)2022-10-172025-04-15Owen Mumford LimitedMedical injector
USD1077210S1 (en)2022-11-182025-05-27Owen Mumford LimitedMedical injector
USD1087349S1 (en)*2023-02-232025-08-05ITXPros LLCDental bone guide

Citations (756)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US1655158A (en)1926-09-081928-01-03Radium Emanation CorpInstrument for implanting radon seeds
FR640907A (en)1927-06-251928-07-24 Automatic flow limiter
DE635692C (en)1936-09-22Herbert Zadow Medical syringe
US2110208A (en)1937-02-121938-03-08U S Standard Products CompanyAntigen preparations
US2168437A (en)1935-04-101939-08-08Kenneth O BuercklinInjection device
US2643653A (en)1951-07-191953-06-30Heidrich JohnPill injector
US3016895A (en)1958-08-011962-01-16Pan American Lab IncInjector for subcutaneous implantation of solids
US3025991A (en)1960-05-231962-03-20Carron Products CoBottle stopper
US3122162A (en)1963-06-201964-02-25Asa D SandsFlow control device
GB1049104A (en)1963-05-111966-11-23Prodotti Antibiotici SpaPharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3523906A (en)1962-07-111970-08-11Gevaert Photo Prod NvProcess for encapsulating water and compounds in aqueous phase by evaporation
US3538916A (en)1968-12-191970-11-10Joseph S WilesInjection pistol
US3620216A (en)1969-06-251971-11-16Abbott LabImplant trocar
US3625214A (en)1970-05-181971-12-07Alza CorpDrug-delivery device
US3632768A (en)1969-10-021972-01-04Upjohn CoTherapeutic composition and method for treating infections with actinospectacin
US3669104A (en)1970-06-151972-06-13PfizerImplant gun
US3691090A (en)1969-01-161972-09-12Fuji Photo Film Co LtdEncapsulation method
US3732865A (en)1971-01-131973-05-15Alza CorpOsmotic dispenser
US3737337A (en)1970-03-041973-06-05Bayer AgProcess for the production of microgranulates
US3766915A (en)1971-12-211973-10-23Illinois Tool WorksPlastic needle holder
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
US3797492A (en)1972-12-271974-03-19Alza CorpDevice for dispensing product with directional guidance member
US3869549A (en)1972-02-171975-03-04Ciba Geigy CorpInjectable oily peptide preparations and processes for their manufacture
US3891570A (en)1972-01-261975-06-24Toyo Jozo KkProcess for preparing microcapsules
US3960757A (en)1973-06-271976-06-01Toyo Jozo Co., Ltd.Process for encapsulation of medicaments
US3987790A (en)1975-10-011976-10-26Alza CorporationOsmotically driven fluid dispenser
US3995631A (en)1971-01-131976-12-07Alza CorporationOsmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3995632A (en)1973-05-041976-12-07Alza CorporationOsmotic dispenser
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4034756A (en)1971-01-131977-07-12Alza CorporationOsmotically driven fluid dispenser
US4078060A (en)1976-05-101978-03-07Richardson-Merrell Inc.Method of inducing an estrogenic response
GB1518683A (en)1974-07-051978-07-19Sandoz LtdPharmaceutical compositions
US4105030A (en)1977-01-031978-08-08Syntex (U.S.A.) Inc.Implant apparatus
US4111202A (en)1976-11-221978-09-05Alza CorporationOsmotic system for the controlled and delivery of agent over time
US4111201A (en)1976-11-221978-09-05Alza CorporationOsmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111203A (en)1976-11-221978-09-05Alza CorporationOsmotic system with means for improving delivery kinetics of system
US4203439A (en)1976-11-221980-05-20Alza CorporationOsmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4211771A (en)1971-06-011980-07-08Robins Ronald KTreatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4221882A (en)1979-01-311980-09-09Exxon Research & Engineering Co.High impact melt-flowable dual continuum melt mixed polymer blends of polypropylene, polyethylene, and ethylene-propylene rubber
US4223674A (en)1978-06-291980-09-23Arthur J. McIntoshImplant gun
US4243030A (en)1978-08-181981-01-06Massachusetts Institute Of TechnologyImplantable programmed microinfusion apparatus
US4305927A (en)1979-02-051981-12-15Alza CorporationMethod for the management of intraocular pressure
US4310516A (en)1980-02-011982-01-12Block Drug Company Inc.Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4340054A (en)1980-12-291982-07-20Alza CorporationDispenser for delivering fluids and solids
US4350271A (en)1980-08-221982-09-21Alza CorporationWater absorbing fluid dispenser
US4373527A (en)1979-04-271983-02-15The Johns Hopkins UniversityImplantable, programmable medication infusion system
US4376118A (en)1980-10-061983-03-08Miles Laboratories, Inc.Stable nonaqueous solution of tetracycline salt
US4384975A (en)1980-06-131983-05-24Sandoz, Inc.Process for preparation of microspheres
EP0079405A1 (en)1980-07-231983-05-25Corless, MarionApparatus for improving blood sugar control in diabetics
US4389330A (en)1980-10-061983-06-21Stolle Research And Development CorporationMicroencapsulation process
US4439196A (en)1982-03-181984-03-27Merck & Co., Inc.Osmotic drug delivery system
US4451253A (en)1980-12-181984-05-29Harman Sherman MMeans and method for administering medicinals
US4455143A (en)1982-03-221984-06-19Alza CorporationOsmotic device for dispensing two different medications
US4455145A (en)1981-07-101984-06-19Alza CorporationDispensing device with internal drive
US4474572A (en)1981-09-291984-10-02Syntex (U.S.A.) Inc.Implanting device and implant magazine
US4530840A (en)1982-07-291985-07-23The Stolle Research And Development CorporationInjectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4552561A (en)1982-12-231985-11-12Alza CorporationBody mounted pump housing and pump assembly employing the same
US4588614A (en)1981-10-201986-05-13Adnovum AgPseudoplastic gel transfer
US4594108A (en)1983-09-191986-06-10The Dow Chemical CompanyHighly pseudoplastic polymer solutions
US4597753A (en)1983-04-211986-07-01Hundon Forge LimitedImplanting method and device
US4609374A (en)1985-04-221986-09-02Alza CorporationOsmotic device comprising means for governing initial time of agent release therefrom
US4639244A (en)1983-05-031987-01-27Nabil I. RizkImplantable electrophoretic pump for ionic drugs and associated methods
US4655462A (en)1985-01-071987-04-07Peter J. BalsellsCanted coiled spring and seal
US4673405A (en)1983-03-041987-06-16Alza CorporationOsmotic system with instant drug availability
US4675184A (en)1981-11-281987-06-23501 Sunstar Kabushiki KaishaPharmaceutical composition containing interferon in stable state
US4695623A (en)1982-05-061987-09-22AmgenConsensus human leukocyte interferon
EP0254394A1 (en)1986-06-161988-01-27Alza CorporationDosage form for delivering a drug comprising solubility regulating member
US4727138A (en)1981-10-191988-02-23Genentech, Inc.Human immune interferon
US4734284A (en)1985-02-191988-03-29Nippon Kayaku Kabushiki KaishaEtoposide preparations
US4743449A (en)1983-09-121988-05-10Fujisawa Pharmaceutical Co., Ltd.Drug-containing lipid vesicle preparation and method for preparing them
US4753651A (en)1982-08-301988-06-28Alza CorporationSelf-driven pump
US4765989A (en)1983-05-111988-08-23Alza CorporationOsmotic device for administering certain drugs
US4783337A (en)1983-05-111988-11-08Alza CorporationOsmotic system comprising plurality of members for dispensing drug
US4787437A (en)1986-03-141988-11-29Stopinc AktiengesellschaftMethod for starting a continuous casting plant
EP0295411A1 (en)1987-05-151988-12-21Sansho Co., Ltd.Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof
FR2616665A2 (en)1987-03-161988-12-23Denance RaymondStabiliser adaptor for hypodermic needle, for adjusting penetration as a function of the angle of attack, formed from a needle guard
EP0304107A1 (en)1987-08-181989-02-22Akzo N.V.Implant injection device
US4818517A (en)1986-01-241989-04-04Akzo N.V.Pharmaceutical preparation for obtaining a highly viscose hydrogel or suspension
US4820267A (en)1985-02-191989-04-11Endocon, Inc.Cartridge injector for pellet medicaments
US4820638A (en)1982-05-281989-04-11Dr. Karl Thomae GmbhNovel alpha interferon species produced by recombinant means
US4826144A (en)1988-04-251989-05-02Peter J. BalsellsInside back angle canted coil spring
WO1989003678A1 (en)1987-10-301989-05-05Stolle Research & Development CorporationLow residual solvent microspheres and microencapsulation process
US4830344A (en)1988-04-251989-05-16Peter J. BalsellsCanted-coil spring with turn angle and seal
US4834708A (en)1987-03-311989-05-30George PillariPuncture needle assembly
US4840896A (en)1983-11-021989-06-20Integrated Genetics, Inc.Heteropolymeric protein
US4845196A (en)1985-06-241989-07-04G. D. Searle & Co.Modified interferon gammas
US4847079A (en)1985-07-291989-07-11Schering CorporationBiologically stable interferon compositions comprising thimerosal
US4851228A (en)1984-06-201989-07-25Merck & Co., Inc.Multiparticulate controlled porosity osmotic
US4865845A (en)1986-03-211989-09-12Alza CorporationRelease rate adjustment of osmotic or diffusional delivery devices
US4871094A (en)1986-12-311989-10-03Alcon Laboratories, Inc.Means and method for dispensing substances
US4873080A (en)1983-06-081989-10-10Dr. Karl Thomae GmbhOral anti-diabetic pharmaceutical compositions and the preparation thereof
US4874388A (en)1987-06-251989-10-17Alza CorporationMulti-layer delivery system
US4876781A (en)1988-04-251989-10-31Peter J. BalsellsMethod of making a garter-type axially resilient coiled spring
US4882166A (en)1981-09-301989-11-21National Research Development CorporationCompositions comprising encapsulated particles and their preparation
US4885166A (en)1985-06-111989-12-05Ciba-Geigy CorporationHybrid interferons
US4886668A (en)1987-09-241989-12-12Merck & Co., Inc.Multiparticulate controlled porosity osmotic pump
US4892778A (en)1987-05-271990-01-09Alza CorporationJuxtaposed laminated arrangement
US4893795A (en)1988-08-151990-01-16Peter J. BalsellsRadially loaded canted coiled spring with turn angle
US4907788A (en)1988-04-251990-03-13Peter J. BalsellsDual concentric canted-coil spring apparatus
US4915366A (en)1988-04-251990-04-10Peter J. BalsellsOutside back angle canted coil spring
US4915954A (en)1987-09-031990-04-10Alza CorporationDosage form for delivering a drug at two different rates
US4915949A (en)1987-07-131990-04-10Alza CorporationDispenser with movable matrix comprising a plurality of tiny pills
US4917895A (en)1987-11-021990-04-17Alza CorporationTransdermal drug delivery device
US4917887A (en)1986-03-101990-04-17Boehringer Ingelheim International GmbhHybrid interferons, their use as pharmaceutical compositions and as intermediate products for the preparation of antibodies and the use thereof and processes for preparing them
US4923805A (en)1983-11-021990-05-08Integrated Genetics, Inc.Fsh
JPH02124814A (en)1988-07-051990-05-14Takeda Chem Ind LtdSustained release microcapsule containing water-soluble drug
EP0368339A2 (en)1988-11-111990-05-16Eisai Co., Ltd.Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt
US4927687A (en)1984-10-011990-05-22Biotek, Inc.Sustained release transdermal drug delivery composition
US4931285A (en)1988-04-281990-06-05Alza CorporationAqueous based pharmaceutical coating composition for dosage forms
US4934666A (en)1988-04-251990-06-19Peter J. BalsellsCoiled spring electromagnetic shielding gasket
EP0373867A1 (en)1988-12-131990-06-20Alza CorporationDelivery system comprising means for governing fluid ingress into the system
US4940588A (en)1984-10-301990-07-10Elan CorporationControlled release powder and process for its preparation
US4940465A (en)1987-05-271990-07-10Felix TheeuwesDispenser comprising displaceable matrix with solid state properties
EP0379147A2 (en)1989-01-171990-07-25Sterling Winthrop Inc.Extrudable elastic gel for use as carrier for therapeutic agent
US4957119A (en)1987-08-081990-09-18Akzo N.V.Contraceptive implant
US4961253A (en)1988-04-251990-10-09Peter J. BalsellsManufacturing method for canted-coil spring with turn angle and seal
US4964204A (en)1988-04-251990-10-23Peter J. BalsellsMethod for making a garter-type axially-resilient coil spring
US4969884A (en)1988-12-281990-11-13Alza CorporationOsmotically driven syringe
WO1990013361A1 (en)1989-05-041990-11-15Southern Research InstituteImproved encapsulation process and products therefrom
WO1990013780A1 (en)1989-05-011990-11-15Enzytech, Inc.Very low temperature casting of controlled release microspheres
WO1990013285A1 (en)1989-05-011990-11-15Enzytech, Inc.Process for producing small particles of biologically active molecules
NL8901004A (en)1989-04-211990-11-16Nedap NvPositioning attachment for animal implanting or injecting tool - has automatically shaped transparent positioning piece with adjustable needle insertion depth
NL9000948A (en)1989-04-211990-11-16Nedap NvInjection and implanting instrument for coding or numbering animals - has handle sliding on guide pin with insertion depth stop parallel to hollow needle and anatomically shaped locating plate
US4974821A (en)1988-04-251990-12-04Peter J. BalsellsCanted-coil spring with major axis radial loading
US4976966A (en)1988-12-291990-12-11Alza CorporationDelayed release osmotically driven fluid dispenser
US4994028A (en)1987-03-181991-02-19Endocon, Inc.Injector for inplanting multiple pellet medicaments
US5004689A (en)1982-02-221991-04-02Biogen, MassachusettsDNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US5006346A (en)1988-04-281991-04-09Alza CorporationDelivery system
US5019382A (en)1986-11-061991-05-28The Texas A&M University SystemTreatment of immuno-resistant disease with low-dose interferon
WO1991007160A1 (en)1989-11-131991-05-30Medicorp Holding S.A.Storage bottle containing a constituent of a medicinal solution
US5023088A (en)1987-06-251991-06-11Alza CorporationMulti-unit delivery system
EP0431942A2 (en)1989-12-061991-06-12Sansho Co., Ltd.Percutaneously absorbable pharmaceutical preparation containing dopamine derivative
US5024842A (en)1988-04-281991-06-18Alza CorporationAnnealed coats
US5030216A (en)1989-12-151991-07-09Alza CorporationOsmotically driven syringe
US5053014A (en)1990-02-011991-10-01Critikon, Inc.Catheter with controlled valve
US5057318A (en)1988-12-131991-10-15Alza CorporationDelivery system for beneficial agent over a broad range of rates
US5059423A (en)1988-12-131991-10-22Alza CorporationDelivery system comprising biocompatible beneficial agent formulation
US5066436A (en)1989-01-041991-11-19Gist-Brocades N.V.Process for microencapsulation
US5071642A (en)1986-10-231991-12-10Dr. Rentschler Arzneimittel Gmbh & Co.Dihydropyridine containing compositions
US5072070A (en)1989-12-011991-12-10Peter J. BalsellsDevice for sealing electromagnetic waves
US5079388A (en)1989-12-011992-01-07Peter J. BalsellsGasket for sealing electromagnetic waves
US5091188A (en)1990-04-261992-02-25Haynes Duncan HPhospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5090962A (en)1989-04-281992-02-25Flp Enterprises, Inc.Non-reusable syringe
US5108078A (en)1988-04-251992-04-28Peter J. BalsellsCanted-coil spring loaded while in a cavity
US5110596A (en)1988-12-131992-05-05Alza CorporationDelivery system comprising means for delivering agent to livestock
US5112614A (en)1989-09-141992-05-12Alza CorporationImplantable delivery dispenser
US5113938A (en)1991-05-071992-05-19Clayton Charley HWhipstock
US5117066A (en)1988-04-251992-05-26Peter J. BalsellsRetaining and locking electromagnetic gasket
EP0486959A1 (en)1990-11-221992-05-27Vectorpharma International S.P.A.Pharmaceutical composition of microparticles with controlled release and process of preparing it
US5118666A (en)1986-05-051992-06-02The General Hospital CorporationInsulinotropic hormone
US5120306A (en)1990-03-211992-06-09Gosselin Leon FDirect delivery of anti-inflammatories to the proximal small bowel
US5120832A (en)1984-08-271992-06-09Genentech, Inc.Distinct family of human leukocyte interferons
US5120712A (en)1986-05-051992-06-09The General Hospital CorporationInsulinotropic hormone
US5122377A (en)1990-11-191992-06-16A.H. Robins, Company, IncorporatedOral delivery system for veterinary drugs
US5122128A (en)1990-03-151992-06-16Alza CorporationOrifice insert for a ruminal bolus
US5126142A (en)1989-07-181992-06-30Alza CorporationDispenser comprising ionophore
US5128147A (en)1989-01-061992-07-07Thermal Developments, Inc.Heat intensifier and localizer for radiofrequency thermotherapy
US5134244A (en)1988-04-251992-07-28Peter J. BalsellsElectromagnetic shielding seal for rotary/reciprocating shaft
EP0497575A1 (en)1991-01-301992-08-05Texas Instruments Holland B.V.Injector
US5137727A (en)1991-06-121992-08-11Alza CorporationDelivery device providing beneficial agent stability
US5147295A (en)1991-01-231992-09-15Ideal Instruments, Inc.Retractable implanter
US5151093A (en)1990-10-291992-09-29Alza CorporationOsmotically driven syringe with programmable agent delivery
US5160122A (en)1990-03-201992-11-03Peter J. BalsellsCoil spring with an elastomer having a hollow coil cross section
US5160743A (en)1988-04-281992-11-03Alza CorporationAnnealed composition for pharmaceutically acceptable drug
US5161806A (en)1990-12-171992-11-10Peter J. BalsellsSpring-loaded, hollow, elliptical ring seal
WO1992019241A1 (en)1991-05-071992-11-12Dynagen, Inc.A controlled, sustained release delivery system for smoking cessation
US5180591A (en)1990-07-111993-01-19Alza CorporationDelivery device with a protective sleeve
US5190765A (en)1991-06-271993-03-02Alza CorporationTherapy delayed
US5192273A (en)1989-07-241993-03-09Steven F. BiermanCatheterization system
WO1993006821A1 (en)1991-10-041993-04-15Yoshitomi Pharmaceutical Industries, Ltd.Sustained-release tablet
WO1993006819A1 (en)1991-10-101993-04-15Alza CorporationOsmotic drug delivery devices with hydrophobic wall materials
US5204108A (en)1987-10-101993-04-20Danbiosyst Uk Ltd.Transmucosal formulations of low molecular weight peptide drugs
US5203849A (en)1990-03-201993-04-20Balsells Peter JCanted coil spring in length filled with an elastomer
US5207752A (en)1990-03-301993-05-04Alza CorporationIontophoretic drug delivery system with two-stage delivery profile
US5209746A (en)1992-02-181993-05-11Alza CorporationOsmotically driven delivery devices with pulsatile effect
WO1993008832A1 (en)1991-11-081993-05-13Dallas Biotherapeutics, Inc.Stabilization of human interferon
US5213809A (en)1990-01-241993-05-25Alza CorporationDelivery system comprising means for controlling internal pressure
US5213810A (en)1990-03-301993-05-25American Cyanamid CompanyStable compositions for parenteral administration and method of making same
WO1993009763A1 (en)1991-11-151993-05-27Isp Investments Inc.Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5219572A (en)1989-03-171993-06-15Pitman-Moore, Inc.Controlled release delivery device for macromolecular proteins
US5221278A (en)1992-03-121993-06-22Alza CorporationOsmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5223265A (en)1992-01-101993-06-29Alza CorporationOsmotic device with delayed activation of drug delivery
US5225205A (en)1989-07-281993-07-06Debiopharm S.A.Pharmaceutical composition in the form of microparticles
US5231176A (en)1984-08-271993-07-27Genentech, Inc.Distinct family DNA encoding of human leukocyte interferons
US5234695A (en)1990-07-241993-08-10Eastman Kodak CompanyWater dispersible vitamin E composition
US5234692A (en)1990-07-111993-08-10Alza CorporationDelivery device with a protective sleeve
US5234424A (en)1988-12-281993-08-10Alza CorporationOsmotically driven syringe
US5234693A (en)1990-07-111993-08-10Alza CorporationDelivery device with a protective sleeve
US5250026A (en)1992-05-271993-10-05Destron/Idi, Inc.Adjustable precision transponder injector
US5252338A (en)1991-06-271993-10-12Alza CorporationTherapy delayed
US5260069A (en)1992-11-271993-11-09Anda Sr Pharmaceuticals Inc.Pulsatile particles drug delivery system
WO1993023083A1 (en)1992-05-111993-11-25Agouron Pharmaceuticals, Inc.Anhydrous formulations for administering lipophilic agents
US5278151A (en)1987-04-021994-01-11Ocular Research Of Boston, Inc.Dry eye treatment solution
US5279555A (en)1992-08-241994-01-18Merck & Co., Inc.Device for injecting implants
US5279544A (en)1990-12-131994-01-18Sil Medics Ltd.Transdermal or interdermal drug delivery devices
US5279608A (en)1990-12-181994-01-18Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)Osmotic pumps
US5279554A (en)1990-02-091994-01-18Rhone MerieuxImplanting device
US5284655A (en)1989-09-211994-02-08Osteotech, Inc.Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects
US5288501A (en)1991-07-041994-02-22Merz + Co. Gmbh & Co.Mechanically-stable, readily-disintegratable tablets made of small preformed particles containing active ingredients
US5288502A (en)1991-10-161994-02-22The University Of Texas SystemPreparation and uses of multi-phase microspheres
US5290271A (en)1990-05-141994-03-01Jernberg Gary RSurgical implant and method for controlled release of chemotherapeutic agents
US5300302A (en)1990-10-041994-04-05Nestec S.A.Pharmaceutical composition in gel form in a dispensing package
US5308348A (en)1992-02-181994-05-03Alza CorporationDelivery devices with pulsatile effect
WO1994009743A1 (en)1992-11-051994-05-11R.P. Scherer CorporationVented capsule
EP0596161A1 (en)1992-11-061994-05-11Texas Instruments IncorporatedApparatus for subcutaneous introduction of a needle
US5312335A (en)1989-11-091994-05-17Bioject Inc.Needleless hypodermic injection device
WO1994010982A1 (en)1992-11-171994-05-26Yoshitomi Pharmaceutical Industries, Ltd.Sustained-release microsphere containing antipsychotic and process for producing the same
US5318780A (en)1991-10-301994-06-07Mediventures Inc.Medical uses of in situ formed gels
US5324280A (en)1990-04-021994-06-28Alza CorporationOsmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5336505A (en)1989-08-281994-08-09Pharmaceutical Delivery SystemsBioerodible polymers useful for the controlled release of therapeutic agents
US5336057A (en)1991-09-301994-08-09Nippon Densan CorporationMicropump with liquid-absorptive polymer gel actuator
US5348544A (en)1993-11-241994-09-20Becton, Dickinson And CompanySingle-handedly actuatable safety shield for needles
WO1994021262A1 (en)1993-03-171994-09-29Alza CorporationDevice for the transdermal administration of alprazolam
US5352662A (en)1991-10-011994-10-04Brooks Norman DInjectable extended release formulations and methods
US5368588A (en)1993-02-261994-11-29Bettinger; David S.Parenteral fluid medication reservoir pump
US5368863A (en)1990-01-241994-11-29Alza CorporationLong-term delivery device with early startup
US5371089A (en)1987-02-261994-12-06Senetek, PlcMethod and composition for ameliorating the adverse effects of aging
US5374620A (en)1990-06-071994-12-20Genentech, Inc.Growth-promoting composition and its use
EP0631794A1 (en)1993-06-231995-01-04Hoechst AktiengesellschaftDevice for administering implants
WO1995001167A2 (en)1993-06-251995-01-12Alza CorporationIncorporating poly-n-vinyl amide in a transdermal system
US5385738A (en)1983-10-141995-01-31Sumitomo Pharmaceuticals Company, Ltd.Sustained-release injection
US5385887A (en)1993-09-101995-01-31Genetics Institute, Inc.Formulations for delivery of osteogenic proteins
US5395319A (en)1991-03-061995-03-07Suddeutsche Feinmechanik GmbhNeedle for inserting an object into the body
WO1995009007A1 (en)1993-09-291995-04-06Alza CorporationMonoglyceride/lactate ester permeation enhancer for oxybutynin
US5411951A (en)1984-10-041995-05-02Monsanto CompanyProlonged release of biologically active somatotropin
US5413672A (en)1992-07-221995-05-09Ngk Insulators, Ltd.Method of etching sendust and method of pattern-etching sendust and chromium films
WO1995013799A1 (en)1993-11-191995-05-26Alkermes Controlled Therapeutics Inc. IiPreparation of biodegradable microparticles containing a biologically active agent
US5424286A (en)1993-05-241995-06-13Eng; JohnExendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5428024A (en)1992-02-281995-06-27Collagen CorporationHigh concentration homogenized collagen compositions
US5429602A (en)1992-04-291995-07-04Hauser; Jean-LucProgrammable portable infusion pump system
JPH07196479A (en)1994-01-041995-08-01Unitika LtdMethod for producing microcapsule
US5439688A (en)1989-07-281995-08-08Debio Recherche Pharmaceutique S.A.Process for preparing a pharmaceutical composition
US5443459A (en)1991-01-301995-08-22Alza CorporationOsmotic device for delayed delivery of agent
US5445829A (en)1989-05-051995-08-29Kv Pharmaceutical CompanyExtended release pharmaceutical formulations
US5456679A (en)1992-02-181995-10-10Alza CorporationDelivery devices with pulsatile effect
US5458888A (en)1994-03-021995-10-17Andrx Pharmaceuticals, Inc.Controlled release tablet formulation
US5464929A (en)1995-03-061995-11-07Ethicon, Inc.Absorbable polyoxaesters
WO1995034285A1 (en)1994-06-131995-12-21Alza CorporationDosage form for administering drug in liquid formulation
US5478564A (en)1990-02-221995-12-26Teva Pharmaceutical Industries, Ltd.Preparation of microparticles for controlled release of water-soluble substances
US5484403A (en)1994-04-051996-01-16Avid Marketing, Inc.Hypodermic syringe for implanting solid objects
WO1996001134A1 (en)1994-07-011996-01-18Alza CorporationOsmotic system for delivering of fluid-sensitive somatotropin to bovine animals
US5486365A (en)1993-09-171996-01-23Fuji Chemical Industry Co., Ltd.Calcium hydrogen phosphate, a method for preparing it, and an excipient utilizing it
WO1996003116A1 (en)1994-07-251996-02-08Alkermes Controlled Therapeutics, Inc.Controlled release of metal cation-stabilized interferon
US5498255A (en)1993-08-171996-03-12Alza CorporationOsmotic device for protracted pulsatile delivery of agent
US5512293A (en)1992-07-231996-04-30Alza CorporationOral sustained release drug delivery device
US5511355A (en)1991-11-151996-04-30Dingler; GerhardConstruction element
US5512549A (en)1994-10-181996-04-30Eli Lilly And CompanyGlucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5514110A (en)1993-03-221996-05-07Teh; Eutiquio L.Automatic flow control device
US5529914A (en)1990-10-151996-06-25The Board Of Regents The Univeristy Of Texas SystemGels for encapsulation of biological materials
US5541172A (en)1991-06-281996-07-30Endorecherche, Inc.Controlled release systems and low dose androgens
US5540665A (en)1994-01-311996-07-30Alza CorporationGas driven dispensing device and gas generating engine therefor
US5540912A (en)1992-03-301996-07-30Alza CorporationViscous suspensions of controlled-release drug particles
US5542682A (en)1995-03-271996-08-06American VarisealSlant coil spring and seal
US5543156A (en)1991-01-091996-08-06Alza CorporationBioerodible devices and compositions for diffusional release of agents
US5545618A (en)1990-01-241996-08-13Buckley; Douglas I.GLP-1 analogs useful for diabetes treatment
EP0729747A1 (en)1995-03-031996-09-04L'orealUse of amphiphilic compounds as thickening agent of non aqueous media and composition obtained
US5557318A (en)1994-07-121996-09-17Koninklijke Ptt Nederland N.V.Method and apparatus for permitting a viewer to scan through a plurality of video signals provided by a transmitter
US5556642A (en)1992-07-161996-09-17Tanabe Seiyaku Co., Ltd.Method for producing sustained release microsphere preparation
US5558637A (en)1993-10-131996-09-24Leiras OyImplant injection device
US5569289A (en)1993-06-241996-10-29Yoon; InbaeSafety penetrating instrument with penetrating member and cannula moving during penetration and triggered safety member protusion
US5571525A (en)1992-03-301996-11-05Alza CorporationErosion rate modifier for use in bioerodible drug delivery devices and method of use
US5574137A (en)1983-12-161996-11-12Genentech, Inc.Recombinant gamma interferons having enhanced stability and methods therefor
US5574008A (en)1994-08-301996-11-12Eli Lilly And CompanyBiologically active fragments of glucagon-like insulinotropic peptide
WO1996036317A1 (en)1995-05-181996-11-21Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1996039142A1 (en)1995-06-061996-12-12F. Hoffmann-La Roche AgPharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
WO1996040139A1 (en)1995-06-071996-12-19Alza CorporationNovel formulations for transdermal delivery of pergolide
WO1996040049A1 (en)1995-06-071996-12-19Alza CorporationPeptide/protein suspended formulations
WO1996040355A1 (en)1995-06-071996-12-19Cygnus, Inc.Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5589167A (en)1993-02-231996-12-31Genentech, Inc.Excipient stabilization of polypeptides treated with organic solvents
US5595751A (en)1995-03-061997-01-21Ethicon, Inc.Absorbable polyoxaesters containing amines and/or amido groups
US5595759A (en)1994-11-101997-01-21Alza CorporationProcess for providing therapeutic composition
US5597579A (en)1995-03-061997-01-28Ethicon, Inc.Blends of absorbable polyoxaamides
US5602010A (en)1986-12-101997-02-11Boehringer Ingelheim International GmbhDNA encoding equine-gamma interferon and recombinant production of equine IFN-γ polypeptides
US5605688A (en)1984-12-181997-02-25Boehringer Ingelheim International GmbhRecombinant dog and horse type I interferons
US5607687A (en)1995-03-061997-03-04Ethicon, Inc.Polymer blends containing absorbable polyoxaesters
US5609885A (en)1992-09-151997-03-11Alza CorporationOsmotic membrane and delivery device
US5613954A (en)1994-11-211997-03-25Stryker CorporationLaparoscopic surgical Y-tube cannula
US5614221A (en)1989-10-231997-03-25MediventMethod of preparing a drug delivery system comprising a drug and a gel using a syringe
US5614492A (en)1986-05-051997-03-25The General Hospital CorporationInsulinotropic hormone GLP-1 (7-36) and uses thereof
US5618552A (en)1995-03-061997-04-08Ethicon, Inc.Absorbable polyoxaesters
US5620698A (en)1995-03-061997-04-15Ethicon, Inc.Blends of absorbable polyoxaesters containing amines and/or amido groups
US5620705A (en)1994-08-041997-04-15Alza CorporationProgestin tablet
WO1997015289A1 (en)1995-10-251997-05-01Cortecs (Uk) LimitedSolubilisation methods
WO1997015296A1 (en)1995-10-231997-05-01Theratech, Inc.Buccal delivery of glucagon-like insulinotropic peptides
EP0771817A2 (en)1995-10-301997-05-07Laboratorios S.A.L.V.A.T., S.A.Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight
US5630796A (en)1993-04-081997-05-20Oxford Biosciences LimitedMethod of delivering powder transdermally with needless injector
US5635213A (en)1992-11-301997-06-03Neopharma Production AbPharmaceutical formulation
US5639477A (en)1993-06-231997-06-17Alza CorporationRuminal drug delivery device
US5639640A (en)1983-11-021997-06-17Genzyme CorporationDNA encoding the beta subunit of human follide stimulating hormone and expression vectors and cells containing same
US5650173A (en)1993-11-191997-07-22Alkermes Controlled Therapeutics Inc. IiPreparation of biodegradable microparticles containing a biologically active agent
US5654010A (en)1992-12-021997-08-05Alkermes, Inc.Composition for sustained release of human growth hormone
WO1997028181A2 (en)1996-02-021997-08-07Rhomed IncorporatedPost-labeling stabilization of radiolabeled proteins and peptides
US5656297A (en)1992-03-121997-08-12Alkermes Controlled Therapeutics, IncorporatedModulated release from biocompatible polymers
US5658593A (en)1992-01-161997-08-19ColeticaInjectable compositions containing collagen microcapsules
US5660861A (en)1994-04-281997-08-26Alza CorporationEffective therapy for epilepsies
US5660858A (en)1996-04-031997-08-26Research Triangle PharmaceuticalsCyclosporin emulsions
WO1997031943A1 (en)1996-03-011997-09-04Novo Nordisk A/SUse of a pharmaceutical composition comprising an appetite-suppressing peptide
JPH09241153A (en)1996-03-041997-09-16Q P Corp Fat emulsion for intravenous injection
US5668170A (en)1994-07-131997-09-16Alza CorporationComposition and method enhancing transdermal electrotransport agent delivery
JPH09509346A (en)1994-02-251997-09-22ズードドイッチェ・フアインメハニーク・ゲーエムベーハー Cannula for subcutaneous fixation of target
US5672549A (en)1996-01-311997-09-30Sumitomo Bakelite Company LimitedMethod of producing epoxy resin-encapsulated semiconductor device
US5676942A (en)1992-02-101997-10-14Interferon Sciences, Inc.Composition containing human alpha interferon species proteins and method for use thereof
WO1997041837A2 (en)1996-05-071997-11-13Alkermes Controlled Therapeutics Inc. IiMicroparticles
US5688801A (en)1993-11-191997-11-18Janssen PharmaceuticaMethod of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5690952A (en)1995-06-071997-11-25Judy A. Magruder et al.Implantable system for delivery of fluid-sensitive agents to animals
US5690925A (en)1983-12-161997-11-25Genentech, Inc.Recombinant gamma interferons having enhanced stability and methods therefor
WO1997044039A1 (en)1996-05-201997-11-27Janssen Pharmaceutica N.V.Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US5695463A (en)1994-09-271997-12-09Societe De Conseils De Recherches Et D'applicationsSafety injection device
WO1997046204A2 (en)1996-06-051997-12-11Ashmont Holdings LimitedInjectable compositions
US5698213A (en)1995-03-061997-12-16Ethicon, Inc.Hydrogels of absorbable polyoxaesters
US5697914A (en)1995-03-161997-12-16Becton Dickinson And CompanyControl forward/flashback forward one hand introducer needle and catheter assembly
WO1997047339A1 (en)1996-06-141997-12-18Filtertek, S.A.Gravity infusion set for medical infusions
US5700583A (en)1995-03-061997-12-23Ethicon, Inc.Hydrogels of absorbable polyoxaesters containing amines or amido groups
US5703200A (en)1996-03-151997-12-30Ethicon, Inc.Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
WO1998000157A1 (en)1996-07-031998-01-08Alza CorporationAqueous formulations of peptides
WO1998000158A1 (en)1996-07-031998-01-08Alza CorporationNon-aqueous polar aprotic peptide formulations
WO1998000152A1 (en)1996-07-031998-01-08Alza CorporationNon-aqueous protic peptide formulations
US5707644A (en)1989-11-041998-01-13Danbiosyst Uk LimitedSmall particle compositions for intranasal drug delivery
WO1998002169A2 (en)1996-07-151998-01-22Alza CorporationNovel formulations for the administration of fluoxetine
US5711967A (en)1991-06-171998-01-27Spirig Ag, Pharmazeutische PraeparateOral diclofenac preparation
US5713847A (en)1994-02-091998-02-03The University Of Iowa Research FoundationHuman drug delivery device for tinnitus
US5718922A (en)1995-05-311998-02-17Schepens Eye Research Institute, Inc.Intravitreal microsphere drug delivery and method of preparation
WO1998007412A1 (en)1996-08-211998-02-26Alkermes Controlled Therapeutics, Inc.Controlled release microparticles with a hydrophobic material
US5725497A (en)1995-06-071998-03-10American Cyanamid CompanyInjection dart system
US5728396A (en)1996-02-021998-03-17Alza CorporationSustained delivery of leuprolide using an implantable system
US5733572A (en)1989-12-221998-03-31Imarx Pharmaceutical Corp.Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
WO1998013092A1 (en)1996-09-271998-04-02American Home Products CorporationTissue penetration guide
WO1998013091A1 (en)1996-09-271998-04-02American Home Products CorporationMedical device for the placement of solid materials
US5736159A (en)1995-04-281998-04-07Andrx Pharmaceuticals, Inc.Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5738845A (en)1989-03-021998-04-14The Women's Research InstituteHuman interferon τ proteins and methods of use
WO1998016250A1 (en)1996-10-161998-04-23Alza CorporationStable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
WO1998017315A2 (en)1996-10-241998-04-30Alza CorporationPermeation enhancers for transdermal drug delivery compositions, devices, and methods
US5747058A (en)1995-06-071998-05-05Southern Biosystems, Inc.High viscosity liquid controlled delivery system
WO1998020930A1 (en)1996-11-151998-05-22Alza CorporationOsmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5756450A (en)1987-09-151998-05-26Novartis CorporationWater soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
WO1998027960A2 (en)1996-12-201998-07-02Bioglan Ireland (R & D) LimitedA nitroimidazole gel composition
WO1998027963A2 (en)1996-12-201998-07-02Alza CorporationGel composition and methods
WO1998030231A1 (en)1997-01-071998-07-16Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the reduction of food intake
US5782396A (en)1995-08-281998-07-21United States Surgical CorporationSurgical stapler
WO1998032463A2 (en)1997-01-281998-07-30Pharmacia & Upjohn CompanyLyophilizate of lipid complex of water insoluble porphyrins
US5795779A (en)1982-11-011998-08-18Berlex Laboratories, Inc.Human interferon-β (IFN-β) produced in Chinese hamster ovary (CHO) cells
US5807876A (en)1996-04-231998-09-15Vertex Pharmaceuticals IncorporatedInhibitors of IMPDH enzyme
US5814323A (en)1995-10-161998-09-29Lever Brothers Company, Division Of Conopco, Inc.Cosmetic composition
WO1998042317A2 (en)1997-03-241998-10-01Alza CorporationImplantable delivery device with self adjustable exit port
US5817129A (en)1996-10-311998-10-06Ethicon, Inc.Process and apparatus for coating surgical sutures
US5827297A (en)1992-10-011998-10-27Medicamat S.A.Device for transplanting small diameter hair grafts
WO1998047487A1 (en)1997-04-171998-10-29Dumex-Alpharma A/SA novel bioadhesive drug delivery system based on liquid crystals
US5830501A (en)1991-12-061998-11-03Alza CorporationDosage form comprising hydrophilic polymer
US5836935A (en)1994-11-101998-11-17Ashton; PaulImplantable refillable controlled release device to deliver drugs directly to an internal portion of the body
WO1998051282A1 (en)1997-05-131998-11-19Imarx Pharmaceutical Corp.Solid porous matrices and methods of making and using the same
US5843891A (en)1993-04-281998-12-01Sherman; Bernard C.Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug
US5844017A (en)1995-03-061998-12-01Ethicon, Inc.Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US5851451A (en)1995-12-151998-12-22Takeda Chemical Industries, Ltd.Production of microspheres
WO1998058698A1 (en)1997-06-201998-12-30Akzo Nobel N.V.Preloaded implantation device
US5858746A (en)1992-04-201999-01-12Board Of Regents, The University Of Texas SystemGels for encapsulation of biological materials
US5859150A (en)1995-03-061999-01-12Ethicon, Inc.Prepolymers of absorbable polyoxaesters
US5861166A (en)1991-03-121999-01-19Alza CorporationDelivery device providing beneficial agent stability
WO1999003453A1 (en)1997-07-141999-01-28Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov , D.D.Novel pharmaceutical formulation with controlled release of active substances
WO1999004768A2 (en)1997-07-251999-02-04Alza CorporationOsmotic delivery system flow modulator apparatus
WO1999004767A2 (en)1997-07-251999-02-04Alza CorporationOsmotic delivery system with semipermeable plug
US5874388A (en)1997-04-021999-02-23Dow Corning CorporationLubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US5882676A (en)1995-05-261999-03-16Alza CorporationSkin permeation enhancer compositions using acyl lactylates
WO1999012549A2 (en)1997-09-091999-03-18West Pharmaceutical Services Drug Delivery & Clinical Research Centre LimitedControlled release microsphere delivery system
WO1999016419A1 (en)1997-09-291999-04-08Inhale Therapeutic Systems, Inc.Perforated microparticles and methods of use
JPH11100353A (en)1997-09-291999-04-13Esupo KkRefined and deodorized liquid ester wax and its composition
US5906830A (en)1995-09-081999-05-25Cygnus, Inc.Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5906816A (en)1995-03-161999-05-25University Of FloridaMethod for treatment of autoimmune diseases
US5906599A (en)1995-11-091999-05-25Intermed, Inc.Device for delivering biological agents
WO1999025728A1 (en)1997-11-141999-05-27Amylin Pharmaceuticals, Inc.Novel exendin agonist compounds
US5908621A (en)1995-11-021999-06-01Schering CorporationPolyethylene glycol modified interferon therapy
WO1999029306A1 (en)1997-12-121999-06-17Biohybrid Technologies, Inc.Devices for cloaking transplanted cells
WO1999033449A1 (en)1997-12-301999-07-08Alza CorporationBeneficial agent delivery system with membrane plug
WO1999033446A1 (en)1997-12-291999-07-08Alza CorporationOsmotic delivery system with membrane plug retention mechanism
US5928666A (en)1996-11-121999-07-27Cygnus Inc.Crystalline form of estradiol and pharmaceutical formulations comprising same
WO1999039700A1 (en)1998-02-061999-08-12Eurand International S.P.A.Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
US5939286A (en)1995-05-101999-08-17University Of FloridaHybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US5938654A (en)1987-06-251999-08-17Alza CorporationOsmotic device for delayed delivery of agent
WO1999040788A1 (en)1998-02-131999-08-19Amylin Pharmaceuticals, Inc.Inotropic and diuretic effects of exendin and glp-1
US5942253A (en)1995-10-121999-08-24Immunex CorporationProlonged release of GM-CSF
US5945126A (en)1997-02-131999-08-31Oakwood Laboratories L.L.C.Continuous microsphere process
US5948430A (en)1996-11-111999-09-07Lts Lohmann Therapie-Systeme GmbhWater soluble film for oral administration with instant wettability
WO1999044659A1 (en)1998-03-021999-09-10Medrad, Inc.Syringes and plungers for use therein
US5951521A (en)1998-09-251999-09-14Minimed Inc.Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
US5962023A (en)1995-03-061999-10-05Ethicon, Inc.Hydrogels containing absorbable polyoxaamides
US5972373A (en)1995-05-021999-10-26Taisho Pharmaceutical Co., Ltd.Taste masking pharmaceutical composition for oral administration
US5976109A (en)1996-04-301999-11-02Medtronic, Inc.Apparatus for drug infusion implanted within a living body
US5980945A (en)1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
US5981719A (en)1993-03-091999-11-09Epic Therapeutics, Inc.Macromolecular microparticles and methods of production and use
US5984890A (en)1996-09-271999-11-16American Home Products CorporationMedical device for the placement of solid materials
US5989463A (en)1997-09-241999-11-23Alkermes Controlled Therapeutics, Inc.Methods for fabricating polymer-based controlled release devices
WO1999062501A1 (en)1998-05-291999-12-09Sumitomo Pharmaceuticals Company, LimitedControlled release preparations having multi-layer structure
WO1999064061A1 (en)1998-06-121999-12-16Bionebraska, Inc.GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
US6007805A (en)1994-03-071999-12-28Imperial College Of Science And TechnologyUse of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US6017545A (en)1998-02-102000-01-25Modi; PankajMixed micellar delivery system and method of preparation
US6022561A (en)1994-02-042000-02-08Scotia Lipidteknik AbBilayers preparations
US6029361A (en)1998-03-252000-02-29Ultratech Stepper, Inc.Air-guage nozzle probe structure for microlithographic image focusing
WO2000013663A1 (en)1998-09-092000-03-16Alza CorporationDosage form comprising liquid formulation
US6053927A (en)1998-10-152000-04-25Rsh-Gs TrustApparatus and method for implant removal
US6056718A (en)1998-03-042000-05-02Minimed Inc.Medication infusion set
WO2000029206A1 (en)1998-11-132000-05-25Sensor Technologies Inc.Monodisperse preparations useful with implanted devices
US6069133A (en)1996-03-142000-05-30The Immune Response CorporationTargeted delivery of genes encoding interferon
US6074660A (en)1998-04-202000-06-13Ethicon, Inc.Absorbable polyoxaesters containing amines and/ or amido groups
US6074673A (en)1996-04-222000-06-13Guillen; ManuelSlow-release, self-absorbing, drug delivery system
US6074377A (en)1996-10-102000-06-13Sanfilippo, Ii; Dominic JosephMethod of installing vascular access device
WO2000039280A2 (en)1998-12-312000-07-06Viragen, Inc.Leukocyte-derived interferon preparations
WO2000038652A1 (en)1998-12-232000-07-06Amgen Inc.Polyol/oil suspensions for the sustained release of proteins
WO2000040273A2 (en)1999-01-082000-07-13Vical IncorporatedTreatment of viral diseases using an interferon omega expressing polynucleotide
WO2000041548A2 (en)1999-01-142000-07-20Amylin Pharmaceuticals, Inc.Methods for glucagon suppression
US6100346A (en)1995-03-062000-08-08Ethicon, Inc.Copolymers of polyoxaamides
WO2000045790A2 (en)1999-02-082000-08-10Alza CorporationStable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
USD430671S (en)1999-05-102000-09-05Shute Wallace BObstetrical forceps
US6113947A (en)1997-06-132000-09-05Genentech, Inc.Controlled release microencapsulated NGF formulation
US6120787A (en)1995-10-192000-09-19Biogram AbSustained release particles
WO2000054745A2 (en)1999-03-182000-09-21Durect CorporationDevices and methods for pain management
US6124281A (en)1996-03-082000-09-26Zeneca LimitedAzolobenzazepine derivatives as neurologically active agents
US6127520A (en)1997-04-152000-10-03Regents Of The University Of MichiganCompositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
US6129761A (en)1995-06-072000-10-10Reprogenesis, Inc.Injectable hydrogel compositions
WO2000059476A1 (en)1999-04-052000-10-12Pharmaceutical Discovery CorporationMethods for fine powder formation
US6133429A (en)1997-10-032000-10-17Becton Dickinson And CompanyChromophores useful for the preparation of novel tandem conjugates
US6132420A (en)1996-02-022000-10-17Alza CorporationOsmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6133249A (en)1995-12-192000-10-17Macnaught Medical Pty LimitedPhospholipid and propylene glycol based lubricant
EP1046399A1 (en)1999-04-192000-10-25Schering CorporationHCV combination therapy, containing ribavirin in association with antioxidants
WO2000066138A2 (en)1999-04-302000-11-09Bionebraska, Inc.Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
WO2000066087A2 (en)1999-05-032000-11-09Southern Biosystems, Inc.Emulsion-based processes for making microparticles
US6146139A (en)1999-06-012000-11-14Harrison, Iii; Louis V.Forceps apparatus
US6147168A (en)1995-03-062000-11-14Ethicon, Inc.Copolymers of absorbable polyoxaesters
WO2000067728A2 (en)1999-05-072000-11-16Pharmasol GmbhLipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US6156331A (en)1996-02-022000-12-05Alza CorporationSustained delivery of an active agent using an implantable system
US6172046B1 (en)1997-09-212001-01-09Schering CorporationCombination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6174547B1 (en)1999-07-142001-01-16Alza CorporationDosage form comprising liquid formulation
US6183461B1 (en)1998-03-112001-02-06Situs CorporationMethod for delivering a medication
US6190700B1 (en)1995-12-152001-02-20Takeda Chemical Industries, Ltd.Production of sustained-release preparation for injection
US6190702B1 (en)1996-03-282001-02-20Takeda Chemical Industries, Ltd.Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
US6191102B1 (en)1996-11-052001-02-20Eli Lilly And CompanyUse of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6190350B1 (en)1997-12-292001-02-20Alza CorporationImplanter device for subcutaneous implants
US6204022B1 (en)1996-04-122001-03-20Pepgen Corporation And University Of FloridaLow-toxicity human interferon-alpha analogs
WO2001019345A1 (en)1999-09-102001-03-22Astrazeneca AbMethod to obtain microparticles
US6217893B1 (en)1997-04-182001-04-17Pharma BiotechSustained-release compositions and method for preparing same
US6218431B1 (en)1996-07-312001-04-17Bayer CorporationSubstituted biphenyls
US6217908B1 (en)1992-04-242001-04-17Brown University Research FoundationBioadhesive microspheres and their use as drug delivery and imaging systems
WO2001028631A1 (en)1999-10-152001-04-26Deschutes Medical Products, Inc.Brachytherapy instrument and methods
WO2001028525A2 (en)1999-10-212001-04-26Alkermes Controlled Therapeutics, Inc.Method of producing sub-micron particles of biologically active agents
US6245349B1 (en)1996-02-232001-06-12éLAN CORPORATION PLCDrug delivery compositions suitable for intravenous injection
US6245357B1 (en)1998-03-062001-06-12Alza CorporationExtended release dosage form
US6248112B1 (en)1998-09-302001-06-19C. R. Bard, Inc.Implant delivery system
WO2001043528A2 (en)1999-12-172001-06-21Durect CorporationDevices and methods in intracerebrospinal delivery of morphine-6-glucuronide
US6258377B1 (en)1996-07-022001-07-10Provalis Uk LimitedHydrophobic preparations containing medium chain monoglycerides
US6261584B1 (en)1996-02-022001-07-17Alza CorporationSustained delivery of an active agent using an implantable system
WO2001051041A1 (en)2000-01-132001-07-19Osmotica Corp.Osmotic device containing venlafaxine and an anti-psychotic agent
US6268343B1 (en)1996-08-302001-07-31Novo Nordisk A/SDerivatives of GLP-1 analogs
US6270700B1 (en)1998-07-232001-08-07Societe De Conseils De Recherches Et D'applications Scientifiques, SasEncapsulation of water soluble peptides
US20010012511A1 (en)1995-03-062001-08-09Bezwada Rao S.Method of preventing adhesions with absorbable polyoxaesters
US6277413B1 (en)1998-07-172001-08-21Skyepharma, Inc.Biodegradable compositions for the controlled release of encapsulated substances
US6284727B1 (en)1993-04-072001-09-04Scios, Inc.Prolonged delivery of peptides
US6283949B1 (en)1999-12-272001-09-04Advanced Cardiovascular Systems, Inc.Refillable implantable drug delivery pump
WO2001068168A1 (en)2000-03-132001-09-20Leiras OyDevice for inserting implants
US20010031940A1 (en)2000-03-232001-10-18Hans-Joachim LoosDevice for administering implants
US20010031790A1 (en)1999-12-222001-10-18Beisswenger Paul J.Treatment for complications of type 2 diabetes
WO2001078683A2 (en)2000-04-192001-10-25Genentech, Inc.Sustained release formulations comprising growth hormone
US20010036472A1 (en)1998-12-172001-11-01Wong Patrick S.-L.Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US20010040326A1 (en)1999-06-142001-11-15Lord CorporationResilient member with deformed element and method of forming same
US6329336B1 (en)1999-05-172001-12-11Conjuchem, Inc.Long lasting insulinotropic peptides
US20020004481A1 (en)1997-06-132002-01-10Jeffrey L. ClelandControlled release microencapsulated ngf formulation
US20020012818A1 (en)2000-01-192002-01-31Sakari RuppiCoated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US20020037309A1 (en)2000-08-102002-03-28Alkermes Controlled Therapeutics, Inc.Process for the preparation of polymer-based sustained release compositions
WO2002028366A2 (en)2000-10-062002-04-11Durect CorporationDevices and methods for management of inflammation
US6372218B1 (en)1986-11-062002-04-16The Texas A&M University SystemInterferon dosage form and method therefor
US6375978B1 (en)1997-12-222002-04-23Alza CorporationRate controlling membranes for controlled drug delivery devices
US20020048600A1 (en)1998-11-022002-04-25Padmanabh BhattControlled delivery of active agents
WO2002036072A2 (en)2000-11-032002-05-10Biomedicines, Inc.Method for short-term and long-term drug dosimetry
US6395292B2 (en)1996-02-022002-05-28Alza CorporationSustained delivery of an active agent using an implantable system
US6395282B1 (en)1998-04-162002-05-28University Of RochesterImmunogenic conjugates of Gram-negative bacterial autoinducer molecules
WO2002043800A2 (en)2000-11-292002-06-06Durect CorporationDevices and methods for controlled delivery from a drug delivery device
US6402716B1 (en)1998-02-202002-06-11Lg Chemical Ltd.Syringe assembly
WO2002045752A2 (en)2000-12-082002-06-13Leo Pharma A/SDermal anti-inflammatory composition
WO2002047716A2 (en)2000-12-132002-06-20Eli Lilly And CompanyChronic treatment regimen using glucagon-like insulinotropic peptides
US20020077599A1 (en)2000-12-192002-06-20Animas CorporationTranscutaneous inserter for low-profile infusion sets
US20020098180A1 (en)2000-03-242002-07-25Huan-Yao LeiFullerene pharmaceutical compositions for preventing or treating disorders
US6428517B1 (en)1999-05-102002-08-06Milestone Scientific, Inc.Hand-piece for injection device with a retractable and rotating needle
US6433144B1 (en)1999-01-122002-08-13Viragen, Inc.Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US6436091B1 (en)1999-11-162002-08-20Microsolutions, Inc.Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
WO2002067895A2 (en)2000-11-162002-09-06Durect CorporationImplant dosage form and use thereof for the delivery of a cholesterol lowering agent
WO2002069983A1 (en)2001-03-012002-09-12Bharat Serums & Vaccines Ltd.Amphotericin b aqueous composition
US6451974B1 (en)1999-03-172002-09-17Novo Nordisk A/SMethod of acylating peptides and novel acylating agents
US20020136848A1 (en)1998-03-122002-09-26Fumio YoshiiLactone-containing resin composition, molded object thereof, and film
US6458924B2 (en)1996-08-302002-10-01Novo Nordisk A/SDerivatives of GLP-1 analogs
US6458387B1 (en)1999-10-182002-10-01Epic Therapeutics, Inc.Sustained release microspheres
US20020141985A1 (en)2000-12-142002-10-03Amylin Parmaceuticals, Inc.Peptide YY and peptide YY agonists for treatment of metabolic disorders
WO2002076344A1 (en)2001-03-232002-10-03Durect CorporationDelivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6461605B1 (en)1995-11-022002-10-08Schering CorporationContinuous low-dose cytokine infusion therapy
US6464688B1 (en)2000-02-152002-10-15Microsolutions, Inc.Osmotic pump delivery system with flexible drug compartment
US6471688B1 (en)2000-02-152002-10-29Microsolutions, Inc.Osmotic pump drug delivery systems and methods
US6472512B1 (en)1998-07-212002-10-29Human Genome Sciences, Inc.Keratinocyte derived interferon
WO2002085428A2 (en)2001-04-192002-10-31Microsolutions, Inc.Implantable osmotic pump
US6478768B1 (en)1997-08-082002-11-12Gaplast GmbhImplant syringe
US6485706B1 (en)1999-06-042002-11-26Delrx Pharmaceutical Corp.Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US6495164B1 (en)2000-05-252002-12-17Alkermes Controlled Therapeutics, Inc. IPreparation of injectable suspensions having improved injectability
US20020197185A1 (en)2001-06-202002-12-26Jamiolkowski Dennis D.Antimicrobial coatings for medical devices
WO2003000230A1 (en)2001-06-222003-01-03Alza CorporationOsmotic implant with membrane and membrane retention means
US20030007992A1 (en)2001-06-222003-01-09Southern Biosystems, Inc.Zero-order prolonged release coaxial implants
US6506724B1 (en)1999-06-012003-01-14Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6508808B1 (en)1999-12-212003-01-21Alza CorporationValve for osmotic devices
WO2003007981A1 (en)2001-07-202003-01-30Intermune, Inc.Methods of treating liver fibrosis
US6514500B1 (en)1999-10-152003-02-04Conjuchem, Inc.Long lasting synthetic glucagon like peptide {GLP-!}
WO2003011892A2 (en)2001-07-312003-02-13The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human ServicesGlp-1 exendin-4 peptide analogs and uses thereof
US6528093B1 (en)1992-12-072003-03-04Takeda Chemical Industries, Ltd.Sustained-release preparation
US6528486B1 (en)1999-07-122003-03-04Zealand Pharma A/SPeptide agonists of GLP-1 activity
US20030045454A1 (en)2001-06-212003-03-06Franklin OkumuSustained release formulation
WO2003020245A1 (en)2001-08-312003-03-13Alkermes Controlled Therapeutics Inc. IiResidual solvent extraction method and microparticles produced thereby
WO2003024503A2 (en)2001-09-172003-03-27Durect CorporationDevice and method for accurate delivery of an active agent
US20030060425A1 (en)1998-11-242003-03-27Ahlem Clarence N.Immune modulation method using steroid compounds
US20030059376A1 (en)1999-06-042003-03-27Libbey Miles A.Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20030059471A1 (en)1997-12-152003-03-27Compton Bruce JonOral delivery formulation
WO2003024357A2 (en)2001-09-142003-03-27Martin Francis JMicrofabricated nanopore device for sustained release of therapeutic agent
US6544239B2 (en)1998-10-162003-04-08Bio-Plexus Delaware, Inc.Releasable locking needle assembly with optional release accessory therefor
US6544252B1 (en)1998-12-312003-04-08Alza CorporationOsmotic delivery system having space efficient piston
EP1300173A2 (en)1997-12-292003-04-09Alza CorporationImplanter device for subcutaneous implants
US6547250B1 (en)2000-08-212003-04-15Westport Research Inc.Seal assembly with two sealing mechanisms for providing static and dynamic sealing
WO2003030923A1 (en)2001-10-052003-04-17Intermune, Inc.Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US6551613B1 (en)1998-09-082003-04-22Alza CorporationDosage form comprising therapeutic formulation
US20030078618A1 (en)2001-10-192003-04-24Fey Kate E.System and method for removing implanted devices
WO2003041684A2 (en)2001-11-142003-05-22Alza CorporationInjectable depot compositions and uses thereof
US20030097121A1 (en)2001-10-242003-05-22Claude JollyImplantable fluid delivery apparatuses and implantable electrode
WO2003041757A2 (en)2001-11-142003-05-22Alza CorporationCatheter injectable depot compositions and uses thereof
US6569420B2 (en)1997-12-082003-05-27Genentech, Inc.Human interferon-ε: a type I interferon
US20030104063A1 (en)2001-06-222003-06-05Babcock Walter C.Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers
US20030108609A1 (en)1999-02-082003-06-12Berry Stephen A.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030108608A1 (en)2001-12-122003-06-12Erik LaridonThermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
US6579851B2 (en)2000-03-142003-06-17Amylin Pharmaceuticals, Inc.Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
EP1323450A1 (en)2001-12-182003-07-02Risdon Pharma GmbHSyringe device
WO2003053400A1 (en)2001-12-192003-07-03Alza CorporationFormulation & dosage form for the controlled delivery of therapeutic agents
US6589157B2 (en)2000-05-182003-07-08Integrated Implant Systems, L.L.C.Drive mechanism for medical instrument
US6592508B1 (en)1995-12-182003-07-15Integrated Implant Systems, LlcFiberoptic-guided interstitial seed manual applicator and seed cartridge
US20030135153A1 (en)2001-12-172003-07-17Charles HagemeierDrug implant injection device
US20030138403A1 (en)2001-06-292003-07-24Maxygen ApsInterferon formulations
US20030138491A1 (en)2000-02-102003-07-24Alkermes Controlled Therapeutics, Inc.Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2003066585A2 (en)2002-02-082003-08-14Alkermes Controlled Therapeutics, Inc.Polymer-based compositions for sustained release
US6607529B1 (en)1995-06-192003-08-19Medtronic Vidamed, Inc.Electrosurgical device
US20030157178A1 (en)2001-11-142003-08-21Guohua ChenInjectable depot composition
WO2003072113A1 (en)2002-02-282003-09-04Norbrook Laboratories LimitedLong acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
WO2003072133A2 (en)2002-02-282003-09-04Norferm DaImmunostimulatory agent comprising a biomass of methanotrophic bacterium
US6626863B1 (en)2000-11-222003-09-30Nusaf, L.L.C.Safety syringe
US20030186858A1 (en)2000-01-312003-10-02Arentsen Anne CharlotteCrystallisation of a GLP-1 analogue
US20030191099A1 (en)2001-11-272003-10-09Schering Ag17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
US6645192B2 (en)1998-09-302003-11-11Ivy Animal Health, Inc.Pellet implant system for immediate and delayed release of antiparasitic drug
US20030211974A1 (en)2000-03-212003-11-13Brodbeck Kevin J.Gel composition and methods
US20030215515A1 (en)2002-04-112003-11-20Medimmune Vaccines, Inc.Preservation of bioactive materials by spray drying
US20030220617A1 (en)2002-05-222003-11-27C. Dickerson Co.Safety needle introducer and universal needle protector for vascular access devices
US20030233101A1 (en)2002-06-172003-12-18Senorx, Inc.Plugged tip delivery tube for marker placement
US6670368B1 (en)1999-04-062003-12-30Astrazeneca AbPyrimidine compounds with pharmaceutical activity
US20040001689A1 (en)2002-06-282004-01-01Intel CorporationSystem and method for improving audio during post-production of video recordings
US20040001889A1 (en)2002-06-252004-01-01Guohua ChenShort duration depot formulations
US20040002442A1 (en)2001-10-052004-01-01Clark PanPeptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
WO2004002565A1 (en)2002-06-262004-01-08Alza CorporationMinimally compliant, volume efficient piston for osmotic drug delivery systems
US20040024069A1 (en)2002-07-312004-02-05Guohua ChenInjectable depot compositions and uses thereof
US20040022859A1 (en)2002-07-312004-02-05Guohua ChenInjectable multimodal polymer depot compositions and uses thereof
US20040024068A1 (en)1998-01-232004-02-05Trustees Of Tufts CollegeAntimicrobial compounds
US20040029784A1 (en)2002-01-222004-02-12Hathaway David R.Methods and compositions for treating polycystic ovary syndrome
US6703359B1 (en)1998-02-132004-03-09Amylin Pharmaceuticals, Inc.Inotropic and diuretic effects of exendin and GLP-1
US6703225B1 (en)1999-01-122004-03-09Sumitomo Pharmaceuticals Company, LimitedInterferon-α
US6706689B2 (en)2000-05-192004-03-16Amylin Pharmaceuticals, Inc.Treatment of acute coronary syndrome with GLP-1
WO2004026106A2 (en)2002-09-182004-04-01Allergan, Inc.Methods and apparatus for delivery of ocular implants
US6720407B1 (en)1998-08-282004-04-13Eli Lilly And CompanyMethod for administering insulinotropic peptides
WO2004034975A2 (en)2002-10-172004-04-29Alkermes Controlled Therapeutics, Inc.Sustained release profile modification
WO2004036186A2 (en)2002-10-172004-04-29Alkermes Controlled Therapeutics, Inc. IiMicroencapsulation and sustained release of biologically active polypeptides
US20040097906A1 (en)2002-06-172004-05-20Fereira Pamela J.Osmotic delivery system with early zero order push power engine
US20040102762A1 (en)2002-11-212004-05-27Gilbert Scott JayOsmotic delivery device having a two-way valve and dynamically self-adjusting flow channel
US20040101557A1 (en)1995-06-072004-05-27Gibson John W.High viscosity liquid controlled delivery system and medical or surgical device
WO2004046338A2 (en)2002-11-202004-06-03North Shore-Long Island Jewish Research InstituteUse of hmgb polypeptides for increasing immune responses
WO2004056338A2 (en)2002-12-192004-07-08Alza CorporationStable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US20040142867A1 (en)2003-01-142004-07-22Kiyomoto OiStabilized proteinic preparation
US20040142902A1 (en)2001-11-082004-07-22Struijker- Boudier Harry A.J.Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US6767887B1 (en)1996-06-052004-07-27Roche Diagnostics GmbhExendin analogues, processes for their preparation and medicaments containing them
US20040151753A1 (en)2002-11-062004-08-05Guohua ChenControlled release depot formulations
US20040199140A1 (en)2003-04-032004-10-07Rue Matthew L.Implanting device and method of using same
US20040198654A1 (en)2001-08-232004-10-07Wolfgang GlaesnerGlucagon-like peptide-1analogs
WO2004089335A2 (en)2003-03-312004-10-21Alza CorporationNon-aqueous single phase vehicles and formulations utilizing such vehicles
US20040209801A1 (en)2002-10-222004-10-21Brand Stephen J.Treatment of diabetes
US20040215133A1 (en)2002-09-182004-10-28Allergan, Inc.Apparatus for delivery of ocular implants
US20040225113A1 (en)1998-07-212004-11-11Lafleur David W.Keratinocyte derived interferon
WO2004103342A2 (en)2003-05-162004-12-02Alkermes Controlled Therapeutics, Inc.Injectable sustained release compositions
US6833256B1 (en)1999-06-222004-12-21University Of MarylandInterferon tau mutants and methods for making them
US6835194B2 (en)1999-03-182004-12-28Durect CorporationImplantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US20040265273A1 (en)1997-04-282004-12-30Hong LiAdenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US20040266683A1 (en)2002-12-172004-12-30Hathaway David RPrevention and treatment of cardiac arrhythmias
US20040266692A1 (en)1996-08-082004-12-30Young Andrew A.Exendin pharmaceutical compositions
US20050004557A1 (en)2003-06-122005-01-06Russell Scott M.Orifice device having multiple channels with varying flow rates for drug delivery
US20050010942A1 (en)2003-07-092005-01-13Samsung Electronics Co., Ltd.Optical disc drive
US20050010196A1 (en)2003-03-312005-01-13Fereira Pamela J.Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
US20050009742A1 (en)2002-11-202005-01-13Goran BertilssonCompounds and methods for increasing neurogenesis
US6849714B1 (en)1999-05-172005-02-01Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849708B1 (en)1986-05-052005-02-01The General Hospital CorporationInsulinotropic hormone and uses thereof
US20050070927A1 (en)2003-09-302005-03-31Feinberg Marc E.Tissue approximation device
US6875748B2 (en)2000-04-212005-04-05Vical IncorporatedCompositions and methods for in vivo delivery of polynucleotide-based therapeutics
US20050079200A1 (en)2003-05-162005-04-14Jorg RathenowBiocompatibly coated medical implants
US20050079202A1 (en)2003-05-302005-04-14Guohua ChenImplantable elastomeric depot compositions and uses thereof
US6887470B1 (en)1999-09-102005-05-03Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20050095284A1 (en)2003-10-312005-05-05Alza CorporationOsmotic pump with self-retaining, fast-start membrane plug
US20050101943A1 (en)2003-11-062005-05-12Alza CorporationModular imbibition rate reducer for use with implantable osmotic pump
US20050106214A1 (en)2003-11-142005-05-19Guohua ChenExcipients in drug delivery vehicles
US20050112188A1 (en)2003-11-172005-05-26Eliaz Rom E.Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US6899898B2 (en)2000-12-212005-05-31Nektar TherapeuticsInduced phase transition method for the production of microparticles containing hydrophobic active agents
WO2005048930A2 (en)2003-11-142005-06-02Alza CorporationSurfactant-based gel as an injectable, sustained drug delivery vehicle
US6902744B1 (en)1999-01-142005-06-07Amylin Pharmaceuticals, Inc.Exendin agonist formulations and methods of administration thereof
US6903186B1 (en)1998-12-072005-06-07Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.SAnalogues of GLP-1
US20050131386A1 (en)2003-12-152005-06-16Freeman Lynetta J.Method and device for minimally invasive implantation of biomaterial
US20050143749A1 (en)2003-12-312005-06-30Depuy Spine, Inc.Inserter instrument and implant clip
US6913767B1 (en)1993-10-252005-07-05Genentech, Inc.Compositions for microencapsulation of antigens for use as vaccines
US6924264B1 (en)1999-04-302005-08-02Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonists
US20050175701A1 (en)2004-02-102005-08-11Alza CorporationCapillary moderator for osmotic delivery system
US20050216087A1 (en)2004-01-052005-09-29St. Francis Medical Technologies, Inc.Disk repair structures for positioning disk repair material
US20050215475A1 (en)2003-05-302005-09-29John OngTransmucosal delivery of peptides and proteins
US6960192B1 (en)2002-04-232005-11-01Insulet CorporationTranscutaneous fluid delivery system
WO2005102293A1 (en)2004-04-152005-11-03Amylin Pharmaceuticals, Inc.Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
WO2005110425A1 (en)2004-04-152005-11-24Alkermes, Inc.Polymer-based sustained release device
US20050266087A1 (en)2004-05-252005-12-01Gunjan JunnarkarFormulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20050281879A1 (en)2003-11-142005-12-22Guohua ChenExcipients in drug delivery vehicles
US20060014678A1 (en)2002-06-282006-01-19Imperial College Innovations Ltd.Modification of feeding behavior
US20060030526A1 (en)2004-08-052006-02-09Kui LiuStable suspension formulations of erythropoietin receptor agonists
WO2006023526A2 (en)2004-08-182006-03-02Waters Investments LimitedDefined leak path for high pressure seal
US7008439B1 (en)1990-09-212006-03-07Datascope Investments Corp.Device and method for sealing puncture wounds
US20060069029A1 (en)1999-01-142006-03-30Kolterman Orville GExendin analog formulations
US7022674B2 (en)1999-12-162006-04-04Eli Lilly And CompanyPolypeptide compositions with improved stability
US20060073182A1 (en)2004-10-012006-04-06Wong Vernon GConveniently implantable sustained release drug compositions
US20060084604A1 (en)2004-10-192006-04-20Chieko KitauraTransepithelial delivery of peptides with incretin hormone activities
US20060084922A1 (en)2002-09-042006-04-20Ruark BothaDevice for securing a blood vessel cannula to a body
US20060094693A1 (en)2004-09-212006-05-04Point Therapeutics, Inc.Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
US20060094652A1 (en)2004-02-112006-05-04Levy Odile EHybrid polypeptides with selectable properties
US20060106399A1 (en)2004-11-182006-05-18Taras John SDrill guide tissue protector
US20060141040A1 (en)2004-12-232006-06-29Guohua ChenInjectable non-aqueous suspension
US20060142234A1 (en)2004-12-232006-06-29Guohua ChenInjectable non-aqueous suspension
US20060160736A1 (en)2004-12-302006-07-20Diakine Therapeutics, Inc.Pharmaceutical compositions and methods for restoring beta-cell mass and function
WO2006077250A1 (en)2005-01-242006-07-27N.V. OrganonApplicator for inserting an implant
WO2006077242A1 (en)2005-01-242006-07-27N.V. OrganonApplicator for inserting an implant
US7084243B2 (en)2000-06-162006-08-01Eli Lilly And CompanyGlucagon-like peptide-1 analogs
WO2006081279A2 (en)2005-01-252006-08-03Microchips, Inc.Control of drug release by transient modification of local microenvironments
WO2006083761A2 (en)2005-02-032006-08-10Alza CorporationSolvent/polymer solutions as suspension vehicles
WO2006084139A2 (en)2005-02-032006-08-10Intarcia Therapeutics, Inc.An implantable interferon-containing device
US20060178304A1 (en)2003-06-032006-08-10Novo Nordisk A/SStabilized pharmaceutical peptide compositions
JP2006213727A (en)1993-04-072006-08-17Scios IncSustained release of peptide
WO2006086727A2 (en)2005-02-092006-08-17Entelos, Inc.Treating diabetes with glucagon-like peptide-1 secretagogues
WO2006101815A2 (en)2005-03-152006-09-28Alza CorporationPharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems
US20060216242A1 (en)2005-02-032006-09-28Rohloff Catherine MSuspending vehicles and pharmaceutical suspensions for drug dosage forms
US20060233841A1 (en)1999-06-042006-10-19Brodbeck Kevin JImplantable gel compositions and method of manufacture
WO2006111169A1 (en)2005-04-212006-10-26Gastrotech Pharma A/SPharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US7138486B2 (en)1986-05-052006-11-21The General Hospital CorporationInsulinotropic hormone derivatives and uses thereof
US20060264890A1 (en)2005-05-062006-11-23Medtronic Minimed, Inc.Needle inserter and method for infusion device
US7141547B2 (en)2001-12-212006-11-28Human Genome Sciences, Inc.Albumin fusion proteins comprising GLP-1 polypeptides
US7144863B2 (en)2001-06-012006-12-05Eli Lilly And CompanyGLP-1 formulations with protracted time action
US20060280795A1 (en)2005-06-082006-12-14Dexcel Pharma Technologies, Ltd.Specific time-delayed burst profile delivery system
WO2006131730A1 (en)2005-06-062006-12-14Camurus AbGlp-1 analogue formulations
US20060293232A1 (en)2004-02-112006-12-28Amylin Pharmaceuticals, Inc.Hybrid polypeptides with selectable properties
US7157555B1 (en)1997-08-082007-01-02Amylin Pharmaceuticals, Inc.Exendin agonist compounds
US7163697B2 (en)2001-06-222007-01-16Johns Hopkins University School Of MedicineBiodegradable polymer compositions, compositions and uses related thereto
US20070027105A1 (en)2005-07-262007-02-01Alza CorporationPeroxide removal from drug delivery vehicle
WO2007024700A2 (en)2005-08-192007-03-01Amylin Pharmaceuticals, Inc.Exendin for treating diabetes and reducing body weight
US7199217B2 (en)2000-12-132007-04-03Eli Lilly And CompanyAmidated glucagon-like peptide-1
US7205409B2 (en)2003-09-042007-04-17Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7207982B2 (en)2003-03-312007-04-24Alza CorporationOsmotic pump with means for dissipating internal pressure
WO2007056681A2 (en)2005-11-042007-05-18Smithkline Beecham CorporationMethods for administering hypoglycemic agents
US20070141102A1 (en)2004-03-242007-06-21N.V. OrganonDrug delivery system based on polyethylene vinylacetate copolymers
US20070149011A1 (en)2003-02-182007-06-28Medconx, Inc.Male medical device electrical connector with engineered friction fit
WO2007075534A2 (en)2005-12-162007-07-05Nektar Therapeutics Al, CorporationPolymer conjugates of glp-1
US7241457B2 (en)2003-09-302007-07-10Alza CorporationOsmotically driven active agent delivery device providing an ascending release profile
WO2007084460A2 (en)2006-01-182007-07-26Qps, LlcPharmaceutical compositions with enhanced stability
WO2007082889A1 (en)2006-01-192007-07-26N.V. OrganonKit for and method of assembling an applicator for inserting an implant
US20070207958A1 (en)2005-11-092007-09-06Bridon Dominique PMethod of treatment of diabetes and/or obesity with reduced nausea side effect
US20070248572A1 (en)2001-11-092007-10-25Intarica Therapeutics, Inc.Method for treating diseases with omega interferon
WO2007133778A2 (en)2006-05-122007-11-22Amylin Pharmaceuticals, Inc.Methods to restore glycemic control
US20070281024A1 (en)2005-02-032007-12-06Alza CorporationTwo-Piece, Internal-Channel Osmotic Delivery System Flow Modulator
US20080020016A1 (en)2006-07-112008-01-24Quest Pharmaceutical Services, LlcPharmaceutical compositions for sustained release delivery of peptides
US20080038316A1 (en)2004-10-012008-02-14Wong Vernon GConveniently implantable sustained release drug compositions
WO2008021133A2 (en)2006-08-092008-02-21Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies
US20080064636A1 (en)2003-01-102008-03-13Imperial College Innovations LimitedModification of Feeding Behaviour
US20080065090A1 (en)1998-08-142008-03-13Scribner Robert MMethods and apparatus for placing materials into bone
USD565179S1 (en)*2005-06-162008-03-25Pentax CorporationBone implant
WO2008041245A2 (en)2006-10-052008-04-10Panacea Biotec Ltd.Injectable depot composition and it's process of preparation
WO2008061355A1 (en)2006-11-242008-05-29Matregen Corp.Glp-1 depot systems, and methods of manufacture and uses thereof
WO2008086086A2 (en)2007-01-052008-07-17Indiana University Research And Technology CorporationGlucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20080200383A1 (en)2005-04-082008-08-21Amylin Pharmaceuticals, Inc.Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US20080207512A1 (en)2004-11-012008-08-28Amylin Pharmaceuticals, Inc.Methods for Treating Obesity and Obesity Related and Disorders
US20080226689A1 (en)1999-02-082008-09-18Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20080260840A1 (en)2005-02-032008-10-23Alessi Thomas RSuspension formulations of insulinotropic peptides and uses thereof
US20080260838A1 (en)2003-08-012008-10-23Mannkind CorporationGlucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20080269725A1 (en)2005-07-222008-10-30Trent DeemOsmotically Driven Dispense Pump and Related Components for Use in High Pressure Applications
WO2008134425A1 (en)2007-04-272008-11-06Cedars-Sinai Medical CenterUse of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US7459432B2 (en)2001-09-242008-12-02Imperial College Innovations Ltd.Modification of feeding behavior
US20080312157A1 (en)2005-02-112008-12-18Amylin Pharmaceuticals, Inc.Gip analog and hybrid polypeptides with selectable properties
US20090022727A1 (en)2007-01-262009-01-22Alza Corp.Injectable, nonaqueous suspension with high concentration of therapeutic agent
US20090036364A1 (en)2005-02-112009-02-05Amylin Pharmaceuticals, Inc.Gip analog and hybrid polypeptides with selectable properties
US20090042781A1 (en)2004-06-282009-02-12Novo Nordisk A/SMethods for Treating Diabetes
US20090074734A1 (en)2006-05-022009-03-19Actogenix N.V.Microbial intestinal delivery of obesity related peptides
US20090156474A1 (en)2004-11-012009-06-18Amylin Pharmaceuticals, Inc.Methods for treating obesity and obesity related diseases and disorders
US20090163447A1 (en)2004-08-252009-06-25Maggio Edward TCompositions for Drug Administration
US20090186817A1 (en)2006-03-212009-07-23Amylin Pharmaceuticals, Inc.Peptide-peptidase inhibitor conjugates and methods of using same
US20090202608A1 (en)2008-02-132009-08-13Alessi Thomas RDevices, formulations, and methods for delivery of multiple beneficial agents
US20090202481A1 (en)2008-02-082009-08-13Qps LlcComposition for Sustained Release Delivery of Proteins or Peptides
US20090210019A1 (en)2008-02-142009-08-20Dennis Dong-Won KimTreatment of excess weight by neural downregulation in combination with compositions
US20090209460A1 (en)2005-12-162009-08-20Amylin Pharmaceuticals, Inc.Compositions and methods for treating obesity and related metabolic disorders
WO2009109927A2 (en)2008-03-052009-09-11Tel Hashomer Medical Research Infrastructure And Services Ltd.Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
US7589169B2 (en)2002-02-272009-09-15Pharmain CorporationCompositions for treatment with glucagon-like peptide, and methods of making and using the same
US20090254143A1 (en)2008-04-042009-10-08Tweden Katherine SMethods and systems for glucose regulation
US7604647B2 (en)2004-10-222009-10-20Medical Instrument Development Laboratories, Inc.Ophthalmic cannula insertion tool and method
US20090286723A1 (en)2005-02-112009-11-19Amylin Pharmaceuticals, Inc.Hybrid Polypeptides with Selectable Properties
WO2009143285A2 (en)2008-05-212009-11-26Amylin Pharmaceuticals, Inc.Exendins to lower cholestrol and triglycerides
US7632256B2 (en)2006-10-242009-12-15Mosler Theodore JCatheter gripping device
US20090312246A1 (en)2005-08-192009-12-17Amylin Pharmaceuticals, Inc.Uses of Glucoregulatory Proteins
US7635463B2 (en)2002-02-272009-12-22Pharmain CorporationCompositions for delivery of therapeutics and other materials
US7666835B2 (en)2001-09-072010-02-23Imperial Innovations LimitedOxyntomodulin for preventing or treating excess weight
US20100094252A1 (en)2008-10-142010-04-15Medtronic, Inc.Subcutaneous delivery tool
US20100092566A1 (en)2008-10-152010-04-15Alessi Thomas RHighly concentrated drug particles, formulations, suspensions and uses thereof
US20100105627A1 (en)2008-09-172010-04-29Paul SalamaPharmaceutical compositions and related methods of delivery
US20100144621A1 (en)2006-08-042010-06-10Dennis KimUse of Exendins and Exendin Agonists and GLP-1 Receptor Agonists for Altering the Concentration of Fibrinogen
US7736665B2 (en)2002-05-312010-06-15Titan Pharmaceuticals, Inc.Implantable polymeric device for sustained release of buprenorphine
US7766924B1 (en)1999-07-282010-08-03Cardica, Inc.System for performing anastomosis
US7790140B2 (en)2002-02-272010-09-07Pharmain CorporationCompositions for delivery of therapeutics and other materials, and methods of making and using the same
US20100298840A1 (en)2009-05-222010-11-25Schwartz Lyman DPhimosis Treatment Device and Method
US20100331868A1 (en)2000-08-242010-12-30Bardy Gust HMethod For Constructing An Instrument With A Two-Part Plunger For Subcutaneous Implantation
US7879794B2 (en)2005-03-312011-02-01Amylin Pharmaceuticals, Inc.Methods for controlling binge eating disorders
US20110076317A1 (en)2009-09-282011-03-31Alessi Thomas RRapid establishment and/or termination of substantial steady-state drug delivery
US20110091527A1 (en)2008-04-012011-04-21Mosamedix B.V.Compositions and methods for reducing scar formation in wound healing
US20110152182A1 (en)2009-12-222011-06-23Eli Lilly And CompanyOxyntomodulin peptide analogue
US20110152181A1 (en)2009-12-222011-06-23Eli Lilly And CompanyOxyntomodulin peptide analogue
US20110306549A1 (en)2010-06-092011-12-15Amylin Pharmaceuticals, Inc.Glp-1 receptor agonists to treat pancreatitis
US8101576B2 (en)2006-12-132012-01-24Imperial Innovations LimitedCompounds and their effects on feeding behaviour
US8202836B2 (en)2005-03-092012-06-19Imperial Innovations LimitedModified PYY (3-36) peptides and their effects on feeding behavior
US20120208755A1 (en)2011-02-162012-08-16Intarcia Therapeutics, Inc.Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8262667B1 (en)2007-02-232012-09-11Holmed CorporationMulti-diameter implant forceps
US8263736B2 (en)2006-07-032012-09-11Imperial Innovations LimitedCompounds and their effects on feeding behaviour
US20120303045A1 (en)2011-05-262012-11-29Derm Instruments & Innovations LlcSkin removal instrument
WO2013004983A1 (en)2011-07-042013-01-10Imperial Innovations LimitedNovel compounds and their effects on feeding behaviour
US8454552B2 (en)2000-08-242013-06-04Cardiac Science CorporationMethod for constructing an instrument with a covered bore for subcutaneous implantation
GB2501400A (en)2012-04-192013-10-23Removaid AsTool for removing a subcutaneous implant
US20130296661A1 (en)2012-05-042013-11-07Pacesetter, Inc.System and method for implanting a physiologic sensor assembly
US20130324977A1 (en)2012-06-042013-12-05Medtronic, Inc.Transcutaneous implant tools, systems and methods
US20140058425A1 (en)2012-08-272014-02-27Amir PoratManually operated surgical devices with operative portions formed of a see-through material
US20140121741A1 (en)1998-06-032014-05-01Spr Therapeutics, LlcSystems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
US8722037B2 (en)2004-03-192014-05-13Meck Sharp & Dohme B.V.X-ray visible drug delivery device
US8747412B2 (en)2011-02-142014-06-10Imds CorporationSystem and method for bone anchor removal
US20140236162A1 (en)2013-02-192014-08-21Mark BaronganApparatus for Removing Devices Implanted in the Body
US8815802B2 (en)2009-12-162014-08-26Novo Nordisk A/SGLP-1 analogues and derivatives
US20140257272A1 (en)2009-08-072014-09-11Ulthera, Inc.Handpiece and methods for performing subcutaneous surgery
US20140324067A1 (en)2013-01-092014-10-30Senseonics, IncorporatedSubcutaneous tunneling and implantation tools for a disk-shaped sensor
US20150001118A1 (en)2011-09-162015-01-01Golden Aluminum, Inc.Application of designs to portion of food container
US20150133791A1 (en)2012-05-292015-05-14National University Corporation Kochi UniversityArtery visualization device and artery imaging device
US9044209B2 (en)2000-04-142015-06-02Attenuex Technologies, Inc.Method of removing an inflated implant
US9078900B2 (en)2008-09-302015-07-14Braeburn Pharmaceuticals Bvba SprlImplantable device for the delivery of risperidone and methods of use thereof
US20150297509A1 (en)2012-11-192015-10-22Braeburn Pharmaceuticals Bvba SprlImplantable drug delivery compositions and methods of treatment thereof
US20150359553A1 (en)2014-06-162015-12-17Med-El Elektromedizinische Geraete GmbhImplant magnet insertion and removal tools
US20160354115A1 (en)*2015-06-032016-12-08Intarcia Therapeutics, Inc.Implant placement and removal systems
USD789539S1 (en)*2015-07-092017-06-13Spinal Surgical Strategies, LlcFusion cage
US20180009871A1 (en)2016-05-162018-01-11Intarcia Therapeutics Inc.Glucagon-receptor selective polypeptides and methods of use thereof
US9889085B1 (en)2014-09-302018-02-13Intarcia Therapeutics, Inc.Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
USD816843S1 (en)*2017-06-072018-05-01Alevio, LlcOrthopedic implant
USD835783S1 (en)*2016-06-022018-12-11Intarcia Therapeutics, Inc.Implant placement guide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2531724A (en)*1948-09-201950-11-28Edmund D CevascoInfant bath mat
US3523296A (en)1967-04-251970-08-04Hellige & Co Gmbh FPortable antenna
JPS523653A (en)1975-06-271977-01-12Fuji Photo Film Co LtdProcess for producing fine polymer particles
USD258837S (en)*1977-10-171981-04-07Gambro Dialysatoren Gmbh And Co. KgDialyzer cartridge
USD259458S (en)*1978-06-091981-06-09Fuller Charles RSupport pad for an infant
US4444498A (en)*1981-02-271984-04-24Bentley LaboratoriesApparatus and method for measuring blood oxygen saturation
USD271990S (en)*1981-09-171983-12-27Arthur W. PulferBaby bath
US4737437A (en)1986-03-271988-04-12East Shore Chemical Co.Light sensitive diazo compound, composition and method of making the composition
USD326718S (en)*1989-12-261992-06-02Minnesota Mining And Manufacturing Co.Blood sensor cassette
US5126147A (en)1990-02-081992-06-30Biosearch, Inc.Sustained release dosage form
USD329278S (en)*1990-10-011992-09-08Gallup Allen IInfant's bathing support
US5276926A (en)*1992-08-041994-01-11Raquel LopezBaby bath and seat
USD342855S (en)*1992-11-201994-01-04Butler Ii George DCombined infant cushion and cover
FR2703501B1 (en)1993-04-011995-05-19Gemplus Card Int Integrated circuit for memory card and method for counting units in a memory card.
USD358644S (en)*1994-01-181995-05-23Bio Medic Data Systems, Inc.Transponder implanter
FI942686A0 (en)1994-06-071994-06-07Alko Ab Oy Composition of the starch acetate with a variety of compounds, for the production and distribution
IL113100A0 (en)*1995-03-231995-06-29Schatz AnatInfant's mattress
US6023802A (en)*1997-09-102000-02-15King; Susan MeltonInfant sleeper
USD399821S (en)*1997-11-071998-10-20Motorola, Inc.Front section of a battery charger
USD408917S (en)*1998-02-261999-04-27Minnesota Mining And Manufacturing CompanyMembrane support structure of a flow through cell for blood gas measurement
JP3405201B2 (en)1998-06-172003-05-12住友電装株式会社 Manufacturing method of equipment connector
USD415073S (en)*1998-08-171999-10-12ScooterBug, Inc.Stroller
USD445975S1 (en)*1999-08-272001-07-31Black & Decker, Inc.Base unit for a hand held vacuum cleaner
USD472896S1 (en)*2000-12-232003-04-08Andreas PeikerTelephone support
USD456776S1 (en)*2001-01-232002-05-07Datex - Ohmeda, Inc.Snap sensor connector
USD587374S1 (en)*2005-01-142009-02-24Edwards Lifesciences CorporationSensor case
US8845726B2 (en)*2006-10-182014-09-30Vertiflex, Inc.Dilator
USD555589S1 (en)*2007-01-232007-11-20Intec, Inc.Battery charger and game controller cradle
US20080208194A1 (en)*2007-02-132008-08-28Christine BickenbachDouble cut shaver
WO2008131440A1 (en)*2007-04-232008-10-30Sid Technologies, LlcMethods and devices for intradermal injection
US20090234392A1 (en)*2008-03-132009-09-17Depuy Spine, Inc.Method for inserting a spinal fixation element using implants having guide tabs
USD638478S1 (en)*2009-07-062011-05-24Performance Designed Products LlcVideo game controller accessory
US20110022165A1 (en)*2009-07-232011-01-27Edwards Lifesciences CorporationIntroducer for prosthetic heart valve
USD791318S1 (en)*2009-09-142017-07-04Bayer OyInserter
IT1396771B1 (en)*2009-10-232012-12-14Surbone GUIDE TUBE FOR A TATTOO MACHINE NEEDLES
USD669589S1 (en)*2010-08-312012-10-23Koninklijke Philips Electronics N.V.Blood system cartridge
TWD149032S (en)*2011-10-042012-09-01虹光精密工業股份有限公司Docking for handheld scanner
USD737972S1 (en)*2012-06-212015-09-01Michael ChenTattoo tube grip
US9332995B2 (en)*2012-09-252016-05-10Russo Inventions, LlcBone-harvesting tool
US9241722B2 (en)*2012-10-082016-01-26Warsaw Orthopedic, Inc.Surgical pin guide and methods of use
US9452273B2 (en)*2012-11-282016-09-27Richard M. LevitanSurgical device for cricothyrotomy and the like
USD731630S1 (en)*2014-04-082015-06-09Bootz Manufacturing CompanyShower pan
USD724740S1 (en)*2014-06-052015-03-17Deka Products Limited PartnershipEnclosure for a peritoneal dialysis device
USD825761S1 (en)*2015-04-242018-08-14Otto Bock Healthcare Products GmbhPart of prosthesis
USD789540S1 (en)*2016-01-292017-06-13Veterinary Implants Direct, Llc.Orthopedic plate
US9931133B2 (en)*2016-03-242018-04-03A.M. Surgical, Inc.Compact endoscopic surgical device and method of use thereof
US20180193059A1 (en)*2017-01-102018-07-12Electronics And Telecommunications Research InstituteAutomatic hair follicle transplant apparatus

Patent Citations (1033)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE635692C (en)1936-09-22Herbert Zadow Medical syringe
US1655158A (en)1926-09-081928-01-03Radium Emanation CorpInstrument for implanting radon seeds
FR640907A (en)1927-06-251928-07-24 Automatic flow limiter
US2168437A (en)1935-04-101939-08-08Kenneth O BuercklinInjection device
US2110208A (en)1937-02-121938-03-08U S Standard Products CompanyAntigen preparations
US2643653A (en)1951-07-191953-06-30Heidrich JohnPill injector
US3016895A (en)1958-08-011962-01-16Pan American Lab IncInjector for subcutaneous implantation of solids
US3025991A (en)1960-05-231962-03-20Carron Products CoBottle stopper
US3523906A (en)1962-07-111970-08-11Gevaert Photo Prod NvProcess for encapsulating water and compounds in aqueous phase by evaporation
GB1049104A (en)1963-05-111966-11-23Prodotti Antibiotici SpaPharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3122162A (en)1963-06-201964-02-25Asa D SandsFlow control device
US3538916A (en)1968-12-191970-11-10Joseph S WilesInjection pistol
US3691090A (en)1969-01-161972-09-12Fuji Photo Film Co LtdEncapsulation method
US3620216A (en)1969-06-251971-11-16Abbott LabImplant trocar
US3632768A (en)1969-10-021972-01-04Upjohn CoTherapeutic composition and method for treating infections with actinospectacin
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
US3737337A (en)1970-03-041973-06-05Bayer AgProcess for the production of microgranulates
US3625214A (en)1970-05-181971-12-07Alza CorpDrug-delivery device
US3669104A (en)1970-06-151972-06-13PfizerImplant gun
US3732865A (en)1971-01-131973-05-15Alza CorpOsmotic dispenser
US4034756A (en)1971-01-131977-07-12Alza CorporationOsmotically driven fluid dispenser
US3995631A (en)1971-01-131976-12-07Alza CorporationOsmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4211771A (en)1971-06-011980-07-08Robins Ronald KTreatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3766915A (en)1971-12-211973-10-23Illinois Tool WorksPlastic needle holder
US3891570A (en)1972-01-261975-06-24Toyo Jozo KkProcess for preparing microcapsules
US3869549A (en)1972-02-171975-03-04Ciba Geigy CorpInjectable oily peptide preparations and processes for their manufacture
US3797492A (en)1972-12-271974-03-19Alza CorpDevice for dispensing product with directional guidance member
US3995632A (en)1973-05-041976-12-07Alza CorporationOsmotic dispenser
US3960757A (en)1973-06-271976-06-01Toyo Jozo Co., Ltd.Process for encapsulation of medicaments
GB1518683A (en)1974-07-051978-07-19Sandoz LtdPharmaceutical compositions
US3987790A (en)1975-10-011976-10-26Alza CorporationOsmotically driven fluid dispenser
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4078060A (en)1976-05-101978-03-07Richardson-Merrell Inc.Method of inducing an estrogenic response
US4111202A (en)1976-11-221978-09-05Alza CorporationOsmotic system for the controlled and delivery of agent over time
US4111201A (en)1976-11-221978-09-05Alza CorporationOsmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111203A (en)1976-11-221978-09-05Alza CorporationOsmotic system with means for improving delivery kinetics of system
US4203439A (en)1976-11-221980-05-20Alza CorporationOsmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4105030A (en)1977-01-031978-08-08Syntex (U.S.A.) Inc.Implant apparatus
US4223674A (en)1978-06-291980-09-23Arthur J. McIntoshImplant gun
US4243030A (en)1978-08-181981-01-06Massachusetts Institute Of TechnologyImplantable programmed microinfusion apparatus
US4221882A (en)1979-01-311980-09-09Exxon Research & Engineering Co.High impact melt-flowable dual continuum melt mixed polymer blends of polypropylene, polyethylene, and ethylene-propylene rubber
US4305927A (en)1979-02-051981-12-15Alza CorporationMethod for the management of intraocular pressure
US4373527A (en)1979-04-271983-02-15The Johns Hopkins UniversityImplantable, programmable medication infusion system
US4373527B1 (en)1979-04-271995-06-27Univ Johns HopkinsImplantable programmable medication infusion system
US4310516A (en)1980-02-011982-01-12Block Drug Company Inc.Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4384975A (en)1980-06-131983-05-24Sandoz, Inc.Process for preparation of microspheres
EP0079405A1 (en)1980-07-231983-05-25Corless, MarionApparatus for improving blood sugar control in diabetics
US4350271A (en)1980-08-221982-09-21Alza CorporationWater absorbing fluid dispenser
US4376118A (en)1980-10-061983-03-08Miles Laboratories, Inc.Stable nonaqueous solution of tetracycline salt
US4389330A (en)1980-10-061983-06-21Stolle Research And Development CorporationMicroencapsulation process
US4451253A (en)1980-12-181984-05-29Harman Sherman MMeans and method for administering medicinals
US4340054A (en)1980-12-291982-07-20Alza CorporationDispenser for delivering fluids and solids
US4455145A (en)1981-07-101984-06-19Alza CorporationDispensing device with internal drive
US4474572A (en)1981-09-291984-10-02Syntex (U.S.A.) Inc.Implanting device and implant magazine
US4882166A (en)1981-09-301989-11-21National Research Development CorporationCompositions comprising encapsulated particles and their preparation
US4762791A (en)1981-10-191988-08-09Genentech, Inc.Human immune interferon
US4929554A (en)1981-10-191990-05-29Goeddel David VHuman immune interferon
US4727138A (en)1981-10-191988-02-23Genentech, Inc.Human immune interferon
US4588614A (en)1981-10-201986-05-13Adnovum AgPseudoplastic gel transfer
US4675184A (en)1981-11-281987-06-23501 Sunstar Kabushiki KaishaPharmaceutical composition containing interferon in stable state
US5004689A (en)1982-02-221991-04-02Biogen, MassachusettsDNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4439196A (en)1982-03-181984-03-27Merck & Co., Inc.Osmotic drug delivery system
US4455143A (en)1982-03-221984-06-19Alza CorporationOsmotic device for dispensing two different medications
US4897471A (en)1982-05-061990-01-30AmgenConsensus human leukocyte interferon
US4695623A (en)1982-05-061987-09-22AmgenConsensus human leukocyte interferon
US4820638A (en)1982-05-281989-04-11Dr. Karl Thomae GmbhNovel alpha interferon species produced by recombinant means
US4530840A (en)1982-07-291985-07-23The Stolle Research And Development CorporationInjectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4753651A (en)1982-08-301988-06-28Alza CorporationSelf-driven pump
US5795779A (en)1982-11-011998-08-18Berlex Laboratories, Inc.Human interferon-β (IFN-β) produced in Chinese hamster ovary (CHO) cells
US4552561A (en)1982-12-231985-11-12Alza CorporationBody mounted pump housing and pump assembly employing the same
US4673405A (en)1983-03-041987-06-16Alza CorporationOsmotic system with instant drug availability
GB2138298B (en)1983-04-211986-11-05Hundon Forge LtdPellet implanter
US4597753A (en)1983-04-211986-07-01Hundon Forge LimitedImplanting method and device
US4639244A (en)1983-05-031987-01-27Nabil I. RizkImplantable electrophoretic pump for ionic drugs and associated methods
US4765989A (en)1983-05-111988-08-23Alza CorporationOsmotic device for administering certain drugs
US4783337A (en)1983-05-111988-11-08Alza CorporationOsmotic system comprising plurality of members for dispensing drug
US4873080A (en)1983-06-081989-10-10Dr. Karl Thomae GmbhOral anti-diabetic pharmaceutical compositions and the preparation thereof
US4743449A (en)1983-09-121988-05-10Fujisawa Pharmaceutical Co., Ltd.Drug-containing lipid vesicle preparation and method for preparing them
US4594108A (en)1983-09-191986-06-10The Dow Chemical CompanyHighly pseudoplastic polymer solutions
US5385738A (en)1983-10-141995-01-31Sumitomo Pharmaceuticals Company, Ltd.Sustained-release injection
US5767251A (en)1983-11-021998-06-16Genzyme CorporationRecombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
US4923805A (en)1983-11-021990-05-08Integrated Genetics, Inc.Fsh
US5639640A (en)1983-11-021997-06-17Genzyme CorporationDNA encoding the beta subunit of human follide stimulating hormone and expression vectors and cells containing same
US4840896A (en)1983-11-021989-06-20Integrated Genetics, Inc.Heteropolymeric protein
US5690925A (en)1983-12-161997-11-25Genentech, Inc.Recombinant gamma interferons having enhanced stability and methods therefor
US5574137A (en)1983-12-161996-11-12Genentech, Inc.Recombinant gamma interferons having enhanced stability and methods therefor
US4851228A (en)1984-06-201989-07-25Merck & Co., Inc.Multiparticulate controlled porosity osmotic
US5231176A (en)1984-08-271993-07-27Genentech, Inc.Distinct family DNA encoding of human leukocyte interferons
US5120832A (en)1984-08-271992-06-09Genentech, Inc.Distinct family of human leukocyte interferons
US4927687A (en)1984-10-011990-05-22Biotek, Inc.Sustained release transdermal drug delivery composition
US5411951A (en)1984-10-041995-05-02Monsanto CompanyProlonged release of biologically active somatotropin
US4940588A (en)1984-10-301990-07-10Elan CorporationControlled release powder and process for its preparation
US4952402A (en)1984-10-301990-08-28Elan Corporation, P.L.C.Controlled release powder and process for its preparation
US5605688A (en)1984-12-181997-02-25Boehringer Ingelheim International GmbhRecombinant dog and horse type I interferons
US4655462A (en)1985-01-071987-04-07Peter J. BalsellsCanted coiled spring and seal
EP0521586A1 (en)1985-01-301993-01-07Applied Research Systems ARS Holding N.V.FSH and other recombinant hormones
US4820267A (en)1985-02-191989-04-11Endocon, Inc.Cartridge injector for pellet medicaments
US4734284A (en)1985-02-191988-03-29Nippon Kayaku Kabushiki KaishaEtoposide preparations
US4609374A (en)1985-04-221986-09-02Alza CorporationOsmotic device comprising means for governing initial time of agent release therefrom
US4885166A (en)1985-06-111989-12-05Ciba-Geigy CorporationHybrid interferons
US4845196A (en)1985-06-241989-07-04G. D. Searle & Co.Modified interferon gammas
US4847079A (en)1985-07-291989-07-11Schering CorporationBiologically stable interferon compositions comprising thimerosal
US4818517A (en)1986-01-241989-04-04Akzo N.V.Pharmaceutical preparation for obtaining a highly viscose hydrogel or suspension
US4917887A (en)1986-03-101990-04-17Boehringer Ingelheim International GmbhHybrid interferons, their use as pharmaceutical compositions and as intermediate products for the preparation of antibodies and the use thereof and processes for preparing them
US4787437A (en)1986-03-141988-11-29Stopinc AktiengesellschaftMethod for starting a continuous casting plant
US4865845A (en)1986-03-211989-09-12Alza CorporationRelease rate adjustment of osmotic or diffusional delivery devices
US5614492A (en)1986-05-051997-03-25The General Hospital CorporationInsulinotropic hormone GLP-1 (7-36) and uses thereof
US5958909A (en)1986-05-051999-09-28The General Hospital CorporationInsulinotropic hormones and uses thereof
US5118666A (en)1986-05-051992-06-02The General Hospital CorporationInsulinotropic hormone
US7138486B2 (en)1986-05-052006-11-21The General Hospital CorporationInsulinotropic hormone derivatives and uses thereof
US5120712A (en)1986-05-051992-06-09The General Hospital CorporationInsulinotropic hormone
US6849708B1 (en)1986-05-052005-02-01The General Hospital CorporationInsulinotropic hormone and uses thereof
EP0254394A1 (en)1986-06-161988-01-27Alza CorporationDosage form for delivering a drug comprising solubility regulating member
US5071642A (en)1986-10-231991-12-10Dr. Rentschler Arzneimittel Gmbh & Co.Dihydropyridine containing compositions
US6372218B1 (en)1986-11-062002-04-16The Texas A&M University SystemInterferon dosage form and method therefor
US5019382A (en)1986-11-061991-05-28The Texas A&M University SystemTreatment of immuno-resistant disease with low-dose interferon
US5602010A (en)1986-12-101997-02-11Boehringer Ingelheim International GmbhDNA encoding equine-gamma interferon and recombinant production of equine IFN-γ polypeptides
US4871094A (en)1986-12-311989-10-03Alcon Laboratories, Inc.Means and method for dispensing substances
US5371089A (en)1987-02-261994-12-06Senetek, PlcMethod and composition for ameliorating the adverse effects of aging
FR2616665A2 (en)1987-03-161988-12-23Denance RaymondStabiliser adaptor for hypodermic needle, for adjusting penetration as a function of the angle of attack, formed from a needle guard
US4994028A (en)1987-03-181991-02-19Endocon, Inc.Injector for inplanting multiple pellet medicaments
US4834708A (en)1987-03-311989-05-30George PillariPuncture needle assembly
US5278151A (en)1987-04-021994-01-11Ocular Research Of Boston, Inc.Dry eye treatment solution
EP0295411A1 (en)1987-05-151988-12-21Sansho Co., Ltd.Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof
US4940465A (en)1987-05-271990-07-10Felix TheeuwesDispenser comprising displaceable matrix with solid state properties
US4892778A (en)1987-05-271990-01-09Alza CorporationJuxtaposed laminated arrangement
US4874388A (en)1987-06-251989-10-17Alza CorporationMulti-layer delivery system
US5023088A (en)1987-06-251991-06-11Alza CorporationMulti-unit delivery system
US5938654A (en)1987-06-251999-08-17Alza CorporationOsmotic device for delayed delivery of agent
US4915949A (en)1987-07-131990-04-10Alza CorporationDispenser with movable matrix comprising a plurality of tiny pills
US4957119A (en)1987-08-081990-09-18Akzo N.V.Contraceptive implant
EP0304107A1 (en)1987-08-181989-02-22Akzo N.V.Implant injection device
US4915954A (en)1987-09-031990-04-10Alza CorporationDosage form for delivering a drug at two different rates
US5756450A (en)1987-09-151998-05-26Novartis CorporationWater soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4886668A (en)1987-09-241989-12-12Merck & Co., Inc.Multiparticulate controlled porosity osmotic pump
US5204108A (en)1987-10-101993-04-20Danbiosyst Uk Ltd.Transmucosal formulations of low molecular weight peptide drugs
WO1989003678A1 (en)1987-10-301989-05-05Stolle Research & Development CorporationLow residual solvent microspheres and microencapsulation process
US4917895A (en)1987-11-021990-04-17Alza CorporationTransdermal drug delivery device
US4876781A (en)1988-04-251989-10-31Peter J. BalsellsMethod of making a garter-type axially resilient coiled spring
US5108078A (en)1988-04-251992-04-28Peter J. BalsellsCanted-coil spring loaded while in a cavity
US4826144A (en)1988-04-251989-05-02Peter J. BalsellsInside back angle canted coil spring
US5134244A (en)1988-04-251992-07-28Peter J. BalsellsElectromagnetic shielding seal for rotary/reciprocating shaft
US4961253A (en)1988-04-251990-10-09Peter J. BalsellsManufacturing method for canted-coil spring with turn angle and seal
US4907788A (en)1988-04-251990-03-13Peter J. BalsellsDual concentric canted-coil spring apparatus
US4830344A (en)1988-04-251989-05-16Peter J. BalsellsCanted-coil spring with turn angle and seal
US4915366A (en)1988-04-251990-04-10Peter J. BalsellsOutside back angle canted coil spring
US4964204A (en)1988-04-251990-10-23Peter J. BalsellsMethod for making a garter-type axially-resilient coil spring
US4934666A (en)1988-04-251990-06-19Peter J. BalsellsCoiled spring electromagnetic shielding gasket
US4974821A (en)1988-04-251990-12-04Peter J. BalsellsCanted-coil spring with major axis radial loading
US5117066A (en)1988-04-251992-05-26Peter J. BalsellsRetaining and locking electromagnetic gasket
US5006346A (en)1988-04-281991-04-09Alza CorporationDelivery system
US4931285A (en)1988-04-281990-06-05Alza CorporationAqueous based pharmaceutical coating composition for dosage forms
US5160743A (en)1988-04-281992-11-03Alza CorporationAnnealed composition for pharmaceutically acceptable drug
US5024842A (en)1988-04-281991-06-18Alza CorporationAnnealed coats
JPH02124814A (en)1988-07-051990-05-14Takeda Chem Ind LtdSustained release microcapsule containing water-soluble drug
US4893795A (en)1988-08-151990-01-16Peter J. BalsellsRadially loaded canted coiled spring with turn angle
EP0368339A2 (en)1988-11-111990-05-16Eisai Co., Ltd.Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt
US5110596A (en)1988-12-131992-05-05Alza CorporationDelivery system comprising means for delivering agent to livestock
US5728088A (en)1988-12-131998-03-17Alza CorporationOsmotic system for delivery of fluid-sensitive somatotropins to bovine animals
EP0373867A1 (en)1988-12-131990-06-20Alza CorporationDelivery system comprising means for governing fluid ingress into the system
US5059423A (en)1988-12-131991-10-22Alza CorporationDelivery system comprising biocompatible beneficial agent formulation
US5057318A (en)1988-12-131991-10-15Alza CorporationDelivery system for beneficial agent over a broad range of rates
US5320616A (en)1988-12-131994-06-14Alza CorporationDelivery system comprising first walled section and second walled section united by fusion, adhesion or telescopic engagement
US5034229A (en)1988-12-131991-07-23Alza CorporationDispenser for increasing feed conversion of hog
US5234424A (en)1988-12-281993-08-10Alza CorporationOsmotically driven syringe
US4969884A (en)1988-12-281990-11-13Alza CorporationOsmotically driven syringe
US4976966A (en)1988-12-291990-12-11Alza CorporationDelayed release osmotically driven fluid dispenser
US5066436A (en)1989-01-041991-11-19Gist-Brocades N.V.Process for microencapsulation
US5128147A (en)1989-01-061992-07-07Thermal Developments, Inc.Heat intensifier and localizer for radiofrequency thermotherapy
EP0379147A2 (en)1989-01-171990-07-25Sterling Winthrop Inc.Extrudable elastic gel for use as carrier for therapeutic agent
US5738845A (en)1989-03-021998-04-14The Women's Research InstituteHuman interferon τ proteins and methods of use
US5942223A (en)1989-03-021999-08-24University Of FloridaAntiviral therapy using ovine or bovine interferon-tau
US5219572A (en)1989-03-171993-06-15Pitman-Moore, Inc.Controlled release delivery device for macromolecular proteins
NL9000948A (en)1989-04-211990-11-16Nedap NvInjection and implanting instrument for coding or numbering animals - has handle sliding on guide pin with insertion depth stop parallel to hollow needle and anatomically shaped locating plate
NL8901004A (en)1989-04-211990-11-16Nedap NvPositioning attachment for animal implanting or injecting tool - has automatically shaped transparent positioning piece with adjustable needle insertion depth
US5090962A (en)1989-04-281992-02-25Flp Enterprises, Inc.Non-reusable syringe
WO1990013285A1 (en)1989-05-011990-11-15Enzytech, Inc.Process for producing small particles of biologically active molecules
WO1990013780A1 (en)1989-05-011990-11-15Enzytech, Inc.Very low temperature casting of controlled release microspheres
US5019400A (en)1989-05-011991-05-28Enzytech, Inc.Very low temperature casting of controlled release microspheres
WO1990013361A1 (en)1989-05-041990-11-15Southern Research InstituteImproved encapsulation process and products therefrom
US5407609A (en)1989-05-041995-04-18Southern Research InstituteMicroencapsulation process and products therefrom
US5445829A (en)1989-05-051995-08-29Kv Pharmaceutical CompanyExtended release pharmaceutical formulations
US5126142A (en)1989-07-181992-06-30Alza CorporationDispenser comprising ionophore
US5192273A (en)1989-07-241993-03-09Steven F. BiermanCatheterization system
US5439688A (en)1989-07-281995-08-08Debio Recherche Pharmaceutique S.A.Process for preparing a pharmaceutical composition
US5225205A (en)1989-07-281993-07-06Debiopharm S.A.Pharmaceutical composition in the form of microparticles
US5336505A (en)1989-08-281994-08-09Pharmaceutical Delivery SystemsBioerodible polymers useful for the controlled release of therapeutic agents
US5112614A (en)1989-09-141992-05-12Alza CorporationImplantable delivery dispenser
US5660847A (en)1989-09-141997-08-26Alza CorporationImplantable delivery dispenser comprising exit port
US5284655A (en)1989-09-211994-02-08Osteotech, Inc.Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects
US5614221A (en)1989-10-231997-03-25MediventMethod of preparing a drug delivery system comprising a drug and a gel using a syringe
US5707644A (en)1989-11-041998-01-13Danbiosyst Uk LimitedSmall particle compositions for intranasal drug delivery
US5312335A (en)1989-11-091994-05-17Bioject Inc.Needleless hypodermic injection device
WO1991007160A1 (en)1989-11-131991-05-30Medicorp Holding S.A.Storage bottle containing a constituent of a medicinal solution
US5079388A (en)1989-12-011992-01-07Peter J. BalsellsGasket for sealing electromagnetic waves
US5072070A (en)1989-12-011991-12-10Peter J. BalsellsDevice for sealing electromagnetic waves
EP0431942A2 (en)1989-12-061991-06-12Sansho Co., Ltd.Percutaneously absorbable pharmaceutical preparation containing dopamine derivative
US5030216A (en)1989-12-151991-07-09Alza CorporationOsmotically driven syringe
US5733572A (en)1989-12-221998-03-31Imarx Pharmaceutical Corp.Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5368863A (en)1990-01-241994-11-29Alza CorporationLong-term delivery device with early startup
US5545618A (en)1990-01-241996-08-13Buckley; Douglas I.GLP-1 analogs useful for diabetes treatment
US5213809A (en)1990-01-241993-05-25Alza CorporationDelivery system comprising means for controlling internal pressure
US5053014A (en)1990-02-011991-10-01Critikon, Inc.Catheter with controlled valve
US5279554A (en)1990-02-091994-01-18Rhone MerieuxImplanting device
US5478564A (en)1990-02-221995-12-26Teva Pharmaceutical Industries, Ltd.Preparation of microparticles for controlled release of water-soluble substances
US5122128A (en)1990-03-151992-06-16Alza CorporationOrifice insert for a ruminal bolus
US5160122A (en)1990-03-201992-11-03Peter J. BalsellsCoil spring with an elastomer having a hollow coil cross section
US5203849A (en)1990-03-201993-04-20Balsells Peter JCanted coil spring in length filled with an elastomer
US5120306A (en)1990-03-211992-06-09Gosselin Leon FDirect delivery of anti-inflammatories to the proximal small bowel
US5207752A (en)1990-03-301993-05-04Alza CorporationIontophoretic drug delivery system with two-stage delivery profile
US5213810A (en)1990-03-301993-05-25American Cyanamid CompanyStable compositions for parenteral administration and method of making same
US5324280A (en)1990-04-021994-06-28Alza CorporationOsmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5413572A (en)1990-04-021995-05-09Alza CorporationOsmotic dosage system for liquid drug delivery
US5091188A (en)1990-04-261992-02-25Haynes Duncan HPhospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5290271A (en)1990-05-141994-03-01Jernberg Gary RSurgical implant and method for controlled release of chemotherapeutic agents
US5374620A (en)1990-06-071994-12-20Genentech, Inc.Growth-promoting composition and its use
US5180591A (en)1990-07-111993-01-19Alza CorporationDelivery device with a protective sleeve
US5234693A (en)1990-07-111993-08-10Alza CorporationDelivery device with a protective sleeve
US5234692A (en)1990-07-111993-08-10Alza CorporationDelivery device with a protective sleeve
US5234695A (en)1990-07-241993-08-10Eastman Kodak CompanyWater dispersible vitamin E composition
US7008439B1 (en)1990-09-212006-03-07Datascope Investments Corp.Device and method for sealing puncture wounds
US5300302A (en)1990-10-041994-04-05Nestec S.A.Pharmaceutical composition in gel form in a dispensing package
US5529914A (en)1990-10-151996-06-25The Board Of Regents The Univeristy Of Texas SystemGels for encapsulation of biological materials
US5312389A (en)1990-10-291994-05-17Felix TheeuwesOsmotically driven syringe with programmable agent delivery
US5151093A (en)1990-10-291992-09-29Alza CorporationOsmotically driven syringe with programmable agent delivery
US5122377A (en)1990-11-191992-06-16A.H. Robins, Company, IncorporatedOral delivery system for veterinary drugs
EP0486959A1 (en)1990-11-221992-05-27Vectorpharma International S.P.A.Pharmaceutical composition of microparticles with controlled release and process of preparing it
US5700486A (en)1990-11-221997-12-23Vectorpharma International S.P.A.Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions
US5279544A (en)1990-12-131994-01-18Sil Medics Ltd.Transdermal or interdermal drug delivery devices
US5161806A (en)1990-12-171992-11-10Peter J. BalsellsSpring-loaded, hollow, elliptical ring seal
US5279608A (en)1990-12-181994-01-18Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)Osmotic pumps
US5543156A (en)1991-01-091996-08-06Alza CorporationBioerodible devices and compositions for diffusional release of agents
US5147295A (en)1991-01-231992-09-15Ideal Instruments, Inc.Retractable implanter
NL9100160A (en)1991-01-301992-08-17Texas Instruments Holland INJECTOR.
EP0497575A1 (en)1991-01-301992-08-05Texas Instruments Holland B.V.Injector
US5443459A (en)1991-01-301995-08-22Alza CorporationOsmotic device for delayed delivery of agent
US5531736A (en)1991-01-301996-07-02Alza CorporationOsmotic device for delayed delivery of agent
US5300079A (en)1991-01-301994-04-05Texas Instruments IncorporatedInjector
US5395319A (en)1991-03-061995-03-07Suddeutsche Feinmechanik GmbhNeedle for inserting an object into the body
US5861166A (en)1991-03-121999-01-19Alza CorporationDelivery device providing beneficial agent stability
US5113938A (en)1991-05-071992-05-19Clayton Charley HWhipstock
WO1992019241A1 (en)1991-05-071992-11-12Dynagen, Inc.A controlled, sustained release delivery system for smoking cessation
US5137727A (en)1991-06-121992-08-11Alza CorporationDelivery device providing beneficial agent stability
US5711967A (en)1991-06-171998-01-27Spirig Ag, Pharmazeutische PraeparateOral diclofenac preparation
US5252338A (en)1991-06-271993-10-12Alza CorporationTherapy delayed
US5190765A (en)1991-06-271993-03-02Alza CorporationTherapy delayed
US5541172A (en)1991-06-281996-07-30Endorecherche, Inc.Controlled release systems and low dose androgens
US5288501A (en)1991-07-041994-02-22Merz + Co. Gmbh & Co.Mechanically-stable, readily-disintegratable tablets made of small preformed particles containing active ingredients
US5336057A (en)1991-09-301994-08-09Nippon Densan CorporationMicropump with liquid-absorptive polymer gel actuator
US5352662A (en)1991-10-011994-10-04Brooks Norman DInjectable extended release formulations and methods
WO1993006821A1 (en)1991-10-041993-04-15Yoshitomi Pharmaceutical Industries, Ltd.Sustained-release tablet
WO1993006819A1 (en)1991-10-101993-04-15Alza CorporationOsmotic drug delivery devices with hydrophobic wall materials
US5795591A (en)1991-10-101998-08-18Alza CorporationOsmotic drug delivery devices with hydrophobic wall materials
US5288502A (en)1991-10-161994-02-22The University Of Texas SystemPreparation and uses of multi-phase microspheres
US5318780A (en)1991-10-301994-06-07Mediventures Inc.Medical uses of in situ formed gels
WO1993008832A1 (en)1991-11-081993-05-13Dallas Biotherapeutics, Inc.Stabilization of human interferon
US5511355A (en)1991-11-151996-04-30Dingler; GerhardConstruction element
WO1993009763A1 (en)1991-11-151993-05-27Isp Investments Inc.Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5830501A (en)1991-12-061998-11-03Alza CorporationDosage form comprising hydrophilic polymer
US5312390A (en)1992-01-101994-05-17Alza CorporationOsmotic device with delayed activation of drug delivery
US5223265A (en)1992-01-101993-06-29Alza CorporationOsmotic device with delayed activation of drug delivery
US5658593A (en)1992-01-161997-08-19ColeticaInjectable compositions containing collagen microcapsules
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5676942A (en)1992-02-101997-10-14Interferon Sciences, Inc.Composition containing human alpha interferon species proteins and method for use thereof
US5209746A (en)1992-02-181993-05-11Alza CorporationOsmotically driven delivery devices with pulsatile effect
US5456679A (en)1992-02-181995-10-10Alza CorporationDelivery devices with pulsatile effect
US5308348A (en)1992-02-181994-05-03Alza CorporationDelivery devices with pulsatile effect
US5428024A (en)1992-02-281995-06-27Collagen CorporationHigh concentration homogenized collagen compositions
US5318558A (en)1992-03-121994-06-07Alza CorporationOsmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5221278A (en)1992-03-121993-06-22Alza CorporationOsmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5656297A (en)1992-03-121997-08-12Alkermes Controlled Therapeutics, IncorporatedModulated release from biocompatible polymers
US5540912A (en)1992-03-301996-07-30Alza CorporationViscous suspensions of controlled-release drug particles
US5571525A (en)1992-03-301996-11-05Alza CorporationErosion rate modifier for use in bioerodible drug delivery devices and method of use
US5858746A (en)1992-04-201999-01-12Board Of Regents, The University Of Texas SystemGels for encapsulation of biological materials
US6217908B1 (en)1992-04-242001-04-17Brown University Research FoundationBioadhesive microspheres and their use as drug delivery and imaging systems
US5429602A (en)1992-04-291995-07-04Hauser; Jean-LucProgrammable portable infusion pump system
WO1993023083A1 (en)1992-05-111993-11-25Agouron Pharmaceuticals, Inc.Anhydrous formulations for administering lipophilic agents
US5250026A (en)1992-05-271993-10-05Destron/Idi, Inc.Adjustable precision transponder injector
US5556642A (en)1992-07-161996-09-17Tanabe Seiyaku Co., Ltd.Method for producing sustained release microsphere preparation
US5413672A (en)1992-07-221995-05-09Ngk Insulators, Ltd.Method of etching sendust and method of pattern-etching sendust and chromium films
US5512293A (en)1992-07-231996-04-30Alza CorporationOral sustained release drug delivery device
US5279555A (en)1992-08-241994-01-18Merck & Co., Inc.Device for injecting implants
US5609885A (en)1992-09-151997-03-11Alza CorporationOsmotic membrane and delivery device
US5827297A (en)1992-10-011998-10-27Medicamat S.A.Device for transplanting small diameter hair grafts
WO1994009743A1 (en)1992-11-051994-05-11R.P. Scherer CorporationVented capsule
EP0596161A1 (en)1992-11-061994-05-11Texas Instruments IncorporatedApparatus for subcutaneous introduction of a needle
EP0596161B1 (en)1992-11-061998-02-04Texas Instruments IncorporatedApparatus for subcutaneous introduction of a needle
US5871778A (en)1992-11-171999-02-16Yoshitomi Pharmaceutical Industries, Ltd.Sustained release microsphere preparation containing antipsychotic drug
WO1994010982A1 (en)1992-11-171994-05-26Yoshitomi Pharmaceutical Industries, Ltd.Sustained-release microsphere containing antipsychotic and process for producing the same
US5656299A (en)1992-11-171997-08-12Yoshitomi Pharmaceutical Industries, Ltd.Sustained release microsphere preparation containing antipsychotic drug and production process thereof
US5472708A (en)1992-11-271995-12-05Andrx Pharmaceuticals Inc.Pulsatile particles drug delivery system
US5260069A (en)1992-11-271993-11-09Anda Sr Pharmaceuticals Inc.Pulsatile particles drug delivery system
US5635213A (en)1992-11-301997-06-03Neopharma Production AbPharmaceutical formulation
US5667808A (en)1992-12-021997-09-16Alkermes, Inc.Composition for sustained release of human growth hormone
US5654010A (en)1992-12-021997-08-05Alkermes, Inc.Composition for sustained release of human growth hormone
US6528093B1 (en)1992-12-072003-03-04Takeda Chemical Industries, Ltd.Sustained-release preparation
US5589167A (en)1993-02-231996-12-31Genentech, Inc.Excipient stabilization of polypeptides treated with organic solvents
US5368588A (en)1993-02-261994-11-29Bettinger; David S.Parenteral fluid medication reservoir pump
US5981719A (en)1993-03-091999-11-09Epic Therapeutics, Inc.Macromolecular microparticles and methods of production and use
WO1994021262A1 (en)1993-03-171994-09-29Alza CorporationDevice for the transdermal administration of alprazolam
US5514110A (en)1993-03-221996-05-07Teh; Eutiquio L.Automatic flow control device
US6284727B1 (en)1993-04-072001-09-04Scios, Inc.Prolonged delivery of peptides
JP2006213727A (en)1993-04-072006-08-17Scios IncSustained release of peptide
US5630796A (en)1993-04-081997-05-20Oxford Biosciences LimitedMethod of delivering powder transdermally with needless injector
US5843891A (en)1993-04-281998-12-01Sherman; Bernard C.Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug
EP0627231A2 (en)1993-05-051994-12-07Alza CorporationDelivery devices with pulsatile effect
US5424286A (en)1993-05-241995-06-13Eng; JohnExendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5997902A (en)1993-06-231999-12-07Alza CorporationRuminal drug delivery device
US5639477A (en)1993-06-231997-06-17Alza CorporationRuminal drug delivery device
EP0631794A1 (en)1993-06-231995-01-04Hoechst AktiengesellschaftDevice for administering implants
US5569289A (en)1993-06-241996-10-29Yoon; InbaeSafety penetrating instrument with penetrating member and cannula moving during penetration and triggered safety member protusion
WO1995001167A2 (en)1993-06-251995-01-12Alza CorporationIncorporating poly-n-vinyl amide in a transdermal system
US5498255A (en)1993-08-171996-03-12Alza CorporationOsmotic device for protracted pulsatile delivery of agent
US5385887A (en)1993-09-101995-01-31Genetics Institute, Inc.Formulations for delivery of osteogenic proteins
US5486365A (en)1993-09-171996-01-23Fuji Chemical Industry Co., Ltd.Calcium hydrogen phosphate, a method for preparing it, and an excipient utilizing it
WO1995009007A1 (en)1993-09-291995-04-06Alza CorporationMonoglyceride/lactate ester permeation enhancer for oxybutynin
WO1995009006A1 (en)1993-09-291995-04-06Alza CorporationMonoglyceride/lactate ester permeation enhancer
US5686097A (en)1993-09-291997-11-11Alza CorporationMonoglyceride/lactate ester permeation enhancer for codelivery of steroids
US5558637A (en)1993-10-131996-09-24Leiras OyImplant injection device
US6913767B1 (en)1993-10-252005-07-05Genentech, Inc.Compositions for microencapsulation of antigens for use as vaccines
US5770231A (en)1993-11-191998-06-23Alkermes Controlled Therapeutics, Inc. IiMicroencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1,2-benzisothiazoles
US5688801A (en)1993-11-191997-11-18Janssen PharmaceuticaMethod of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5965168A (en)1993-11-191999-10-12Alkermes Controlled Therapeutics, Inc. IiMicroencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
WO1995013799A1 (en)1993-11-191995-05-26Alkermes Controlled Therapeutics Inc. IiPreparation of biodegradable microparticles containing a biologically active agent
US5650173A (en)1993-11-191997-07-22Alkermes Controlled Therapeutics Inc. IiPreparation of biodegradable microparticles containing a biologically active agent
US5654008A (en)1993-11-191997-08-05Alkermes Controlled Therapeutics Inc. IiPreparation of biodegradable microparticles containing a biologically active agent
US5348544A (en)1993-11-241994-09-20Becton, Dickinson And CompanySingle-handedly actuatable safety shield for needles
JPH07196479A (en)1994-01-041995-08-01Unitika LtdMethod for producing microcapsule
US5540665A (en)1994-01-311996-07-30Alza CorporationGas driven dispensing device and gas generating engine therefor
US6022561A (en)1994-02-042000-02-08Scotia Lipidteknik AbBilayers preparations
US5713847A (en)1994-02-091998-02-03The University Of Iowa Research FoundationHuman drug delivery device for tinnitus
JPH09509346A (en)1994-02-251997-09-22ズードドイッチェ・フアインメハニーク・ゲーエムベーハー Cannula for subcutaneous fixation of target
US5810769A (en)1994-02-251998-09-22Suddeutsche Feinmechanik GmbhCannula for the subcutaneous deposition of an object
US5458888A (en)1994-03-021995-10-17Andrx Pharmaceuticals, Inc.Controlled release tablet formulation
US6007805A (en)1994-03-071999-12-28Imperial College Of Science And TechnologyUse of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US5484403A (en)1994-04-051996-01-16Avid Marketing, Inc.Hypodermic syringe for implanting solid objects
US5660861A (en)1994-04-281997-08-26Alza CorporationEffective therapy for epilepsies
WO1995034285A1 (en)1994-06-131995-12-21Alza CorporationDosage form for administering drug in liquid formulation
WO1996001134A1 (en)1994-07-011996-01-18Alza CorporationOsmotic system for delivering of fluid-sensitive somatotropin to bovine animals
EP0767689A1 (en)1994-07-011997-04-16Alza CorporationOsmotic system for delivering of fluid-sensitive somatotropin to bovine animals
US5557318A (en)1994-07-121996-09-17Koninklijke Ptt Nederland N.V.Method and apparatus for permitting a viewer to scan through a plurality of video signals provided by a transmitter
US5668170A (en)1994-07-131997-09-16Alza CorporationComposition and method enhancing transdermal electrotransport agent delivery
WO1996003116A1 (en)1994-07-251996-02-08Alkermes Controlled Therapeutics, Inc.Controlled release of metal cation-stabilized interferon
US5620705A (en)1994-08-041997-04-15Alza CorporationProgestin tablet
US5633011A (en)1994-08-041997-05-27Alza CorporationProgesterone replacement therapy
US5574008A (en)1994-08-301996-11-12Eli Lilly And CompanyBiologically active fragments of glucagon-like insulinotropic peptide
US5695463A (en)1994-09-271997-12-09Societe De Conseils De Recherches Et D'applicationsSafety injection device
US5512549A (en)1994-10-181996-04-30Eli Lilly And CompanyGlucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5836935A (en)1994-11-101998-11-17Ashton; PaulImplantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5595759A (en)1994-11-101997-01-21Alza CorporationProcess for providing therapeutic composition
US5613954A (en)1994-11-211997-03-25Stryker CorporationLaparoscopic surgical Y-tube cannula
EP0729747A1 (en)1995-03-031996-09-04L'orealUse of amphiphilic compounds as thickening agent of non aqueous media and composition obtained
US20010012511A1 (en)1995-03-062001-08-09Bezwada Rao S.Method of preventing adhesions with absorbable polyoxaesters
US5597579A (en)1995-03-061997-01-28Ethicon, Inc.Blends of absorbable polyoxaamides
US6147168A (en)1995-03-062000-11-14Ethicon, Inc.Copolymers of absorbable polyoxaesters
US6403655B1 (en)1995-03-062002-06-11Ethicon, Inc.Method of preventing adhesions with absorbable polyoxaesters
US6458385B2 (en)1995-03-062002-10-01Ethicon, Inc.Hydrogels containing absorbable polyoxaamides
US5607687A (en)1995-03-061997-03-04Ethicon, Inc.Polymer blends containing absorbable polyoxaesters
US20010026793A1 (en)1995-03-062001-10-04Jamiolkowski Dennis D.Hydrogels containing absorbable polyoxaamides
US20010021377A1 (en)1995-03-062001-09-13Jamiolkowski Dennis D.Hydrogels containing absorbable polyoxaamides
US5618552A (en)1995-03-061997-04-08Ethicon, Inc.Absorbable polyoxaesters
US5620698A (en)1995-03-061997-04-15Ethicon, Inc.Blends of absorbable polyoxaesters containing amines and/or amido groups
US5859150A (en)1995-03-061999-01-12Ethicon, Inc.Prepolymers of absorbable polyoxaesters
US6100346A (en)1995-03-062000-08-08Ethicon, Inc.Copolymers of polyoxaamides
US5648088A (en)1995-03-061997-07-15Ethicon, Inc.Blends of absorbable polyoxaesters containing amines and/or amide groups
US5464929A (en)1995-03-061995-11-07Ethicon, Inc.Absorbable polyoxaesters
US5844017A (en)1995-03-061998-12-01Ethicon, Inc.Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US6372256B2 (en)1995-03-062002-04-16Ethicon, Inc.Hydrogels containing absorbable polyoxaamides
US5962023A (en)1995-03-061999-10-05Ethicon, Inc.Hydrogels containing absorbable polyoxaamides
US6224894B1 (en)1995-03-062001-05-01Ethicon, Inc.Copolymers of absorbable polyoxaesters
US5700583A (en)1995-03-061997-12-23Ethicon, Inc.Hydrogels of absorbable polyoxaesters containing amines or amido groups
US6251435B1 (en)1995-03-062001-06-26Ethicon, Inc.Hydrogels containing absorbable polyoxaamides
US5645850A (en)1995-03-061997-07-08Ethicon, Inc.Blending containing absorbable polyoxaamides
US5595751A (en)1995-03-061997-01-21Ethicon, Inc.Absorbable polyoxaesters containing amines and/or amido groups
US5698213A (en)1995-03-061997-12-16Ethicon, Inc.Hydrogels of absorbable polyoxaesters
US5697914A (en)1995-03-161997-12-16Becton Dickinson And CompanyControl forward/flashback forward one hand introducer needle and catheter assembly
US5906816A (en)1995-03-161999-05-25University Of FloridaMethod for treatment of autoimmune diseases
US6060450A (en)1995-03-162000-05-09University Of FloridaMethod for treatment of autoimmune diseases
US5542682A (en)1995-03-271996-08-06American VarisealSlant coil spring and seal
US5736159A (en)1995-04-281998-04-07Andrx Pharmaceuticals, Inc.Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5972373A (en)1995-05-021999-10-26Taisho Pharmaceutical Co., Ltd.Taste masking pharmaceutical composition for oral administration
US5939286A (en)1995-05-101999-08-17University Of FloridaHybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US5922253A (en)1995-05-181999-07-13Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
WO1996036317A1 (en)1995-05-181996-11-21Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
US5882676A (en)1995-05-261999-03-16Alza CorporationSkin permeation enhancer compositions using acyl lactylates
US5718922A (en)1995-05-311998-02-17Schepens Eye Research Institute, Inc.Intravitreal microsphere drug delivery and method of preparation
WO1996039142A1 (en)1995-06-061996-12-12F. Hoffmann-La Roche AgPharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
US5690952A (en)1995-06-071997-11-25Judy A. Magruder et al.Implantable system for delivery of fluid-sensitive agents to animals
US5904935A (en)1995-06-071999-05-18Alza CorporationPeptide/protein suspending formulations
US5871770A (en)1995-06-071999-02-16Alza CorporationImplantable system for delivery of fluid-sensitive agents to animals
US5876746A (en)1995-06-071999-03-02Cygnus, Inc.Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US20040101557A1 (en)1995-06-072004-05-27Gibson John W.High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en)1995-06-071998-05-05Southern Biosystems, Inc.High viscosity liquid controlled delivery system
US5725497A (en)1995-06-071998-03-10American Cyanamid CompanyInjection dart system
WO1996040355A1 (en)1995-06-071996-12-19Cygnus, Inc.Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5972370A (en)1995-06-071999-10-26Alza CorporationPeptide/protein suspending formulations
WO1996040139A1 (en)1995-06-071996-12-19Alza CorporationNovel formulations for transdermal delivery of pergolide
US7833543B2 (en)1995-06-072010-11-16Durect CorporationHigh viscosity liquid controlled delivery system and medical or surgical device
US6129761A (en)1995-06-072000-10-10Reprogenesis, Inc.Injectable hydrogel compositions
WO1996040049A1 (en)1995-06-071996-12-19Alza CorporationPeptide/protein suspended formulations
US6607529B1 (en)1995-06-192003-08-19Medtronic Vidamed, Inc.Electrosurgical device
US5782396A (en)1995-08-281998-07-21United States Surgical CorporationSurgical stapler
US5906830A (en)1995-09-081999-05-25Cygnus, Inc.Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5942253A (en)1995-10-121999-08-24Immunex CorporationProlonged release of GM-CSF
US5814323A (en)1995-10-161998-09-29Lever Brothers Company, Division Of Conopco, Inc.Cosmetic composition
US6120787A (en)1995-10-192000-09-19Biogram AbSustained release particles
WO1997015296A1 (en)1995-10-231997-05-01Theratech, Inc.Buccal delivery of glucagon-like insulinotropic peptides
WO1997015289A1 (en)1995-10-251997-05-01Cortecs (Uk) LimitedSolubilisation methods
EP0771817A2 (en)1995-10-301997-05-07Laboratorios S.A.L.V.A.T., S.A.Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight
US5908621A (en)1995-11-021999-06-01Schering CorporationPolyethylene glycol modified interferon therapy
US6461605B1 (en)1995-11-022002-10-08Schering CorporationContinuous low-dose cytokine infusion therapy
US5906599A (en)1995-11-091999-05-25Intermed, Inc.Device for delivering biological agents
US5851451A (en)1995-12-151998-12-22Takeda Chemical Industries, Ltd.Production of microspheres
US6190700B1 (en)1995-12-152001-02-20Takeda Chemical Industries, Ltd.Production of sustained-release preparation for injection
US6592508B1 (en)1995-12-182003-07-15Integrated Implant Systems, LlcFiberoptic-guided interstitial seed manual applicator and seed cartridge
US6133249A (en)1995-12-192000-10-17Macnaught Medical Pty LimitedPhospholipid and propylene glycol based lubricant
US5980945A (en)1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
US5672549A (en)1996-01-311997-09-30Sumitomo Bakelite Company LimitedMethod of producing epoxy resin-encapsulated semiconductor device
US6635268B2 (en)1996-02-022003-10-21Alza CorporationSustained delivery of an active agent using an implantable system
US5985305A (en)1996-02-021999-11-16Alza CorporationSustained delivery of an active agent using an implantable system
US5728396A (en)1996-02-021998-03-17Alza CorporationSustained delivery of leuprolide using an implantable system
US6156331A (en)1996-02-022000-12-05Alza CorporationSustained delivery of an active agent using an implantable system
US20040039376A1 (en)1996-02-022004-02-26Peery John R.Sustained delivery of an active agent using an implantable system
US6395292B2 (en)1996-02-022002-05-28Alza CorporationSustained delivery of an active agent using an implantable system
US7655257B2 (en)1996-02-022010-02-02Intarcia Therapeutics, Inc.Sustained delivery of an active agent using an implantable system
WO1997028181A2 (en)1996-02-021997-08-07Rhomed IncorporatedPost-labeling stabilization of radiolabeled proteins and peptides
US6261584B1 (en)1996-02-022001-07-17Alza CorporationSustained delivery of an active agent using an implantable system
US6132420A (en)1996-02-022000-10-17Alza CorporationOsmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6245349B1 (en)1996-02-232001-06-12éLAN CORPORATION PLCDrug delivery compositions suitable for intravenous injection
WO1997031943A1 (en)1996-03-011997-09-04Novo Nordisk A/SUse of a pharmaceutical composition comprising an appetite-suppressing peptide
JPH09241153A (en)1996-03-041997-09-16Q P Corp Fat emulsion for intravenous injection
US6124281A (en)1996-03-082000-09-26Zeneca LimitedAzolobenzazepine derivatives as neurologically active agents
US6069133A (en)1996-03-142000-05-30The Immune Response CorporationTargeted delivery of genes encoding interferon
US5703200A (en)1996-03-151997-12-30Ethicon, Inc.Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
US6190702B1 (en)1996-03-282001-02-20Takeda Chemical Industries, Ltd.Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
US5660858A (en)1996-04-031997-08-26Research Triangle PharmaceuticalsCyclosporin emulsions
US6204022B1 (en)1996-04-122001-03-20Pepgen Corporation And University Of FloridaLow-toxicity human interferon-alpha analogs
US6074673A (en)1996-04-222000-06-13Guillen; ManuelSlow-release, self-absorbing, drug delivery system
US5807876A (en)1996-04-231998-09-15Vertex Pharmaceuticals IncorporatedInhibitors of IMPDH enzyme
US5976109A (en)1996-04-301999-11-02Medtronic, Inc.Apparatus for drug infusion implanted within a living body
WO1997041837A3 (en)1996-05-071998-02-26Alkermes IncMicroparticles
WO1997041837A2 (en)1996-05-071997-11-13Alkermes Controlled Therapeutics Inc. IiMicroparticles
US5916598A (en)1996-05-071999-06-29Alkermes Controlled Therapeutics Inc. IiPreparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5792477A (en)1996-05-071998-08-11Alkermes Controlled Therapeutics, Inc. IiPreparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6110503A (en)1996-05-072000-08-29Alkermes Controlled Therapeutics Inc.Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
WO1997044039A1 (en)1996-05-201997-11-27Janssen Pharmaceutica N.V.Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6767887B1 (en)1996-06-052004-07-27Roche Diagnostics GmbhExendin analogues, processes for their preparation and medicaments containing them
WO1997046204A2 (en)1996-06-051997-12-11Ashmont Holdings LimitedInjectable compositions
WO1997047339A1 (en)1996-06-141997-12-18Filtertek, S.A.Gravity infusion set for medical infusions
US6258377B1 (en)1996-07-022001-07-10Provalis Uk LimitedHydrophobic preparations containing medium chain monoglycerides
US5932547A (en)1996-07-031999-08-03Alza CorporationNon-aqueous polar aprotic peptide formulations
WO1998000157A1 (en)1996-07-031998-01-08Alza CorporationAqueous formulations of peptides
US6235712B1 (en)1996-07-032001-05-22Alza CorporationNon-aqueous polar aprotic peptide formulations
US6124261A (en)1996-07-032000-09-26Alza CorporationNon-aqueous polar aprotic peptide formulations
WO1998000152A1 (en)1996-07-031998-01-08Alza CorporationNon-aqueous protic peptide formulations
WO1998000158A1 (en)1996-07-031998-01-08Alza CorporationNon-aqueous polar aprotic peptide formulations
WO1998002169A2 (en)1996-07-151998-01-22Alza CorporationNovel formulations for the administration of fluoxetine
US6218431B1 (en)1996-07-312001-04-17Bayer CorporationSubstituted biphenyls
US7521423B2 (en)1996-08-082009-04-21Amylin Pharmaceuticals, Inc.Exendin pharmaceutical compositions
US20040266692A1 (en)1996-08-082004-12-30Young Andrew A.Exendin pharmaceutical compositions
US6858576B1 (en)1996-08-082005-02-22Amylin Pharmaceuticals, Inc.Methods for regulating gastrointestinal motility
US7297761B2 (en)1996-08-082007-11-20Amylin Pharmaceuticals, Inc.Pharmaceutical compositions containing exendins
US7741269B2 (en)1996-08-082010-06-22Amylin Pharmaceuticals, Inc.Exendins and exendin agonists for weight reduction and obesity
US8288338B2 (en)1996-08-082012-10-16Amylin Pharmaceuticals, LlcExendin and exendin agonists for eating disorders
WO1998007412A1 (en)1996-08-211998-02-26Alkermes Controlled Therapeutics, Inc.Controlled release microparticles with a hydrophobic material
US6268343B1 (en)1996-08-302001-07-31Novo Nordisk A/SDerivatives of GLP-1 analogs
US6458924B2 (en)1996-08-302002-10-01Novo Nordisk A/SDerivatives of GLP-1 analogs
WO1998013091A1 (en)1996-09-271998-04-02American Home Products CorporationMedical device for the placement of solid materials
US5984890A (en)1996-09-271999-11-16American Home Products CorporationMedical device for the placement of solid materials
WO1998013092A1 (en)1996-09-271998-04-02American Home Products CorporationTissue penetration guide
US6074377A (en)1996-10-102000-06-13Sanfilippo, Ii; Dominic JosephMethod of installing vascular access device
WO1998016250A1 (en)1996-10-161998-04-23Alza CorporationStable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
US6730328B2 (en)1996-10-162004-05-04Victoria Knepp MaskiewiczStable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
WO1998017315A2 (en)1996-10-241998-04-30Alza CorporationPermeation enhancers for transdermal drug delivery compositions, devices, and methods
US6187095B1 (en)1996-10-312001-02-13Samsel K. LabrecqueProcess and apparatus for coating surgical sutures
US5817129A (en)1996-10-311998-10-06Ethicon, Inc.Process and apparatus for coating surgical sutures
US6191102B1 (en)1996-11-052001-02-20Eli Lilly And CompanyUse of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
EP0841359A1 (en)1996-11-061998-05-13Ethicon, Inc.Hydrogels of absorbable polyoxaesters
US5948430A (en)1996-11-111999-09-07Lts Lohmann Therapie-Systeme GmbhWater soluble film for oral administration with instant wettability
US6177096B1 (en)1996-11-112001-01-23Lts Lohmann Therapie-Systeme GmbhWater soluble film for oral administration with instant wettability
US6284264B1 (en)1996-11-112001-09-04Lts Lohmann Therapie-Systeme GmbhWater soluble film for oral administration with instant wettability
US6592887B2 (en)1996-11-112003-07-15Lts Lohmann Therapie-Systeme AgWater soluble film for oral administration with instant wettability
US6709671B2 (en)1996-11-112004-03-23Lts Lohmann Therapie-Systeme AgWater soluble film for oral administration with instant wettability
US8865202B2 (en)1996-11-112014-10-21Lts Lohmann Therapie-Systeme AgWater soluble film for oral administration with instant wettability
US5928666A (en)1996-11-121999-07-27Cygnus Inc.Crystalline form of estradiol and pharmaceutical formulations comprising same
WO1998020930A1 (en)1996-11-151998-05-22Alza CorporationOsmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US20060013879A9 (en)1996-12-202006-01-19Brodbeck Kevin JGel composition and methods
US20020034532A1 (en)1996-12-202002-03-21Brodbeck Kevin J.Injectable depot gel composition and method of preparing the composition
US6673767B1 (en)1996-12-202004-01-06Alza CorporationGel composition and methods
WO1998027960A2 (en)1996-12-201998-07-02Bioglan Ireland (R & D) LimitedA nitroimidazole gel composition
WO1998027963A2 (en)1996-12-201998-07-02Alza CorporationGel composition and methods
US6331311B1 (en)1996-12-202001-12-18Alza CorporationInjectable depot gel composition and method of preparing the composition
WO1998027962A2 (en)1996-12-201998-07-02Alza CorporationInjectable depot gel composition and method of preparing the composition
US6130200A (en)1996-12-202000-10-10Alza CorporationGel composition and methods
US20030044467A1 (en)1996-12-202003-03-06Brodbeck Kevin J.Gel composition and methods
US6468961B1 (en)1996-12-202002-10-22Alza CorporationGel composition and methods
US7115569B2 (en)1997-01-072006-10-03Amylin Pharmaceuticals, Inc.Exendins, exendin agonists, and methods for their use
US6989366B2 (en)1997-01-072006-01-24Amylin Pharmaceuticals, Inc.Exendins, exendin agonists, and methods for their use
WO1998030231A1 (en)1997-01-071998-07-16Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the reduction of food intake
US6956026B2 (en)1997-01-072005-10-18Amylin Pharmaceuticals, Inc.Use of exendins for the reduction of food intake
US7138375B2 (en)1997-01-072006-11-21Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for lowering plasma lipid
US20020137666A1 (en)1997-01-072002-09-26Nigel Robert Arnold BeeleyUse of exendins and agonists thereof for the reduction of food intake
WO1998032463A2 (en)1997-01-281998-07-30Pharmacia & Upjohn CompanyLyophilizate of lipid complex of water insoluble porphyrins
US5945126A (en)1997-02-131999-08-31Oakwood Laboratories L.L.C.Continuous microsphere process
US6217906B1 (en)1997-03-242001-04-17Alza CorporationSelf adjustable exit port
US5997527A (en)1997-03-241999-12-07Alza CorporationSelf adjustable exit port
WO1998042317A2 (en)1997-03-241998-10-01Alza CorporationImplantable delivery device with self adjustable exit port
US5874388A (en)1997-04-021999-02-23Dow Corning CorporationLubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US6127520A (en)1997-04-152000-10-03Regents Of The University Of MichiganCompositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
WO1998047487A1 (en)1997-04-171998-10-29Dumex-Alpharma A/SA novel bioadhesive drug delivery system based on liquid crystals
US6217893B1 (en)1997-04-182001-04-17Pharma BiotechSustained-release compositions and method for preparing same
US20040265273A1 (en)1997-04-282004-12-30Hong LiAdenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
WO1998051282A1 (en)1997-05-131998-11-19Imarx Pharmaceutical Corp.Solid porous matrices and methods of making and using the same
US6113947A (en)1997-06-132000-09-05Genentech, Inc.Controlled release microencapsulated NGF formulation
US20020004481A1 (en)1997-06-132002-01-10Jeffrey L. ClelandControlled release microencapsulated ngf formulation
WO1998058698A1 (en)1997-06-201998-12-30Akzo Nobel N.V.Preloaded implantation device
WO1999003453A1 (en)1997-07-141999-01-28Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov , D.D.Novel pharmaceutical formulation with controlled release of active substances
US6287295B1 (en)1997-07-252001-09-11Alza CorporationOsmotic delivery system, osmotic delivery system semimpermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6923800B2 (en)1997-07-252005-08-02Alza CorporationOsmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US20050131389A1 (en)1997-07-252005-06-16Peterson Lewis L.Osmotic delivery system flow modulator apparatus and method
US6840931B2 (en)1997-07-252005-01-11Alza CorporationOsmotic delivery system flow modulator apparatus and method
US20010027311A1 (en)1997-07-252001-10-04Guohua ChenOsmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6524305B1 (en)1997-07-252003-02-25Alza CorporationOsmotic delivery system flow modulator apparatus and method
US20030114837A1 (en)1997-07-252003-06-19Peterson Lewis L.Osmotic delivery system flow modulator apparatus and method
WO1999004767A2 (en)1997-07-251999-02-04Alza CorporationOsmotic delivery system with semipermeable plug
WO1999004768A2 (en)1997-07-251999-02-04Alza CorporationOsmotic delivery system flow modulator apparatus
US6478768B1 (en)1997-08-082002-11-12Gaplast GmbhImplant syringe
US7157555B1 (en)1997-08-082007-01-02Amylin Pharmaceuticals, Inc.Exendin agonist compounds
WO1999012549A2 (en)1997-09-091999-03-18West Pharmaceutical Services Drug Delivery & Clinical Research Centre LimitedControlled release microsphere delivery system
US6172046B1 (en)1997-09-212001-01-09Schering CorporationCombination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5989463A (en)1997-09-241999-11-23Alkermes Controlled Therapeutics, Inc.Methods for fabricating polymer-based controlled release devices
JPH11100353A (en)1997-09-291999-04-13Esupo KkRefined and deodorized liquid ester wax and its composition
WO1999016419A1 (en)1997-09-291999-04-08Inhale Therapeutic Systems, Inc.Perforated microparticles and methods of use
US6133429A (en)1997-10-032000-10-17Becton Dickinson And CompanyChromophores useful for the preparation of novel tandem conjugates
WO1999025728A1 (en)1997-11-141999-05-27Amylin Pharmaceuticals, Inc.Novel exendin agonist compounds
US6569420B2 (en)1997-12-082003-05-27Genentech, Inc.Human interferon-ε: a type I interferon
WO1999029306A1 (en)1997-12-121999-06-17Biohybrid Technologies, Inc.Devices for cloaking transplanted cells
US20030059471A1 (en)1997-12-152003-03-27Compton Bruce JonOral delivery formulation
US6375978B1 (en)1997-12-222002-04-23Alza CorporationRate controlling membranes for controlled drug delivery devices
EP1300129A3 (en)1997-12-292003-05-14Alza CorporationImplant vial
US6899887B2 (en)1997-12-292005-05-31Micron Technology, Inc.Osmotic delivery system with membrane plug retention mechanism
US6270787B1 (en)1997-12-292001-08-07Alza CorporationOsmotic delivery system with membrane plug retention mechanism
US20040243106A1 (en)1997-12-292004-12-02Rupal AyerOsmotic delivery device with membrane plug retention mechanism
US20010021822A1 (en)1997-12-292001-09-13Rupal AyerOsmotic delivery system with membrane plug retention mechanism
EP1300173A2 (en)1997-12-292003-04-09Alza CorporationImplanter device for subcutaneous implants
EP1300129A2 (en)1997-12-292003-04-09Alza CorporationImplant vial
US6976981B2 (en)1997-12-292005-12-20Alza CorporationOsmotic delivery system with membrane plug retention mechanism
WO1999033446A1 (en)1997-12-291999-07-08Alza CorporationOsmotic delivery system with membrane plug retention mechanism
US20010022974A1 (en)1997-12-292001-09-20Rupal AyerOsmotic delivery system with membrane plug retention mechanism
US6190350B1 (en)1997-12-292001-02-20Alza CorporationImplanter device for subcutaneous implants
US6113938A (en)1997-12-302000-09-05Alza CorporationBeneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
WO1999033449A1 (en)1997-12-301999-07-08Alza CorporationBeneficial agent delivery system with membrane plug
US20040024068A1 (en)1998-01-232004-02-05Trustees Of Tufts CollegeAntimicrobial compounds
WO1999039700A1 (en)1998-02-061999-08-12Eurand International S.P.A.Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
US6017545A (en)1998-02-102000-01-25Modi; PankajMixed micellar delivery system and method of preparation
US7928065B2 (en)1998-02-132011-04-19Amylin Pharmaceuticals, Inc.Methods of treatment using exendin peptides or GLP-1 peptides
WO1999040788A1 (en)1998-02-131999-08-19Amylin Pharmaceuticals, Inc.Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en)1998-02-132004-03-09Amylin Pharmaceuticals, Inc.Inotropic and diuretic effects of exendin and GLP-1
US6402716B1 (en)1998-02-202002-06-11Lg Chemical Ltd.Syringe assembly
WO1999044659A1 (en)1998-03-021999-09-10Medrad, Inc.Syringes and plungers for use therein
US6056718A (en)1998-03-042000-05-02Minimed Inc.Medication infusion set
US6245357B1 (en)1998-03-062001-06-12Alza CorporationExtended release dosage form
US6183461B1 (en)1998-03-112001-02-06Situs CorporationMethod for delivering a medication
US20020136848A1 (en)1998-03-122002-09-26Fumio YoshiiLactone-containing resin composition, molded object thereof, and film
US6029361A (en)1998-03-252000-02-29Ultratech Stepper, Inc.Air-guage nozzle probe structure for microlithographic image focusing
US6395282B1 (en)1998-04-162002-05-28University Of RochesterImmunogenic conjugates of Gram-negative bacterial autoinducer molecules
US6074660A (en)1998-04-202000-06-13Ethicon, Inc.Absorbable polyoxaesters containing amines and/ or amido groups
WO1999062501A1 (en)1998-05-291999-12-09Sumitomo Pharmaceuticals Company, LimitedControlled release preparations having multi-layer structure
US7101567B1 (en)1998-05-292006-09-05Dainippon Sumitomo Pharma Co., Ltd.Controlled release preparations having multi-layer structure
EP1084703A1 (en)1998-05-292001-03-21Sumitomo Pharmaceuticals Company, LimitedControlled release preparations having multi-layer structure
US20140121741A1 (en)1998-06-032014-05-01Spr Therapeutics, LlcSystems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
WO1999064061A1 (en)1998-06-121999-12-16Bionebraska, Inc.GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
US6277413B1 (en)1998-07-172001-08-21Skyepharma, Inc.Biodegradable compositions for the controlled release of encapsulated substances
US20040225113A1 (en)1998-07-212004-11-11Lafleur David W.Keratinocyte derived interferon
US6472512B1 (en)1998-07-212002-10-29Human Genome Sciences, Inc.Keratinocyte derived interferon
US6270700B1 (en)1998-07-232001-08-07Societe De Conseils De Recherches Et D'applications Scientifiques, SasEncapsulation of water soluble peptides
US20080065090A1 (en)1998-08-142008-03-13Scribner Robert MMethods and apparatus for placing materials into bone
US6720407B1 (en)1998-08-282004-04-13Eli Lilly And CompanyMethod for administering insulinotropic peptides
US6551613B1 (en)1998-09-082003-04-22Alza CorporationDosage form comprising therapeutic formulation
WO2000013663A1 (en)1998-09-092000-03-16Alza CorporationDosage form comprising liquid formulation
US5951521A (en)1998-09-251999-09-14Minimed Inc.Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
US20040047888A1 (en)1998-09-302004-03-11Kenison Dale C.Pellet implant system for immediate and delayed release of antiparasitic drug
US6248112B1 (en)1998-09-302001-06-19C. R. Bard, Inc.Implant delivery system
US6447522B2 (en)1998-09-302002-09-10C. R. Bard, Inc.Implant delivery system
US6645192B2 (en)1998-09-302003-11-11Ivy Animal Health, Inc.Pellet implant system for immediate and delayed release of antiparasitic drug
US6284725B1 (en)1998-10-082001-09-04Bionebraska, Inc.Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6053927A (en)1998-10-152000-04-25Rsh-Gs TrustApparatus and method for implant removal
US6544239B2 (en)1998-10-162003-04-08Bio-Plexus Delaware, Inc.Releasable locking needle assembly with optional release accessory therefor
US20020048600A1 (en)1998-11-022002-04-25Padmanabh BhattControlled delivery of active agents
US20040157951A1 (en)1998-11-132004-08-12Wolf David E.Monodisperse preparations useful with implanted devices
WO2000029206A1 (en)1998-11-132000-05-25Sensor Technologies Inc.Monodisperse preparations useful with implanted devices
US20030060425A1 (en)1998-11-242003-03-27Ahlem Clarence N.Immune modulation method using steroid compounds
US6903186B1 (en)1998-12-072005-06-07Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.SAnalogues of GLP-1
US6419952B2 (en)1998-12-172002-07-16Alza CorporationConversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US20010036472A1 (en)1998-12-172001-11-01Wong Patrick S.-L.Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
WO2000038652A1 (en)1998-12-232000-07-06Amgen Inc.Polyol/oil suspensions for the sustained release of proteins
WO2000039280A2 (en)1998-12-312000-07-06Viragen, Inc.Leukocyte-derived interferon preparations
US6997922B2 (en)1998-12-312006-02-14Alza CorporationOsmotic delivery system having space efficient piston
US6544252B1 (en)1998-12-312003-04-08Alza CorporationOsmotic delivery system having space efficient piston
WO2000040273A2 (en)1999-01-082000-07-13Vical IncorporatedTreatment of viral diseases using an interferon omega expressing polynucleotide
US6703225B1 (en)1999-01-122004-03-09Sumitomo Pharmaceuticals Company, LimitedInterferon-α
US6433144B1 (en)1999-01-122002-08-13Viragen, Inc.Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US20090215694A1 (en)1999-01-142009-08-27Amylin Pharmaceuticals, IncLyophilized Formulations of Exendins and Exendin Agonist Analogs
US6902744B1 (en)1999-01-142005-06-07Amylin Pharmaceuticals, Inc.Exendin agonist formulations and methods of administration thereof
US20060069029A1 (en)1999-01-142006-03-30Kolterman Orville GExendin analog formulations
WO2000041548A2 (en)1999-01-142000-07-20Amylin Pharmaceuticals, Inc.Methods for glucagon suppression
US6872700B1 (en)1999-01-142005-03-29Amylin Pharmaceuticals, Inc.Methods for glucagon suppression
US7153825B2 (en)1999-01-142006-12-26Amylin Pharmaceuticals, Inc.Methods for glucagon suppression using modified exendins
US20080226689A1 (en)1999-02-082008-09-18Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20170319662A1 (en)1999-02-082017-11-09Intarcia Therapeutics Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20110160708A1 (en)1999-02-082011-06-30Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles
US7919109B2 (en)1999-02-082011-04-05Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20080226625A1 (en)1999-02-082008-09-18Intarcia Therapeutics, Inc.Stable non- aqueous single phase viscous vehicles and formulations utlizing such vehicles
US8048438B2 (en)1999-02-082011-11-01Intarcia Therapeutics, Inc.Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20170119855A1 (en)1999-02-082017-05-04Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en)1999-02-082007-08-21Alza CorporationStable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US8173150B2 (en)1999-02-082012-05-08Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles
US8372424B2 (en)1999-02-082013-02-12Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
WO2000045790A2 (en)1999-02-082000-08-10Alza CorporationStable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8992961B2 (en)1999-02-082015-03-31Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8268341B2 (en)1999-02-082012-09-18Intarcia Therapeutics, Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20150231256A1 (en)1999-02-082015-08-20Intarcia Therapeutics Inc.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030108609A1 (en)1999-02-082003-06-12Berry Stephen A.Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6451974B1 (en)1999-03-172002-09-17Novo Nordisk A/SMethod of acylating peptides and novel acylating agents
WO2000054745A2 (en)1999-03-182000-09-21Durect CorporationDevices and methods for pain management
US6835194B2 (en)1999-03-182004-12-28Durect CorporationImplantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en)1999-03-182003-04-01Durect CorporationDevices and methods for pain management
WO2000059476A1 (en)1999-04-052000-10-12Pharmaceutical Discovery CorporationMethods for fine powder formation
US6670368B1 (en)1999-04-062003-12-30Astrazeneca AbPyrimidine compounds with pharmaceutical activity
EP1046399A1 (en)1999-04-192000-10-25Schering CorporationHCV combination therapy, containing ribavirin in association with antioxidants
WO2000066138A2 (en)1999-04-302000-11-09Bionebraska, Inc.Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
US6924264B1 (en)1999-04-302005-08-02Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonists
WO2000066087A2 (en)1999-05-032000-11-09Southern Biosystems, Inc.Emulsion-based processes for making microparticles
WO2000067728A2 (en)1999-05-072000-11-16Pharmasol GmbhLipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US6428517B1 (en)1999-05-102002-08-06Milestone Scientific, Inc.Hand-piece for injection device with a retractable and rotating needle
USD430671S (en)1999-05-102000-09-05Shute Wallace BObstetrical forceps
US6593295B2 (en)1999-05-172003-07-15Conjuchem, Inc.Long lasting insulinotropic peptides
US6329336B1 (en)1999-05-172001-12-11Conjuchem, Inc.Long lasting insulinotropic peptides
US6849714B1 (en)1999-05-172005-02-01Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6146139A (en)1999-06-012000-11-14Harrison, Iii; Louis V.Forceps apparatus
US6506724B1 (en)1999-06-012003-01-14Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20060233841A1 (en)1999-06-042006-10-19Brodbeck Kevin JImplantable gel compositions and method of manufacture
US20030059376A1 (en)1999-06-042003-03-27Libbey Miles A.Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6485706B1 (en)1999-06-042002-11-26Delrx Pharmaceutical Corp.Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US20010040326A1 (en)1999-06-142001-11-15Lord CorporationResilient member with deformed element and method of forming same
US6833256B1 (en)1999-06-222004-12-21University Of MarylandInterferon tau mutants and methods for making them
US6528486B1 (en)1999-07-122003-03-04Zealand Pharma A/SPeptide agonists of GLP-1 activity
US6174547B1 (en)1999-07-142001-01-16Alza CorporationDosage form comprising liquid formulation
US7766924B1 (en)1999-07-282010-08-03Cardica, Inc.System for performing anastomosis
WO2001019345A1 (en)1999-09-102001-03-22Astrazeneca AbMethod to obtain microparticles
US6887470B1 (en)1999-09-102005-05-03Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887849B2 (en)1999-10-152005-05-03Conjuchem, Inc.Long lasting synthetic glucagon-like peptide {GLP-1}
WO2001028631A1 (en)1999-10-152001-04-26Deschutes Medical Products, Inc.Brachytherapy instrument and methods
US6821949B2 (en)1999-10-152004-11-23Conjuchem, Inc.Long lasting synthetic glucagon-like peptide (GLP-1)
US6514500B1 (en)1999-10-152003-02-04Conjuchem, Inc.Long lasting synthetic glucagon like peptide {GLP-!}
US6458387B1 (en)1999-10-182002-10-01Epic Therapeutics, Inc.Sustained release microspheres
WO2001028525A2 (en)1999-10-212001-04-26Alkermes Controlled Therapeutics, Inc.Method of producing sub-micron particles of biologically active agents
US6436091B1 (en)1999-11-162002-08-20Microsolutions, Inc.Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7022674B2 (en)1999-12-162006-04-04Eli Lilly And CompanyPolypeptide compositions with improved stability
WO2001043528A2 (en)1999-12-172001-06-21Durect CorporationDevices and methods in intracerebrospinal delivery of morphine-6-glucuronide
US6508808B1 (en)1999-12-212003-01-21Alza CorporationValve for osmotic devices
US6682522B2 (en)1999-12-212004-01-27Alza CorporationValve for osmotic devices
US20010031790A1 (en)1999-12-222001-10-18Beisswenger Paul J.Treatment for complications of type 2 diabetes
US6283949B1 (en)1999-12-272001-09-04Advanced Cardiovascular Systems, Inc.Refillable implantable drug delivery pump
US6572890B2 (en)2000-01-132003-06-03Osmotica Corp.Osmotic device containing venlafaxine and an anti-psychotic agent
WO2001051041A1 (en)2000-01-132001-07-19Osmotica Corp.Osmotic device containing venlafaxine and an anti-psychotic agent
US20020012818A1 (en)2000-01-192002-01-31Sakari RuppiCoated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US20030186858A1 (en)2000-01-312003-10-02Arentsen Anne CharlotteCrystallisation of a GLP-1 analogue
US20030138491A1 (en)2000-02-102003-07-24Alkermes Controlled Therapeutics, Inc.Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030032947A1 (en)2000-02-152003-02-13Microsolutions, Inc.Osmotic pump drug delivery systems and methods
US6471688B1 (en)2000-02-152002-10-29Microsolutions, Inc.Osmotic pump drug delivery systems and methods
US6464688B1 (en)2000-02-152002-10-15Microsolutions, Inc.Osmotic pump delivery system with flexible drug compartment
WO2001068168A1 (en)2000-03-132001-09-20Leiras OyDevice for inserting implants
US20030040699A1 (en)2000-03-132003-02-27Christine TallingDevice for inserting implants
US6579851B2 (en)2000-03-142003-06-17Amylin Pharmaceuticals, Inc.Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20030211974A1 (en)2000-03-212003-11-13Brodbeck Kevin J.Gel composition and methods
US20010031940A1 (en)2000-03-232001-10-18Hans-Joachim LoosDevice for administering implants
US20020098180A1 (en)2000-03-242002-07-25Huan-Yao LeiFullerene pharmaceutical compositions for preventing or treating disorders
US9044209B2 (en)2000-04-142015-06-02Attenuex Technologies, Inc.Method of removing an inflated implant
WO2001078683A2 (en)2000-04-192001-10-25Genentech, Inc.Sustained release formulations comprising growth hormone
US20020001631A1 (en)2000-04-192002-01-03Franklin OkumuSustained release formulations
US6992065B2 (en)2000-04-192006-01-31Genentech, Inc.Sustained release formulations
US6875748B2 (en)2000-04-212005-04-05Vical IncorporatedCompositions and methods for in vivo delivery of polynucleotide-based therapeutics
US6589157B2 (en)2000-05-182003-07-08Integrated Implant Systems, L.L.C.Drive mechanism for medical instrument
US6706689B2 (en)2000-05-192004-03-16Amylin Pharmaceuticals, Inc.Treatment of acute coronary syndrome with GLP-1
US6667061B2 (en)2000-05-252003-12-23Alkermes Controlled Therapeutics, Inc.Preparation of injectable suspensions having improved injectability
US20030113380A1 (en)2000-05-252003-06-19Alkermes Controlled Therapeutics, Inc. IPreparation of injectable suspensions having improved injectability
US6495164B1 (en)2000-05-252002-12-17Alkermes Controlled Therapeutics, Inc. IPreparation of injectable suspensions having improved injectability
US7084243B2 (en)2000-06-162006-08-01Eli Lilly And CompanyGlucagon-like peptide-1 analogs
US20020037309A1 (en)2000-08-102002-03-28Alkermes Controlled Therapeutics, Inc.Process for the preparation of polymer-based sustained release compositions
US6547250B1 (en)2000-08-212003-04-15Westport Research Inc.Seal assembly with two sealing mechanisms for providing static and dynamic sealing
US20100331868A1 (en)2000-08-242010-12-30Bardy Gust HMethod For Constructing An Instrument With A Two-Part Plunger For Subcutaneous Implantation
US8251946B2 (en)2000-08-242012-08-28Cardiac Science, Inc.Method for constructing an instrument with a two-part plunger for subcutaneous implantation
US8454552B2 (en)2000-08-242013-06-04Cardiac Science CorporationMethod for constructing an instrument with a covered bore for subcutaneous implantation
WO2002028366A2 (en)2000-10-062002-04-11Durect CorporationDevices and methods for management of inflammation
US20040115236A1 (en)2000-10-062004-06-17Chan Tai WahDevices and methods for management of inflammation
US20020197235A1 (en)2000-11-032002-12-26Moran Stanford MarkMethod for short-term and long-term drug dosimetry
WO2002036072A2 (en)2000-11-032002-05-10Biomedicines, Inc.Method for short-term and long-term drug dosimetry
US7727519B2 (en)2000-11-032010-06-01Intarcia Therapeutics, Inc.Method for treating hepatitis C virus with omega interferon
US20050201980A1 (en)2000-11-032005-09-15Moran Stanford M.Method for short-term and long-term drug dosimetry
WO2002067895A2 (en)2000-11-162002-09-06Durect CorporationImplant dosage form and use thereof for the delivery of a cholesterol lowering agent
US6626863B1 (en)2000-11-222003-09-30Nusaf, L.L.C.Safety syringe
US20050070883A1 (en)2000-11-292005-03-31Brown James EDevices and methods for controlled delivery from a drug delivery device
WO2002043800A2 (en)2000-11-292002-06-06Durect CorporationDevices and methods for controlled delivery from a drug delivery device
WO2002045752A2 (en)2000-12-082002-06-13Leo Pharma A/SDermal anti-inflammatory composition
US7199217B2 (en)2000-12-132007-04-03Eli Lilly And CompanyAmidated glucagon-like peptide-1
WO2002047716A2 (en)2000-12-132002-06-20Eli Lilly And CompanyChronic treatment regimen using glucagon-like insulinotropic peptides
US8273713B2 (en)2000-12-142012-09-25Amylin Pharmaceuticals, LlcMethods of treating obesity using PYY[3-36]
US20020141985A1 (en)2000-12-142002-10-03Amylin Parmaceuticals, Inc.Peptide YY and peptide YY agonists for treatment of metabolic disorders
US20020077599A1 (en)2000-12-192002-06-20Animas CorporationTranscutaneous inserter for low-profile infusion sets
US6899898B2 (en)2000-12-212005-05-31Nektar TherapeuticsInduced phase transition method for the production of microparticles containing hydrophobic active agents
WO2002069983A1 (en)2001-03-012002-09-12Bharat Serums & Vaccines Ltd.Amphotericin b aqueous composition
WO2002076344A1 (en)2001-03-232002-10-03Durect CorporationDelivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
WO2002085428A2 (en)2001-04-192002-10-31Microsolutions, Inc.Implantable osmotic pump
US7144863B2 (en)2001-06-012006-12-05Eli Lilly And CompanyGLP-1 formulations with protracted time action
US20020197185A1 (en)2001-06-202002-12-26Jamiolkowski Dennis D.Antimicrobial coatings for medical devices
US6514517B2 (en)2001-06-202003-02-04Ethicon, Inc.Antimicrobial coatings for medical devices
US20030045454A1 (en)2001-06-212003-03-06Franklin OkumuSustained release formulation
US7163688B2 (en)2001-06-222007-01-16Alza CorporationOsmotic implant with membrane and membrane retention means
US7163697B2 (en)2001-06-222007-01-16Johns Hopkins University School Of MedicineBiodegradable polymer compositions, compositions and uses related thereto
WO2003000230A1 (en)2001-06-222003-01-03Alza CorporationOsmotic implant with membrane and membrane retention means
US20030104063A1 (en)2001-06-222003-06-05Babcock Walter C.Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers
US20030007992A1 (en)2001-06-222003-01-09Southern Biosystems, Inc.Zero-order prolonged release coaxial implants
US20030138403A1 (en)2001-06-292003-07-24Maxygen ApsInterferon formulations
WO2003007981A1 (en)2001-07-202003-01-30Intermune, Inc.Methods of treating liver fibrosis
WO2003011892A2 (en)2001-07-312003-02-13The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human ServicesGlp-1 exendin-4 peptide analogs and uses thereof
US20040198654A1 (en)2001-08-232004-10-07Wolfgang GlaesnerGlucagon-like peptide-1analogs
US7101843B2 (en)2001-08-232006-09-05Eli Lilly And CompanyGlucagon-like peptide-1 analogs
WO2003020245A1 (en)2001-08-312003-03-13Alkermes Controlled Therapeutics Inc. IiResidual solvent extraction method and microparticles produced thereby
US20030118660A1 (en)2001-08-312003-06-26Alkermes Controlled Therapeutics Inc. IiResidual solvent extraction method and microparticles produced thereby
US7666835B2 (en)2001-09-072010-02-23Imperial Innovations LimitedOxyntomodulin for preventing or treating excess weight
WO2003024357A2 (en)2001-09-142003-03-27Martin Francis JMicrofabricated nanopore device for sustained release of therapeutic agent
US20060224145A1 (en)2001-09-172006-10-05Gillis Edward MDevice and method for accurate delivery of an active agent
WO2003024503A2 (en)2001-09-172003-03-27Durect CorporationDevice and method for accurate delivery of an active agent
US7459432B2 (en)2001-09-242008-12-02Imperial College Innovations Ltd.Modification of feeding behavior
US8217001B2 (en)2001-09-242012-07-10Imperial Innovations LimitedModification of feeding behavior
US20040002442A1 (en)2001-10-052004-01-01Clark PanPeptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US7041646B2 (en)2001-10-052006-05-09Bayer Pharmaceuticals CorporationMethods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
WO2003030923A1 (en)2001-10-052003-04-17Intermune, Inc.Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US20030078618A1 (en)2001-10-192003-04-24Fey Kate E.System and method for removing implanted devices
US20030097121A1 (en)2001-10-242003-05-22Claude JollyImplantable fluid delivery apparatuses and implantable electrode
US20040142902A1 (en)2001-11-082004-07-22Struijker- Boudier Harry A.J.Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20070248572A1 (en)2001-11-092007-10-25Intarica Therapeutics, Inc.Method for treating diseases with omega interferon
WO2003041684A2 (en)2001-11-142003-05-22Alza CorporationInjectable depot compositions and uses thereof
US20030157178A1 (en)2001-11-142003-08-21Guohua ChenInjectable depot composition
US20030180364A1 (en)2001-11-142003-09-25Guohua ChenCatheter injectable depot compositions and uses thereof
US7829109B2 (en)2001-11-142010-11-09Durect CorporationCatheter injectable depot compositions and uses thereof
WO2003041757A2 (en)2001-11-142003-05-22Alza CorporationCatheter injectable depot compositions and uses thereof
US20030170289A1 (en)2001-11-142003-09-11Guohua ChenInjectable depot compositions and uses thereof
US20030191099A1 (en)2001-11-272003-10-09Schering Ag17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
US20030108608A1 (en)2001-12-122003-06-12Erik LaridonThermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
US20030135153A1 (en)2001-12-172003-07-17Charles HagemeierDrug implant injection device
EP1323450A1 (en)2001-12-182003-07-02Risdon Pharma GmbHSyringe device
WO2003053400A1 (en)2001-12-192003-07-03Alza CorporationFormulation & dosage form for the controlled delivery of therapeutic agents
US7141547B2 (en)2001-12-212006-11-28Human Genome Sciences, Inc.Albumin fusion proteins comprising GLP-1 polypeptides
US8058233B2 (en)2002-01-102011-11-15Oregon Health And Science UniversityModification of feeding behavior using PYY and GLP-1
US20040029784A1 (en)2002-01-222004-02-12Hathaway David R.Methods and compositions for treating polycystic ovary syndrome
WO2003066585A2 (en)2002-02-082003-08-14Alkermes Controlled Therapeutics, Inc.Polymer-based compositions for sustained release
US8257682B2 (en)2002-02-272012-09-04Pharmain CorporationCompositions for delivery of therapeutics and other materials
US7635463B2 (en)2002-02-272009-12-22Pharmain CorporationCompositions for delivery of therapeutics and other materials
US8231859B2 (en)2002-02-272012-07-31Pharmain CorporationCompositions for delivery of therapeutics and other materials
US8277776B2 (en)2002-02-272012-10-02Pharmain CorporationCompositions for delivery of therapeutics and other materials
US7790140B2 (en)2002-02-272010-09-07Pharmain CorporationCompositions for delivery of therapeutics and other materials, and methods of making and using the same
US7589169B2 (en)2002-02-272009-09-15Pharmain CorporationCompositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2003072133A2 (en)2002-02-282003-09-04Norferm DaImmunostimulatory agent comprising a biomass of methanotrophic bacterium
WO2003072113A1 (en)2002-02-282003-09-04Norbrook Laboratories LimitedLong acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
US20050118221A1 (en)2002-02-282005-06-02William BlakelyLong acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
US20030215515A1 (en)2002-04-112003-11-20Medimmune Vaccines, Inc.Preservation of bioactive materials by spray drying
US6960192B1 (en)2002-04-232005-11-01Insulet CorporationTranscutaneous fluid delivery system
US20030220617A1 (en)2002-05-222003-11-27C. Dickerson Co.Safety needle introducer and universal needle protector for vascular access devices
US20140163057A1 (en)2002-05-312014-06-12Titan Pharmaceuticals, Inc.Implantable Polymeric Device for Sustained Release of Buprenorphine
US7736665B2 (en)2002-05-312010-06-15Titan Pharmaceuticals, Inc.Implantable polymeric device for sustained release of buprenorphine
US7074423B2 (en)2002-06-172006-07-11Alza CorporationOsmotic delivery system with early zero order push power engine
US20030233101A1 (en)2002-06-172003-12-18Senorx, Inc.Plugged tip delivery tube for marker placement
US20040097906A1 (en)2002-06-172004-05-20Fereira Pamela J.Osmotic delivery system with early zero order push power engine
US20040001889A1 (en)2002-06-252004-01-01Guohua ChenShort duration depot formulations
US6939556B2 (en)2002-06-262005-09-06Alza CorporationMinimally compliant, volume efficient piston for osmotic drug delivery systems
WO2004002565A1 (en)2002-06-262004-01-08Alza CorporationMinimally compliant, volume efficient piston for osmotic drug delivery systems
US7112335B2 (en)2002-06-262006-09-26Alza CorporationMinimally compliant, volume-efficient piston for osmotic drug delivery systems
US20060014678A1 (en)2002-06-282006-01-19Imperial College Innovations Ltd.Modification of feeding behavior
US20040001689A1 (en)2002-06-282004-01-01Intel CorporationSystem and method for improving audio during post-production of video recordings
US20040022859A1 (en)2002-07-312004-02-05Guohua ChenInjectable multimodal polymer depot compositions and uses thereof
US20040024069A1 (en)2002-07-312004-02-05Guohua ChenInjectable depot compositions and uses thereof
US20060084922A1 (en)2002-09-042006-04-20Ruark BothaDevice for securing a blood vessel cannula to a body
US20040215133A1 (en)2002-09-182004-10-28Allergan, Inc.Apparatus for delivery of ocular implants
WO2004026106A2 (en)2002-09-182004-04-01Allergan, Inc.Methods and apparatus for delivery of ocular implants
WO2004035762A2 (en)2002-10-172004-04-29Alkermes Controlled Therapeutics, Inc. IiMicroencapsulation and sustained release of biologically active polypeptides
WO2004034975A2 (en)2002-10-172004-04-29Alkermes Controlled Therapeutics, Inc.Sustained release profile modification
WO2004036186A2 (en)2002-10-172004-04-29Alkermes Controlled Therapeutics, Inc. IiMicroencapsulation and sustained release of biologically active polypeptides
WO2004035754A2 (en)2002-10-172004-04-29Alkermes Controlled Therapeutics, Inc. IiMicroencapsulation and sustained release of biologically active polypeptides
US20040209801A1 (en)2002-10-222004-10-21Brand Stephen J.Treatment of diabetes
US20040151753A1 (en)2002-11-062004-08-05Guohua ChenControlled release depot formulations
US6969702B2 (en)2002-11-202005-11-29Neuronova AbCompounds and methods for increasing neurogenesis
WO2004046338A2 (en)2002-11-202004-06-03North Shore-Long Island Jewish Research InstituteUse of hmgb polypeptides for increasing immune responses
US20050009742A1 (en)2002-11-202005-01-13Goran BertilssonCompounds and methods for increasing neurogenesis
US7014636B2 (en)2002-11-212006-03-21Alza CorporationOsmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7316680B2 (en)2002-11-212008-01-08Intarcia Therapeutics, Inc.Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US20040102762A1 (en)2002-11-212004-05-27Gilbert Scott JayOsmotic delivery device having a two-way valve and dynamically self-adjusting flow channel
WO2004052336A2 (en)2002-12-102004-06-24Durect CorporationHigh viscosity liquid controlled delivery system and medical or surgical device
US20040266683A1 (en)2002-12-172004-12-30Hathaway David RPrevention and treatment of cardiac arrhythmias
US20040224903A1 (en)2002-12-192004-11-11Stephen BerryStable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US8398967B2 (en)2002-12-192013-03-19Intarcia Therapeutics, Inc.Particle formulations for use in pharmaceutical compositions
US20090087408A1 (en)2002-12-192009-04-02Intarcia Therapeutics, Inc.Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
WO2004056338A2 (en)2002-12-192004-07-08Alza CorporationStable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US7825091B2 (en)2003-01-102010-11-02Imperial Innovations LimitedModification of feeding behaviour
US20080064636A1 (en)2003-01-102008-03-13Imperial College Innovations LimitedModification of Feeding Behaviour
US20040142867A1 (en)2003-01-142004-07-22Kiyomoto OiStabilized proteinic preparation
US20070149011A1 (en)2003-02-182007-06-28Medconx, Inc.Male medical device electrical connector with engineered friction fit
WO2004089335A2 (en)2003-03-312004-10-21Alza CorporationNon-aqueous single phase vehicles and formulations utilizing such vehicles
US20050008661A1 (en)2003-03-312005-01-13Fereira Pamela J.Non-aqueous single phase vehicles and formulations utilizing such vehicles
US7207982B2 (en)2003-03-312007-04-24Alza CorporationOsmotic pump with means for dissipating internal pressure
US20050276856A1 (en)2003-03-312005-12-15Fereira Pamela JNon-aqueous single phase vehicles and formulations utilizing such vehicles
US20050010196A1 (en)2003-03-312005-01-13Fereira Pamela J.Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
WO2004089458A1 (en)2003-04-032004-10-21Valera Pharmaceuticals, Inc.Implanting device and method of using same
US20040199140A1 (en)2003-04-032004-10-07Rue Matthew L.Implanting device and method of using same
US7214206B2 (en)2003-04-032007-05-08Valera Pharmaceuticals, Inc.Implanting device and method of using same
WO2004103342A2 (en)2003-05-162004-12-02Alkermes Controlled Therapeutics, Inc.Injectable sustained release compositions
US20050079200A1 (en)2003-05-162005-04-14Jorg RathenowBiocompatibly coated medical implants
US20050215475A1 (en)2003-05-302005-09-29John OngTransmucosal delivery of peptides and proteins
US20050079202A1 (en)2003-05-302005-04-14Guohua ChenImplantable elastomeric depot compositions and uses thereof
US20060178304A1 (en)2003-06-032006-08-10Novo Nordisk A/SStabilized pharmaceutical peptide compositions
US20050004557A1 (en)2003-06-122005-01-06Russell Scott M.Orifice device having multiple channels with varying flow rates for drug delivery
US20050010942A1 (en)2003-07-092005-01-13Samsung Electronics Co., Ltd.Optical disc drive
US20080260838A1 (en)2003-08-012008-10-23Mannkind CorporationGlucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7205409B2 (en)2003-09-042007-04-17Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050070927A1 (en)2003-09-302005-03-31Feinberg Marc E.Tissue approximation device
US7241457B2 (en)2003-09-302007-07-10Alza CorporationOsmotically driven active agent delivery device providing an ascending release profile
US20050095284A1 (en)2003-10-312005-05-05Alza CorporationOsmotic pump with self-retaining, fast-start membrane plug
US7407499B2 (en)2003-10-312008-08-05Intarcia Therapeutics, Inc.Osmotic pump with self-retaining, fast-start membrane plug
US20050101943A1 (en)2003-11-062005-05-12Alza CorporationModular imbibition rate reducer for use with implantable osmotic pump
US20050281879A1 (en)2003-11-142005-12-22Guohua ChenExcipients in drug delivery vehicles
US20050106214A1 (en)2003-11-142005-05-19Guohua ChenExcipients in drug delivery vehicles
US20050118206A1 (en)2003-11-142005-06-02Luk Andrew S.Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2005048930A2 (en)2003-11-142005-06-02Alza CorporationSurfactant-based gel as an injectable, sustained drug delivery vehicle
US20170319470A1 (en)2003-11-172017-11-09Intarcia Therapeutics, Inc.Methods of manufacturing viscous liquid pharmaceutical formulations
US20130052237A1 (en)2003-11-172013-02-28Intarcia Therapeutics, Inc.Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations
US7964183B2 (en)2003-11-172011-06-21Intarcia Therapeutics, Inc.Composition and dosage form comprising a particle formulation and suspending vehicle
US20050112188A1 (en)2003-11-172005-05-26Eliaz Rom E.Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US7731947B2 (en)2003-11-172010-06-08Intarcia Therapeutics, Inc.Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005048952A2 (en)2003-11-172005-06-02Alza CorporationComposition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US8257691B2 (en)2003-11-172012-09-04Intarcia Therapeutics, Inc.Composition and dosage form comprising a particle formulation and suspending vehicle
US20050131386A1 (en)2003-12-152005-06-16Freeman Lynetta J.Method and device for minimally invasive implantation of biomaterial
US20050143749A1 (en)2003-12-312005-06-30Depuy Spine, Inc.Inserter instrument and implant clip
US20050216087A1 (en)2004-01-052005-09-29St. Francis Medical Technologies, Inc.Disk repair structures for positioning disk repair material
US20050175701A1 (en)2004-02-102005-08-11Alza CorporationCapillary moderator for osmotic delivery system
US20060094652A1 (en)2004-02-112006-05-04Levy Odile EHybrid polypeptides with selectable properties
US20060293232A1 (en)2004-02-112006-12-28Amylin Pharmaceuticals, Inc.Hybrid polypeptides with selectable properties
US8722037B2 (en)2004-03-192014-05-13Meck Sharp & Dohme B.V.X-ray visible drug delivery device
US20070141102A1 (en)2004-03-242007-06-21N.V. OrganonDrug delivery system based on polyethylene vinylacetate copolymers
US7612176B2 (en)2004-04-152009-11-03Alkermes, Inc.Polymer-based sustained release device
EP2133073A1 (en)2004-04-152009-12-16Amylin Pharmaceuticals, Inc.Poly(lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
US20070166352A1 (en)2004-04-152007-07-19Alkermes, Inc.Polymer-based sustained release device
US7563871B2 (en)2004-04-152009-07-21Alkermes, Inc.Polymer-based sustained release device
US20090247463A1 (en)2004-04-152009-10-01Alkermes, Inc.Polymer-based sustained release device
US7456254B2 (en)2004-04-152008-11-25Alkermes, Inc.Polymer-based sustained release device
WO2005102293A1 (en)2004-04-152005-11-03Amylin Pharmaceuticals, Inc.Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
US20050271702A1 (en)2004-04-152005-12-08Wright Steven GPolymer-based sustained release device
WO2005110425A1 (en)2004-04-152005-11-24Alkermes, Inc.Polymer-based sustained release device
US20080112994A1 (en)2004-05-252008-05-15Intarcia Therapeutics, Inc.Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20050266087A1 (en)2004-05-252005-12-01Gunjan JunnarkarFormulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
EP1600187A2 (en)2004-05-272005-11-30Cordis CorporationOrifice device having multiple channels with varying flow rates for drug delivery
US20090042781A1 (en)2004-06-282009-02-12Novo Nordisk A/SMethods for Treating Diabetes
US20060030526A1 (en)2004-08-052006-02-09Kui LiuStable suspension formulations of erythropoietin receptor agonists
WO2006017772A1 (en)2004-08-052006-02-16Alza CorporationStable suspension formulations of erythropoietin receptor agonists
WO2006023526A2 (en)2004-08-182006-03-02Waters Investments LimitedDefined leak path for high pressure seal
US20080110515A1 (en)2004-08-182008-05-15Waters Investments LimitedDefined Lead Path For High Pressure Seal
US20090163447A1 (en)2004-08-252009-06-25Maggio Edward TCompositions for Drug Administration
US20060094693A1 (en)2004-09-212006-05-04Point Therapeutics, Inc.Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
US20060073182A1 (en)2004-10-012006-04-06Wong Vernon GConveniently implantable sustained release drug compositions
US20080038316A1 (en)2004-10-012008-02-14Wong Vernon GConveniently implantable sustained release drug compositions
US7442682B2 (en)2004-10-192008-10-28Nitto Denko CorporationTransepithelial delivery of peptides with incretin hormone activities
US20060084604A1 (en)2004-10-192006-04-20Chieko KitauraTransepithelial delivery of peptides with incretin hormone activities
US7604647B2 (en)2004-10-222009-10-20Medical Instrument Development Laboratories, Inc.Ophthalmic cannula insertion tool and method
US20090156474A1 (en)2004-11-012009-06-18Amylin Pharmaceuticals, Inc.Methods for treating obesity and obesity related diseases and disorders
US20080207512A1 (en)2004-11-012008-08-28Amylin Pharmaceuticals, Inc.Methods for Treating Obesity and Obesity Related and Disorders
US20060106399A1 (en)2004-11-182006-05-18Taras John SDrill guide tissue protector
US20060141040A1 (en)2004-12-232006-06-29Guohua ChenInjectable non-aqueous suspension
US20060142234A1 (en)2004-12-232006-06-29Guohua ChenInjectable non-aqueous suspension
US7393827B2 (en)2004-12-302008-07-01Diakine Therapeutics, Inc.Pharmaceutical compositions and methods for restoring β-cell mass and function
US20060160736A1 (en)2004-12-302006-07-20Diakine Therapeutics, Inc.Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8888745B2 (en)2005-01-242014-11-18Merck Sharp & Dohme B.V.Applicator for inserting an implant
WO2006077250A1 (en)2005-01-242006-07-27N.V. OrganonApplicator for inserting an implant
WO2006077242A1 (en)2005-01-242006-07-27N.V. OrganonApplicator for inserting an implant
US20100298807A1 (en)2005-01-242010-11-25Akzo Nobel N.V.Applicator for inserting an implant
WO2006081279A2 (en)2005-01-252006-08-03Microchips, Inc.Control of drug release by transient modification of local microenvironments
US20100297209A1 (en)2005-02-032010-11-25Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
US20170368145A1 (en)2005-02-032017-12-28Intarcia Therapeutics, Inc.Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US9526763B2 (en)2005-02-032016-12-27Intarcia Therapeutics Inc.Solvent/polymer solutions as suspension vehicles
US9682127B2 (en)2005-02-032017-06-20Intarcia Therapeutics, Inc.Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US8940316B2 (en)2005-02-032015-01-27Intarcia Therapeutics, Inc.Osmotic delivery comprising an insulinotropic peptide and uses thereof
US8273365B2 (en)2005-02-032012-09-25Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US20150231062A1 (en)2005-02-032015-08-20Intarcia Therapeutics Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US20120178687A1 (en)2005-02-032012-07-12Intarcia Therapeutics, Inc.Suspension formulations of insulinotropic peptides and uses thereof
US9095553B2 (en)2005-02-032015-08-04Intarcia Therapeutics Inc.Solvent/polymer solutions as suspension vehicles
US8211467B2 (en)2005-02-032012-07-03Intarcia Therapeutics, Inc.Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles
US7655254B2 (en)2005-02-032010-02-02Intarcia Therapeutics, Inc.Implantable device for continuous delivery of interferon
US8206745B2 (en)2005-02-032012-06-26Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
US8158150B2 (en)2005-02-032012-04-17Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US8114437B2 (en)2005-02-032012-02-14Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
US8992962B2 (en)2005-02-032015-03-31Intarcia Therapeutics Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US9539200B2 (en)2005-02-032017-01-10Intarcia Therapeutics Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US8470353B2 (en)2005-02-032013-06-25Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US20170056476A1 (en)2005-02-032017-03-02Intarcia Therapeutics Inc.Solvent/polymer solutions as suspension vehicles
US20060263433A1 (en)2005-02-032006-11-23Ayer Rupal ASuspension formulation of interferon
US8460694B2 (en)2005-02-032013-06-11Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
US8052996B2 (en)2005-02-032011-11-08Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US20170348392A1 (en)2005-02-032017-12-07Intarcia Therapeutics Inc.Solvent/polymer solutions as suspension vehicles
US20060251618A1 (en)2005-02-032006-11-09Paula DennisImplantable device for continuous delivery of interferon
US20110264077A1 (en)2005-02-032011-10-27Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
US8299025B2 (en)2005-02-032012-10-30Intarcia Therapeutics, Inc.Suspension formulations of insulinotropic peptides and uses thereof
US20070281024A1 (en)2005-02-032007-12-06Alza CorporationTwo-Piece, Internal-Channel Osmotic Delivery System Flow Modulator
US20080260840A1 (en)2005-02-032008-10-23Alessi Thomas RSuspension formulations of insulinotropic peptides and uses thereof
TW200634060A (en)2005-02-032006-10-01Alza CorpSolvent/polymer solutions as suspension vehicles
US20170181964A1 (en)2005-02-032017-06-29Intarcia Therapeutics Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US8440226B2 (en)2005-02-032013-05-14Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
US8367095B2 (en)2005-02-032013-02-05Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US20060216242A1 (en)2005-02-032006-09-28Rohloff Catherine MSuspending vehicles and pharmaceutical suspensions for drug dosage forms
US20130034210A1 (en)2005-02-032013-02-07Intarcia Therapeutics, Inc.Solvent/polymer solutions as suspension vehicles
WO2006083761A2 (en)2005-02-032006-08-10Alza CorporationSolvent/polymer solutions as suspension vehicles
US20060193918A1 (en)2005-02-032006-08-31Rohloff Catherine MSolvent/polymer solutions as suspension vehicles
US20110104111A1 (en)2005-02-032011-05-05Intarcia Therapeutics, Inc.Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles
WO2006084139A2 (en)2005-02-032006-08-10Intarcia Therapeutics, Inc.An implantable interferon-containing device
WO2006086727A2 (en)2005-02-092006-08-17Entelos, Inc.Treating diabetes with glucagon-like peptide-1 secretagogues
US20090036364A1 (en)2005-02-112009-02-05Amylin Pharmaceuticals, Inc.Gip analog and hybrid polypeptides with selectable properties
US20080312157A1 (en)2005-02-112008-12-18Amylin Pharmaceuticals, Inc.Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en)2005-02-112012-09-11Amylin Pharmaceuticals, Inc.GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en)2005-02-112009-11-19Amylin Pharmaceuticals, Inc.Hybrid Polypeptides with Selectable Properties
US8202836B2 (en)2005-03-092012-06-19Imperial Innovations LimitedModified PYY (3-36) peptides and their effects on feeding behavior
US8114430B2 (en)2005-03-152012-02-14Intarcia Therapeutics, Inc.Polyoxaester suspending vehicles for use with implantable delivery systems
US20060246138A1 (en)2005-03-152006-11-02Rohloff Catherine MPolyoxaester suspending vehicles for use with implantable delivery systems
US7959938B2 (en)2005-03-152011-06-14Intarcia Therapeutics, Inc.Polyoxaester suspending vehicles for use with implantable delivery systems
WO2006101815A2 (en)2005-03-152006-09-28Alza CorporationPharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems
US7879794B2 (en)2005-03-312011-02-01Amylin Pharmaceuticals, Inc.Methods for controlling binge eating disorders
US8278267B2 (en)2005-03-312012-10-02Amylin Pharmaceuticals, LlcMethod of modifying food preference comprising administering amylin or amylin agonist
US20080200383A1 (en)2005-04-082008-08-21Amylin Pharmaceuticals, Inc.Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
WO2006111169A1 (en)2005-04-212006-10-26Gastrotech Pharma A/SPharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US20060264890A1 (en)2005-05-062006-11-23Medtronic Minimed, Inc.Needle inserter and method for infusion device
WO2006131730A1 (en)2005-06-062006-12-14Camurus AbGlp-1 analogue formulations
US20060280795A1 (en)2005-06-082006-12-14Dexcel Pharma Technologies, Ltd.Specific time-delayed burst profile delivery system
USD565179S1 (en)*2005-06-162008-03-25Pentax CorporationBone implant
US20080269725A1 (en)2005-07-222008-10-30Trent DeemOsmotically Driven Dispense Pump and Related Components for Use in High Pressure Applications
US20070027105A1 (en)2005-07-262007-02-01Alza CorporationPeroxide removal from drug delivery vehicle
US20090312246A1 (en)2005-08-192009-12-17Amylin Pharmaceuticals, Inc.Uses of Glucoregulatory Proteins
WO2007024700A2 (en)2005-08-192007-03-01Amylin Pharmaceuticals, Inc.Exendin for treating diabetes and reducing body weight
WO2007056681A2 (en)2005-11-042007-05-18Smithkline Beecham CorporationMethods for administering hypoglycemic agents
US20070207958A1 (en)2005-11-092007-09-06Bridon Dominique PMethod of treatment of diabetes and/or obesity with reduced nausea side effect
US8039432B2 (en)2005-11-092011-10-18Conjuchem, LlcMethod of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007075534A2 (en)2005-12-162007-07-05Nektar Therapeutics Al, CorporationPolymer conjugates of glp-1
US20090209460A1 (en)2005-12-162009-08-20Amylin Pharmaceuticals, Inc.Compositions and methods for treating obesity and related metabolic disorders
WO2007084460A2 (en)2006-01-182007-07-26Qps, LlcPharmaceutical compositions with enhanced stability
US20090012463A1 (en)2006-01-192009-01-08N.V. OrganonKit for and method of assembling an applicator for inserting an implant
WO2007082889A1 (en)2006-01-192007-07-26N.V. OrganonKit for and method of assembling an applicator for inserting an implant
US20090186817A1 (en)2006-03-212009-07-23Amylin Pharmaceuticals, Inc.Peptide-peptidase inhibitor conjugates and methods of using same
US20090074734A1 (en)2006-05-022009-03-19Actogenix N.V.Microbial intestinal delivery of obesity related peptides
WO2007133778A2 (en)2006-05-122007-11-22Amylin Pharmaceuticals, Inc.Methods to restore glycemic control
EP2020990A2 (en)2006-05-302009-02-11Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
WO2007140416A2 (en)2006-05-302007-12-06Intarcia Therapeutics, Inc.Two-piece, internal-channel osmotic delivery system flow modulator
US8263736B2 (en)2006-07-032012-09-11Imperial Innovations LimitedCompounds and their effects on feeding behaviour
US20080020016A1 (en)2006-07-112008-01-24Quest Pharmaceutical Services, LlcPharmaceutical compositions for sustained release delivery of peptides
US20100144621A1 (en)2006-08-042010-06-10Dennis KimUse of Exendins and Exendin Agonists and GLP-1 Receptor Agonists for Altering the Concentration of Fibrinogen
WO2008021133A2 (en)2006-08-092008-02-21Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies
US20110166554A1 (en)2006-08-092011-07-07Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies for use therein
US20080091176A1 (en)2006-08-092008-04-17Alessi Thomas ROsmotic delivery systems and piston assemblies for use therein
US20140378900A1 (en)2006-08-092014-12-25Intarcia Therapeutics, Inc.Osmotic Delivery Systems and Piston Assemblies for Use Therein
US7682356B2 (en)2006-08-092010-03-23Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies for use therein
US8801700B2 (en)2006-08-092014-08-12Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies for use therein
US7879028B2 (en)2006-08-092011-02-01Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies for use therein
US20100185184A1 (en)2006-08-092010-07-22Intarcia Therapeutics, Inc.Osmotic delivery systems and piston assemblies for use therein
WO2008041245A2 (en)2006-10-052008-04-10Panacea Biotec Ltd.Injectable depot composition and it's process of preparation
US7632256B2 (en)2006-10-242009-12-15Mosler Theodore JCatheter gripping device
WO2008061355A1 (en)2006-11-242008-05-29Matregen Corp.Glp-1 depot systems, and methods of manufacture and uses thereof
US8101576B2 (en)2006-12-132012-01-24Imperial Innovations LimitedCompounds and their effects on feeding behaviour
WO2008086086A2 (en)2007-01-052008-07-17Indiana University Research And Technology CorporationGlucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20090022727A1 (en)2007-01-262009-01-22Alza Corp.Injectable, nonaqueous suspension with high concentration of therapeutic agent
US8262667B1 (en)2007-02-232012-09-11Holmed CorporationMulti-diameter implant forceps
WO2008133908A2 (en)2007-04-232008-11-06Intarcia Therapeutics, Inc.Suspension formulations of insulinotropic peptides and uses thereof
WO2008134425A1 (en)2007-04-272008-11-06Cedars-Sinai Medical CenterUse of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US20090202481A1 (en)2008-02-082009-08-13Qps LlcComposition for Sustained Release Delivery of Proteins or Peptides
US20170079906A1 (en)2008-02-132017-03-23Intarcia Therapeutics Inc.Devices, formulations, and methods for delivery of multiple beneficial agents
US9572889B2 (en)2008-02-132017-02-21Intarcia Therapeutics, Inc.Devices, formulations, and methods for delivery of multiple beneficial agents
US8343140B2 (en)2008-02-132013-01-01Intarcia Therapeutics, Inc.Devices, formulations, and methods for delivery of multiple beneficial agents
US20090202608A1 (en)2008-02-132009-08-13Alessi Thomas RDevices, formulations, and methods for delivery of multiple beneficial agents
US20150111818A1 (en)2008-02-132015-04-23Intarcia Therapeutics, Inc.Devices, formulations, and methods for delivery of multiple beneficial agents
US8926595B2 (en)2008-02-132015-01-06Intarcia Therapeutics, Inc.Devices, formulations, and methods for delivery of multiple beneficial agents
US20090210019A1 (en)2008-02-142009-08-20Dennis Dong-Won KimTreatment of excess weight by neural downregulation in combination with compositions
WO2009109927A2 (en)2008-03-052009-09-11Tel Hashomer Medical Research Infrastructure And Services Ltd.Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
US20110091527A1 (en)2008-04-012011-04-21Mosamedix B.V.Compositions and methods for reducing scar formation in wound healing
US20090254143A1 (en)2008-04-042009-10-08Tweden Katherine SMethods and systems for glucose regulation
WO2009143285A2 (en)2008-05-212009-11-26Amylin Pharmaceuticals, Inc.Exendins to lower cholestrol and triglycerides
US20100105627A1 (en)2008-09-172010-04-29Paul SalamaPharmaceutical compositions and related methods of delivery
US20160030337A1 (en)2008-09-302016-02-04Braeburn Pharmaceuticals Bvba SprlImplantable device for the delivery of risperidone and methods of use thereof
US9078900B2 (en)2008-09-302015-07-14Braeburn Pharmaceuticals Bvba SprlImplantable device for the delivery of risperidone and methods of use thereof
WO2010045169A1 (en)2008-10-142010-04-22Medtronic, Inc.Subcutaneous delivery tool
US20100094252A1 (en)2008-10-142010-04-15Medtronic, Inc.Subcutaneous delivery tool
US20170119854A1 (en)2008-10-152017-05-04Intarcia Therapeutics, Inc.Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100092566A1 (en)2008-10-152010-04-15Alessi Thomas RHighly concentrated drug particles, formulations, suspensions and uses thereof
US20160022582A1 (en)2008-10-152016-01-28Intarcia Therapeutics, Inc.Highly concentrated drug particles, formulations, suspensions and uses thereof
NZ592113A (en)2008-10-152012-04-27Intarcia Therapeutics IncHighly concentrated drug particles, formulations, suspensions and uses thereof
US20100298840A1 (en)2009-05-222010-11-25Schwartz Lyman DPhimosis Treatment Device and Method
US20140257272A1 (en)2009-08-072014-09-11Ulthera, Inc.Handpiece and methods for performing subcutaneous surgery
US20130030417A1 (en)2009-09-282013-01-31Intarcia Therapeutics, Inc.Rapid Establishment and/or Termination of Substantial Steady-State Drug Delivery
US20160354305A1 (en)2009-09-282016-12-08Intarcia Therapeutics, Inc.Rapid establishment and/or termination of substantial steady-state drug delivery
US20110076317A1 (en)2009-09-282011-03-31Alessi Thomas RRapid establishment and/or termination of substantial steady-state drug delivery
US8298561B2 (en)2009-09-282012-10-30Intarcia Therapeutics, Inc.Rapid establishment and/or termination of substantial steady-state drug delivery
US8815802B2 (en)2009-12-162014-08-26Novo Nordisk A/SGLP-1 analogues and derivatives
US20110152181A1 (en)2009-12-222011-06-23Eli Lilly And CompanyOxyntomodulin peptide analogue
US20110152182A1 (en)2009-12-222011-06-23Eli Lilly And CompanyOxyntomodulin peptide analogue
US20110306549A1 (en)2010-06-092011-12-15Amylin Pharmaceuticals, Inc.Glp-1 receptor agonists to treat pancreatitis
US8747412B2 (en)2011-02-142014-06-10Imds CorporationSystem and method for bone anchor removal
US20150057227A1 (en)2011-02-162015-02-26Intarcia Therapeutics, Inc.Compositions, devices and methods of use thereof for the treatment of cancers
US20120208755A1 (en)2011-02-162012-08-16Intarcia Therapeutics, Inc.Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20170252409A1 (en)2011-02-162017-09-07Intarcia Therapeutics, Inc.Compositions, devices and methods of use thereof for the treatment of cancers
US20120303045A1 (en)2011-05-262012-11-29Derm Instruments & Innovations LlcSkin removal instrument
WO2013004983A1 (en)2011-07-042013-01-10Imperial Innovations LimitedNovel compounds and their effects on feeding behaviour
US20150001118A1 (en)2011-09-162015-01-01Golden Aluminum, Inc.Application of designs to portion of food container
US20140058409A1 (en)2012-04-192014-02-27Removaid AsDevice for removing an item implanted underneath the skin
GB2501400A (en)2012-04-192013-10-23Removaid AsTool for removing a subcutaneous implant
US20130296661A1 (en)2012-05-042013-11-07Pacesetter, Inc.System and method for implanting a physiologic sensor assembly
US20150133791A1 (en)2012-05-292015-05-14National University Corporation Kochi UniversityArtery visualization device and artery imaging device
US20130324977A1 (en)2012-06-042013-12-05Medtronic, Inc.Transcutaneous implant tools, systems and methods
WO2013184235A1 (en)2012-06-042013-12-12Medtronic, Inc.Transcutaneous implant tools, systems and methods
US20140058425A1 (en)2012-08-272014-02-27Amir PoratManually operated surgical devices with operative portions formed of a see-through material
US20150297509A1 (en)2012-11-192015-10-22Braeburn Pharmaceuticals Bvba SprlImplantable drug delivery compositions and methods of treatment thereof
US20140324067A1 (en)2013-01-092014-10-30Senseonics, IncorporatedSubcutaneous tunneling and implantation tools for a disk-shaped sensor
US20140236162A1 (en)2013-02-192014-08-21Mark BaronganApparatus for Removing Devices Implanted in the Body
US20150359553A1 (en)2014-06-162015-12-17Med-El Elektromedizinische Geraete GmbhImplant magnet insertion and removal tools
US9889085B1 (en)2014-09-302018-02-13Intarcia Therapeutics, Inc.Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160354115A1 (en)*2015-06-032016-12-08Intarcia Therapeutics, Inc.Implant placement and removal systems
USD789539S1 (en)*2015-07-092017-06-13Spinal Surgical Strategies, LlcFusion cage
US20180009871A1 (en)2016-05-162018-01-11Intarcia Therapeutics Inc.Glucagon-receptor selective polypeptides and methods of use thereof
USD835783S1 (en)*2016-06-022018-12-11Intarcia Therapeutics, Inc.Implant placement guide
USD840030S1 (en)*2016-06-022019-02-05Intarcia Therapeutics, Inc.Implant placement guide
USD816843S1 (en)*2017-06-072018-05-01Alevio, LlcOrthopedic implant

Non-Patent Citations (265)

* Cited by examiner, † Cited by third party
Title
"Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment - John G McHutchison, Paul J Pockros, Scripps Clinic, La Jolla, CA; Peter Langecker, Dennis Blanchett, William - Lang, Mark Moran, BioMedicines, Inc, Emeryville, CA", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 34, no. 4, 1 October 2001 (2001-10-01), US , pages A333, XP004716177, ISSN: 0270-9139, DOI: 10.1053/jhep.2001.21410
"Open-label phase II study of omega interferon in previously untreated HCV infected patients - Mathias Plauth, Stadisches Klinikum, Dessau Germany; Helga Meisel, Institut fur Medizinische Virologie, Berlin Germany; Peter Langecker, Mark Moran, William Lang, Dennis Blachett, BioMedicines, Emeryville,", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 34, no. 4, 1 October 2001 (2001-10-01), US , pages A331, XP004716169, ISSN: 0270-9139
"Abstracts 2007," Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (XP002538652).
"Implantable infusion pumps: technology poised for takeoff," BBI Newsletter 17(12):209-211 (Dec. 1994).
"Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,"Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release).
"Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1," NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release).
"Introduction to Antibodies", http://www.chemicon.com/resource/ANT101/al.asp, 8 pages (retrieved May 2, 2007).
"Search Report and Written Opinion" dated Dec. 19, 2008 for PCT/US2008/005235, filed Apr. 22, 2008.
"Sequence Listings for International Patent Application Publication No. W02009109927, Wipo Patentscope", http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012).
Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer," J. Clin. Oncol. 15(ll):3330-3337 (Nov. 1997).
Adolf et al., "Antigenic structure of human interferon ω1 (Interferon α11 1): comparison with other human interferons," J. Gen. Virol. 68(6): 1669-1676 (Jun. 1987).
Adolf et al., "Human interferon ω1. isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochim. Biophys. Acta 108(9): 167-174 (Jun. 1991).
Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1. evidence that IFN-ω1 is a component of human leukocyte IFN," Virology 175(2):410-471 (Apr. 1990).
Adolf et al., "Purification and characterization of natural human interferon ω1," J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
Adolf, "Human interferon omega-a review," Mult. Sclr. ES44-47 (1995).
Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116.
Akers, et al., "Formulation Design and Development of Parenteral Suspensions," Journal of Parenteral Science & Technology, 41(3): 88-96 (1987).
Alonso, et al., "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," Pharmaceutical Research, 10(7):945-953 (1993).
Amylin Pharmaceuticals, Inc., Prescribing Information for BYETTA® (Exenatide) Injection, rev. Oct. 2009, 34 pages.
ANDRX Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984).
Astrazeneca Pharmaceuticals LP, Prescribing Information for BYDUREON® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages.
Aulitzky, " Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama," Journal of Clinical Oncology 7(12):1875-1884 (1989).
Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," Bioconjugate Chemistry 12(2):195-202 (2001).
Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," J. Pharm. Sci., 85(9):908-914 (1996).
Bakhtiar et al., "Taking Delivery," Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
Balkwill, F., "Interferons," Lancet 1(8646): 1060-1063 (May 1989).
Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
Beck, et al., "Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive," Biology of Reproduction, 28(1): 186-195 (1983).
Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," Hepatology 33(2):419-423 (Feb. 2001).
Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," Nature 302:716-718 (1983).
Bell et al., "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995).
Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," Int. J. Radiat. Biol. 67(1):57-64 (1995).
Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988).
Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," Euro. J. Pharm. Sci. 2(4):271-279 (1994).
Bolinger et al., "Recombinant interferon y for treatment of chronic granulomatous disease and other disorders," Clin. Pharm. 11(10):834-850 (Oct. 1992).
Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
Borden et al., "Second-generation interferons for cancer: clinical targets," Semin. Cancer Biol. 10(2): 125-144 (Apr. 2000).
Boue et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN-col. obtained from Pichia pastoris," J. Interferon & Cytokine Res. 20:677-683 (2000).
Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
Buckwold et al. "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," Antiviral Res. 73(2): 118-25 (Feb. 2007) (Epub Sep. 11, 2006).
Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence," J. Chem. Physics 104(20):8082-8095 (1996).
CAS No. 56-81-5 (Nov. 16, 1984).
Cha and Pitt, "A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules," Journal of Controlled Release, 7: 69-78 (1988).
Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," Journal of Controlled Release, 8: 259-265 (1989).
Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," Pharm. Tech. 20(1):80-84 (1996).
Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," Chem. & Physics of Lipids 1(5):445-475 (1967).
Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
Clark et al., "The diabetic Zucker fatty rat," Proc. Soc. Exp. Biol. 173( 1):68-75 (1983).
Cohen, et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," Pharmaceutical Research, 8(6): 713-720 (1991).
Condino-Neto, "Interferon-y improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," Blood 95(11):3548-3554 (Jun. 2000).
Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," Journal of Microencapsulation, 9(2): 153-166 (1992).
Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," J. Pharm. Sci. 91:388-395 (2002).
Croxatto. "Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant." Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8.
Darney, "Subdermal progestin implant contraception," Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," BioPharm, 2(11):44-51 (1999).
Dash et al., "Therapeutic applications of implantable drug delivery systems," Journal of Pharmacological and Toxicological Methods, 40(1): 1-12 (1998).
Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ).
Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," J. Am. Chem. Soc. 116(21):9420-9422 (1994).
Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
Dorr et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days," J. Interferon Res. 8:717-725 (1988).
Efendic et al., "Overview of incretin hormones," Horn. Metab. Res., 36(11-12):742-746 (2004).
Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," Life Sci., 55(8):629-634 (1994).
Eli Lilly & Company, Prescribing Information for TRULICITY® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages.
Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study," Cancer 89(3):597-603 (Aug. 2000).
Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," J. Biol. Chem., 267(11):7402-7405 (1992).
Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom," J. Biol. Chem., 265(33):20259-20262 (1990).
Eppstein et al., "Biological activity of liposome-encapsulated murine interferon y is mediated by a cell membrane receptor," PNAS USA 82:3688-3692 (1985).
Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," Proc.-Conf. Colloid Chem. 193-196 (1993).
EROWID,"Introduction to the Federal Controlled Substance Analog Act" 2001,4 pages.
Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," Vaccine 14(9):879-885.(1996).
Fang et al., "The impact of baseline liver histology on virologic response to interferon α-2b±ρ ribavirin therapy in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," J. Nutritional Biochem. 4(1):630-634 (1993).
Ferenci et al., "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977).
Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α," Lancet 356(9223):41 (Jul. 2000).
Franchetti et al., "Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," J. Medicinal Chem. 38(19)3829-3837 (1995).
Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001).
Fujii et al., "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)," Int'l J. Pharmaceutics 234(1-2): 121-128 (2002).
Gan To Kagaku Ry Oho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract).
Gappa et al., "Juvenile laryngeal papillomatosis—a case report," Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
GAPPA M; FREIHORST J; SEIDENBERG J; VOLLRATH M; VON DER HARDT H: "ÄJUVENILE LARYNGEAL PAPILLOMATOSIS--A CASE REPORTÜ", PNEUMOLOGIE, THIEME, STUTTGART, DE, vol. 45, no. 11, 1 November 1991 (1991-11-01), DE , pages 936 - 938, XP009079028, ISSN: 0934-8387
Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Diabetologia 27:599-600 (1984).
Glaxosmithkline LLC, Prescribing Information for TANZEUM® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages.
Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
Glumetza Brochure 2009, 13 Pages.
Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting betacells," J. Biol. Chem., 268(26): 19650-19655 (1993).
Gonzales et al., "Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975).
Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," Salud Publica Mex 55:462-468 (2013).
Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha," Cancer Chemother. Pharmacol. 37(l-2):39-46 (1995).
Grant et al., "Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," J. Med. Virol. 61(4):439-442 (Aug. 2000).
Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," N. Engl. J. Med., 326(20): 1316-1322 (1992).
Hageman, "The Role of Moisture in Protein Stability," Drug Dev. & Ind. Pharm. 14(14):2047-2070(1988).
Hauck, "Engineer's Guide to Plastics," Materials Engineering 5(72):38-45 (Jul. 17, 1972).
Heathcote et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," New England J. Med. 343(23): 1673-1680 (2000).
Heim et al., "Intracellular signaling and antiviral effects of interferons," Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," Endocrinol., 115:2176-2181 (1984).
Hellstrand et al., "Histamine and cytokine therapy," Acta Oncol. 37(4):347-353 (1998).
Hellstrand et al., "Histamine and the response to IFN-α in chronic hepatitis C," Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, 21 pages (Sep. 20-24, 2010).
Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," J. Toxicol. Sci., 18(3): 1-9 (1993).
Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953).
Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," International Journal of Pharmaceutics, 146(1): 81-92 (1997).
Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999).
Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia 11 Suppl 5:S47-S51 (Dec. 1997).
Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," Am. J. Clin. Oncol. 18(1):27-31 (1995).
IFNB Multiple Sclerosis Study Group, "Interferonβ-1b is effective in relapsing-remitting multiple sclerosis," Neurology 43(4):655-667 (Apr. 1993).
Implanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Intermuner® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
International Search Report and Written Opinion for PCT Application No. PCT/US2016/035602 dated Nov. 29, 2016.
Isaacs et al., "Virus interference. I. The interferon," Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267(1957).
Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8):911-917 (1998).
Jain et al., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," J. Microencapsulation 17(3):343-362 (2000).
Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990).
Jetschmann et al., "Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C," Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454).
Johnson et al., "How interferons fight disease," Sci. Am. 270(5):68-75 (May 1994).
Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," The Oncologist 12(9): 1143-1150(2007).
Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
Kabalnov et al., "Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability," Journal of Colloid and Interface Science 184(1):227-235 (1996).
Khalili et al., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," Am. J. Gastroenterol. 95(5): 1284-1289 (May 2000).
Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," J. Pharma. Sci. 29(11): 1634-01637 (Nov. 17, 1970).
Kirkwood et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," J. Clin. Oncol. 14(1):7-17 (1996).
Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ," Drug Des. Deliv. 6(3): 157-0167 (Sep. 1990).
Knepp et al., "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," J. Pharm. Sci. Tech. 50(3): 163-171 (1996).
Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures," Pharma. Res. 15(7): 1090-1095 (1998).
Knobler et al., "Systemic α-interferon therapy of multiple sclerosis," Neurology 34(10): 1273-1279 (Oct. 1984).
Kovacevic et al., "Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon," Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon P-lb therapy in patients with MS," Neurology 54(1): 193-199 (Jan. 2000).
Kronenberger et al., "Influence of interferon-a on CD82-expression in HCV-positive patients," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976).
Krown et al., "Interferons and interferon inducers in cancer treatment," Semin. Oncol. 13(2):207-217(1986).
Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon-ω," J. Interferon Res. 14:57-59 (1994).
Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication," J. Interferon Cytokine Res. 16(ll):919-927(Nov. 1996).
Larsson, "Stability of emulsions formed by polar lipids," Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
Lee and Timasheff, "The stabilization of proteins by sucrose," J. Biological Chem., 256(14): 7193-7201 (Jul. 1981).
Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).
LEE W M: "THERAPY OF HEPATITIS C: INTERFERON ALFA-2A TRIALS", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 26, 1 September 1997 (1997-09-01), US , pages 89S - 95S, XP000981288, ISSN: 0270-9139, DOI: 10.1002/hep.510260716
Lee, "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
Li et al. "Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010.
Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," Journal of Controlled Release, 37:199-214 (1995).
Lopez et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
Lublin et al., "Defining the clinical course of multiple sclerosis: results of an international survey," Neurology. 46:907-911 (1996).
Luft et al., "Electro-osmotic valve for the controlled administration of drugs," Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract).
Lukaszewski et al., "Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," J. Virol. 74(11):5006-5015 (Jun. 2000).
Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," J. Pharm. & Pharmacol. 49(1): 16-21 (1997).
Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996).
Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results," Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
Magnuson et al. "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," Protein Expression & Purification 7:220-228 (1996).
Malley et al., "Chronic Toxicity And Oncogenicity Of N-Methylpyrrolidone (Nmp) In Rats And Mice By Dietary Administration," Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
Manning et al., "Stability of protein pharmaceuticals," Pharm. Res. 6(11): 903-918 (1989).
Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," J. Clinical Oncol. 13(5): 1110-1122 (1995) (XP009078965).
MARINCOLA FRANCESCO M; WHITE DONALD E; WISE ALLISON P; ROSENBERG STEVEN A: "COMBINATION THERAPY WITH INTERFERON ALFA-2A AND INTERLEUKIN-2 FOR THE TREATMENT OF METASTATIC CANCER", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 13, no. 5, 1 January 1995 (1995-01-01), US , pages 1110 - 1122, XP009078965, ISSN: 0732-183X
Massey, "Interaction of vitamin E with saturated phospholipid bilayers," Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," Journal of Controlled Release, 3: 103-117 (1986).
McHutchison et al., "Interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," N. Engl. J. Med. 339(21): 1485-1492 (Nov. 1998).
McHutchison et al., "Open-label phase IB study of hepatitis C viral dynamics with omega interferon treatment," Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only).
Mehta, et al.,"Peptide containing microspheres from low molecular weight and hydrophilic poly(d,1-lactide-co-glycolide)," Journal of Controlled Release, 41: 249-257 (1996).
Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-aplus IL-2 and IL-12)," J. Immunother. 23(3):369-378 (May-Jun. 2000).
Milella et al., "Neutralizing antibodies to recombinant a-interferon and response to therapy in chronic hepatitis C infection," Liver 13(3): 146-150 (Jun. 1993).
Mohler, "Primer on electrodeposited coatings," Materials Engineering 5:38-45 (1972).
Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," Int. J. Peptide Protein Research, 40:333-343 (1992).
Morgan, "Structure and Moisture Permeability of Film-Forming Poloyers," Ind. Eng. Chem. 45(10):2296-2306 (1953).
Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," J. Clinical Oncol. 19(5): 1312-1319 (2001).
Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," Diabet. Med., 15(11):937-945(1998).
Neumann et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," Science 282:103-107 (Dec. 1998).
Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-a-2a and a polyethylene glycol-modified derivative in healthy subjects," Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," Drug Discovery Today 10(10):703-710 (May 15, 2005).
Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration," Eur. J. Pharm. Sci. 13(4):393-401 (2001).
Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, vol. 1, Jan. 2010, 23 pages.
Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
Ortiz et al., "A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids," Biochim et Biophys Acta 898(2):214-222 (1987).
Palmeri et al., "5-Fluorouracil and recombinant a-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327-330 (Oct. 1990).
Palmeri et al., "5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327-330 (Oct. 1990).
Panitch, "Interferons in multiple sclerosis," Drugs 44(6):946-962 (Dec. 1992).
PARKES D, ET AL: "Abstracts 2007, EXENATIDE REVERSES HYPERTENSION IN A RAT MODEL OF METABOLIC SYNDROME", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 50, no. SUPPL. 1, 0586, 21 August 2007 (2007-08-21), Berlin, DE , pages S243, XP002538652, ISSN: 1432-0428
Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondaryprogressive multiple sclerosis patients: two-year study," Acta. Neurol. Scand. 100:283-289 (1999).
Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," Neurology 43:662-667 (1993).
Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," Nature, 282:260-266 (1979).
PCT International Search Report for PCT/US2009/000916, 4 pages (dated Aug. 12, 2009).
Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," Frontiers in diabetes research. Lessons from Animal Diabetes 111, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," ILAR Journal, 32(3): 16-19 (1990).
Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24-2000) (Abstract 973).
Plauth et al., "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
Plauth et al., "Open-label study of omega interferon in previously untreated HCV-infected patients," J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
PLAUTH MATHIAS MATHIAS, ET AL: "Open-label study of omega interferon in previously untreated HCV-infected patients.", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 36, no. Supplement 1, 1 April 2002 (2002-04-01), AMSTERDAM, NL , pages 125, XP002511882, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(02)80444-5
Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," J. Biol. Chem., 273(16):9778-9784 (1998).
Poynard et al., "Is an ‘a la carte’ combined interferon a 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," Hepatology 31(1):211-218 (Jan. 2000).
Poynard et al., "Randomized trial of interferon a 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," Lancet 352(9138): 1426-1432 (Oct. 1998).
Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," Rev. Diabet. Stud., 5(2):73-94 (2008).
Probuphine Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016.
Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., U. Tex. 487-495 (1987).
Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," US Endocrinology 7(2): 104-109 (2011).
Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," Pharm. Res. 14(2): 119-127 (1997).
Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma," Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial," Diabetic Medicine 27(9): 1024-1032 (Sep. 2010).
Roberts et al., "The Evolution of the Type I Interferons 1," J. Interferon Cytokine Res. 18(10):805-816(Oct. 1998).
Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971).
Rogers et al., "Permeability Valves," Ind. & Eng. Chem. 49(11): 1933-1936 (Nov. 17, 1957).
Rohloff et al., "DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," Transplantation 48(4):554-558 (1989).
Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," Endocrinol. 148(12):6054-61 (Dec. 2007).
Roth et al., "High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," Acta Oncol. 38(5):613-617 (1999).
Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," Pharmaceutical Research, 13(3): 360-367 (1996).
Sanofi-Aventis U.S. LLC, Prescribing Information for ADLYXIN® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages.
Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," Pharmaceutical Research, 5(1): 21-30 (1988).
Schepp et al., "Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2," Eur. J. Pharmacol., 269(2):183-191 (1994).
Schering Corp., Intron® A for Injection, 6 pages (2001).
Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
Schmalfub et al., "Modification of drug penetration into human skin using microemulsions," J. Controlled Release 46(3):279-285 (1997).
Sen et al., "The interferon system: a bird's eye view of its biochemistry," I. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000).
Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," Ann. Int. Med. 132(7):517-524 (Apr. 2000).
Shire et al., "Challenges in the Development of High Protein Concentration Formulations," J. Pharm. Sci. 93:1390-1402 (2004).
Shtffman et al., "A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567).
Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β1a," Neurology 55(2): 185-192 (Jul. 2000).
Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
Sparks et al., "Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," Metabolism, 47(11): 1315-1324 (1998).
Sulkowski et al., "Peginterferon-a-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," Biodrugs 16(2): 105-109 (2002).
Sulkowski et al., "Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study," Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236).
Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," Endocrinology, 141(6): 1936-1941 (2000).
Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," Blood 98(6):1708-1713 (2001).
Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," Endocrinology 146(9):3748-56 (Sep. 2005).
Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," Int. J. Cancer 87(5):741-749 (Sep. 2000).
Thomasin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996).
Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," Journal of Controlled Release 43(l):9-22 (1997).
Tong et al., "Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," Hepatology 26(6): 1640-01645 (Dec. 1997).
Touza Rey et al., "The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus," Ann. Med. Int. 17(2):86-87 (Feb. 2000).
Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro." Biomaterials. 20(11:): 1057-1062(1999).
Trudeau et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," PNAS USA, 90(5): 1992-1996 (1993).
Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," J. Pharm. Sci. 86(5):603-7 (May 1997).
Uhlig et al., "The electro-osmotic actuation of implantable insulin micropumps," J. Biomed. Materials Res. 17:931-943 (1983).
Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8): 1915-1923 (Jun. 27, 2006).
Van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997).
Vokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest," Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
Wang et al., "Parenteral formulations of proteins and peptides: stability and stabilizers," J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
Wang et al., "Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," Eur. J. Biochem. 267(21):6362-6368 (2000).
Wang et al., "Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines," Archives of Biochem. & Biophys. 377(2):304-314 (2000).
Wang et al., "The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine," Biochimica et Biophy sica Acta-Biomembranes 1509(1-2):361-372 (2000).
Weinstock-Guttman et al., "What is new in the treatment of multiple sclerosis?" Drugs 59(3):401-410 (Mar. 2000).
Weissmann et al., "The interferon genes," Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986).
Wright et al., "Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients," Transplantation 53(1): 121-123 (Jan. 1992).
Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011).
Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macacamulatta)," Diabetes, 48(5): 1026-1034 (1999).
Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with a interferons, in the treatment of chronic hepatitis C," Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," J. Pharm. Sci. 85(4):396-401 (1996).
Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine," Antivir. Res. 11(3): 147-0160 (Apr. 1989).
Zein, "Interferons in the management of viral hepatitis," Cytokines Cell Mol. Ther. 4(4)229-241 (Dec. 1998).
Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon a on viral turnover," Hepatology 28(1)245-252 (Jul. 1998).
Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," New Engl. J. Med. 343(23): 1666-1672 (2000).
Zhang et al., "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor," Pharm. Res. 12(10): 1447-1452 (1995).
Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," Current Physician 2(12):45-46 (1997).
Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," J. Clinical Pediatrics 14(2):83-84 (1996).
Zheng et al. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," Beijing Med. J. 13(2):80-81 (1998).
Ziesche et al., "A preliminary study of long-term treatment with interferon γ-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," New Engl. J. Med. 341(17): 1264-1269 (Oct. 1999).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
USD985377S1 (en)*2021-11-042023-05-09Arjo Ip Holding AbCaster cover

Also Published As

Publication numberPublication date
JP1595316S (en)2018-01-22
USD840030S1 (en)2019-02-05
AU201710844S (en)2017-02-28
USD835783S1 (en)2018-12-11
AU201710848S (en)2017-02-28
AU201710845S (en)2017-02-28
CA171690S (en)2017-07-28
JP1595274S (en)2018-01-22
AU201616507S (en)2017-02-28
JP1595315S (en)2018-01-22
CA174919S (en)2017-07-28
AU201710846S (en)2017-02-28
AU201710847S (en)2017-02-28
CA174920S (en)2017-07-28

Similar Documents

PublicationPublication DateTitle
USD962433S1 (en)Implant placement guide
USD1024510S1 (en)Shoe
USD888835S1 (en)Gaming machine
USD919600S1 (en)Speaker
USD831894S1 (en)Helmet
USD862969S1 (en)Oven
USD831893S1 (en)Helmet
USD825899S1 (en)Footwear
USD856642S1 (en)Footwear
USD816077S1 (en)Kiosk
USD808856S1 (en)Hoverboard
USD808857S1 (en)Hoverboard
USD1034144S1 (en)Hinge
USD831892S1 (en)Helmet
USD898661S1 (en)Solar cell
USD830857S1 (en)Digital-in-wall multifunctional timer
USD790030S1 (en)Loader
USD822906S1 (en)Helmet
USD868055S1 (en)Preamble
USD872618S1 (en)Band
USD864253S1 (en)Compressor
USD797863S1 (en)Toy figure
USD943507S1 (en)Photovoltaic device
USD799202S1 (en)Case
USD874782S1 (en)Hoist

Legal Events

DateCodeTitleDescription
FEPPFee payment procedure

Free format text:ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPPFee payment procedure

Free format text:ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY


[8]ページ先頭

©2009-2025 Movatter.jp